Investigation of the role of tau gene transcription in neurodegeneration by Anaya, JF
 1 
 
Investigation of the role of tau 
gene transcriptional regulation 
in neurodegeneration 
 
 
 
 
 
 
 
 
Reta Lila Weston Institute of Neurological Studies 
Institute of Neurology 
University College London (UCL) 
University of London 
 
 
December 2011 
 
 
Juan Fidel Anaya 
PhD 
 2 
I, Juan Fidel Anaya, confirm that the work presented in this thesis is my own. Where 
information has been derived from other sources, I confirm that this has been indicated in 
the thesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 3 
Abstract 
 
Although the tau gene (MAPT) is not mutated in the majority of tauopathies, there 
are pathological disturbances in tau-isoform homeostasis. Investigation into MAPT linkage 
disequilibrium and haplotype structure, and the common variation of MAPT associated with 
increased risk of progressive supranuclear palsy (PSP) and corticobasal degeneration 
(CBD) identified a possible basis for the disturbances in tau-isoform homeostasis. Of 
multiple haplotypes in the H1 clade, the H1c sub-haplotype drives the association with PSP 
and CBD, suggesting that it carries the pathogenic variation leading to increased risk of 
these largely sporadic disorders. The aim of this project was to investigate the regulation of 
the transcription of MAPT by first identifying transcription factors (TFs) and TF complexes 
that bind to the MAPT core promoter and its conserved regulatory domains. The specific 
aim was to determine if differential binding of TFs and TF complexes to the allelic variants 
of the SNPs in the MAPT promoter region forms the basis of the allele-specific differences 
in MAPT transcription and splicing that we have observed in vitro and in vivo.  
 
Results from electrophoretic mobility shift assays, pull-down experiments and mass 
spectrometry had shown potentially novel proteins binding to the disease-associated SNP 
under investigation. Bioinformatic analyses helped to stratify these proteins according to 
possible relevance. While immunoblotting alongside co-transfection of siRNA and 
luciferase promoter construct experiments had shown initial evidence of a complicated 
relationship between cis and trans factors within the tau promoter region. These findings 
were novel and they provide new insight into the regulation of one of the most important 
genes in neurodegeneration. The identification of MAPT transcriptional machinery would 
provide further insight into the role of MAPT in neurodegeneration and the basis for 
therapeutic intervention. 
 
 
 
(280 words) 
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1 Introduction 
 
1.1  Overview 
  
In 1975, Kirschner’s group suggested either phosphorylation of tubulins or the 
presence of an exchangeable factor that might be responsible for microtubule elongation 
and dynamics. In search of this factor, tubulin was purified and proteins bound to tubulin 
were separated.
1
 One of the first proteins eluted was a factor termed tau for its involvement 
in tubulin elongation. When added to purified tubulin under non-polymerizing conditions, 
tau was sufficient for both nucleation and elongation of microtubules from purified tubulin 
as seen by electron microscopy.
2
 This formed the basis of the assay for which to monitor 
the purification of tau’s activity. Research into microtubule-associated proteins (MAPs) and 
their importance as regulators of microtubule dynamics due to their direct and intimate 
binding with microtubules began to intensify.
3, 4, 5
 
 
As brain was used due to its significantly greater amounts of tubulin than other 
tissues, the discovery and function of tau has had been intimately placed in a neuronal 
context. This became more apparent when neurofibrillary tangles (NFTs) such as those 
seen in Alzheimer’s disease (AD) were found to contain tau. NFTs are intra-neuronal 
cytoplasmic inclusions consisting of non-membrane bound bundles of paired, helically 
wound filaments (PHFs) which are 10 nm in diameter. The sub-unit of PHFs is the MAP, 
tau which is hyperphosphorylated. These have been shown to exist in other tauopathies 
such as frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17), 
progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD). However, little 
is known about the molecular and cellular biology of tau to fully appreciate the significance 
of PHFs in the disease. 
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1.2  Molecular properties of tau 
  
Human tau is encoded by a single gene, MAPT; approximately 150 kb large on 
chromosome 17q21.3 consisting of 1 non-coding and 14 coding exons.
6
 Exon -1 is 
transcribed but not translated and comprises the core promoter region. Exons 2, 3 which 
encode N-terminal inserts and exon 10 which encode 1 of 4 microtubule binding domains 
are alternative spliced in the adult human central nervous system (CNS), leading to 6 tau 
isoforms (0N/3R, 1N/3R, 2N/3R, 0N/4R, 1N/4R, 2N/4R where N is an N-terminal insert 
and R is a microtubule-binding repeat). Exons 4a, 6 and 8 are expressed in neuronal 
subtypes such as in the peripheral nervous system (PNS) (Figure 1.1).
6, 7 
Complimentary 
DNA cloning has yielded tau sequences from mouse, rat and cow.
8
 As examples, 
orthologues have been found in Caenorhabditis elegans, Drosophila melanogaster and 
Xenopus laevis.
5, 9
  
  
Figure 1.2.1: Tau gene, MAPT structure. Exon -1 is located in the 5’ untranslated region. 
Exons 2, 3 and 10 in yellow are alternatively spliced in the CNS. Exons 4A, 6 and 8 in red 
are absent in the CNS but exon 4A is present mostly in the PNS, very few in the CNS. 
Modified from reference 
6
. 
The 6 tau isoforms produced in the adult CNS have apparent molecular weights 
between 48 and 67 kDa due to the alternative mRNA splicing of exons 2, 3 and 10 (Figure 
1.2.1). Alternative splicing of exons 2 or 3 leads to either 0, 1 or 2 N-terminal insert 
(termed 0, 1 or 2 N tau). Alternative splicing of exon 10 leads to an addition of the repeat 
binding domain either 3- or 4-R tau. In foetal brain only the shortest isoform, 0N, 3R is 
expressed. Circular dichroism was used to establish the secondary structure of 2N, 4R tau 
protein in solution. A 12% α-helical and 20% β-sheet composition was estimated, although 
this is likely to be an overestimate and tau’s structure is probably best described as a 
random coil.
10
 This hinders structural studies of tau’s interaction with microtubules and 
other proteins.  
6 
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Figure 1.2.2: 6 Tau isoforms in adult human CNS. This shows the tau isoforms in adult 
CNS. The number of amino acids are indicated at the right (# aa). The protein is broadly 
divided into 3 domains, the N-terminal acidic region with either exon 2 or both exons 2 and 
3 or neither, the middle proline-rich domain and the C-terminal microtubule binding 
domain with or without the 2
nd
 microtubule binding repeat (R2) to yield either 4 or 3 
microtubule binding domains. Modified from reference
11
. 
 
 Each N-terminal insert has 29 amino acids and is rich in proline and positively 
charged residues. These are flanked by 2 acidic domains followed by a basic stretch before 
a proline-rich domain that separates the projection domain from the assembly domain 
(Figure 1.2.2). The C-terminus is rich in basic residues as well as the microtubule binding 
repeats (31-32 amino acids) each containing a characteristic PGGG motif as well as a 
conserved KXGS motif that can be phosphorylated.
5, 8
 Each repeat can be divided to an 18 
residue minimal tubulin binding region and a less conserved inter repeat of 13/14 
residues.
12
 Furthermore, there is a pseudo repeat (Figure 1.2.3). The regions that flank the 
microtubule binding regions also influence its microtubule interactions. 
 
 
 
2N, 4R 
2N, 3R 
0N, 4R 
2N, 3R 
1N, 3R 
0N, 3R 
 23 
 
Figure 1.2.3: Protein domains of hTau
441
. Chymotryptic cleavage separates regions that 
bind (C-terminal half) or do not bind (N-terminal half) to microtubules. The 29-residue 
inserts near the N-terminal are sandwiched between 2 acidic regions followed by a basic 
region, a middle proline rich region, 4 microtubule binding repeats and a pseudo repeat. 
Modified from references
13,14
. 
 
1.3  Tauopathies 
 
Tauopathies are diseases that are characterized by tau pathology. These include AD, 
PSP, CBD, FTDP-17, Pick’s disease (PiD), argyrophillic grain disease (AgD), amyotrophic 
lateral sclerosis (ALS), Niemann-Pick type C (NPC), dementia pugilistica, tangle-only 
dementia, subacute sclerosing panencephalitis, Wernicke’s encephalopathy, Parkinson’s 
dementia complex of Guam, pantothenate kinase-associated neurodegeneration (PKAN), 
progressive nonfluent aphasia, Down’s syndrome, several variants of Prion diseases, 
myotonic dystrophy, sporadic inclusion body myositis (s-IBM), hereditary inclusion body 
myopathy (h-IBM) and glaucoma.
15, 16, 17, 18, 19, 20, 21, 22, 23, 24
 Until a consensus in 1994, 
frontotemporal dementia (FTD) was often classified as PiD.
25
 FTD is the second most 
common form of primary degenerative dementia after AD and accounts for 20% of 
presenile dementia cases.
26
 Mutations in MAPT accounts for 18% of all FTD and 41% of 
familial FTD cases.
27
 With PSP being the second most common cause of parkinsonism, the 
deregulation of tau has far and wide implications in neurology. According to the World 
Health Organization (WHO), almost one billion people worldwide are expected to be 60 
years or older by 2025 and 42 million people are expected to have dementia by 2020, 
therefore the need for greater understanding for the basis of these diseases cannot be 
overstated (http://www.who.int/ageing/en/).    
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1.4  Tau mutations 
 
Since the cloning of human MAPT and the establishment of linkage between FTD 
and 17q21.31, FTDP-17, originally defined in 1996, has been described as a collection of 
autosomal dominant inherited tauopathies.
24,28,29
 Intensive research was carried out on 
characterizing the various mutations in MAPT and how these enlighten our understanding 
of the pathologies mentioned above. More than 100 families with FTDP-17 were described 
worldwide with 42 different mutations in MAPT.
30
 These include 26 missense, 19 intronic, 
3 silent and 2 amino acid deletion mutations. A pictorial representation of these mutations 
along the tau protein can be seen in Figure 1.4.1. Approximately half of the mutations had 
their primary effect at the RNA level while the other half had their primary effect at the 
protein function level. While these mutations might exert different effects at the molecular 
level, there was extensive clinical overlap between them.  
 
 
Figure 1.4.1: List of most FTDP-17 mutations along the tau protein. Modified from
31
.                                                             
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1.5  Clinicopathology of tau mutations 
 
Generally, dementia predominant FTDP-17 was usually seen in families with 
mutations in exons 1, 9, 10, 11, 12 and 13. Mutant tau can be mostly found in both neuronal 
and glial tissues as narrow twisted ribbons.
31
 However, parkinsonism-plus predominant 
FTDP-17 was usually seen in families with intronic and exonic mutations affecting exon 10. 
Most of these led to neuronal tau pathology and very little glial tau pathology except for 
R5L/H, I260V, L266V and L315R which had more glial tau pathology. Intronic mutations 
and those in exons 1 and 10 were mostly associated with neuronal and glial tau deposition 
which looked like CBD while those in exons 9, 11, 12 and 13 were predominantly neuronal. 
Three mutations (K257T, L266V, G272V) in exon 9, one in exon 10, two (L315R, S320F) 
in exon 11, three (Q336R, E342V, K369I) in exon 12 and two (G389R, T427M) in exon 13 
were associated with Pick-body-like inclusions. Other mutations in exons 12 (V337M) and 
13 (R406W) led to tangles similar to those seen in AD.
17
 The R5L, N279K, ΔN296, S305S 
and +16 mutations had phenotypes similar to PSP. 
 
The R5L mutation in exon 1 generated a PSP-like phenotype.
32
 Unlike the R5H 
mutation which showed prominent glial tau deposits, the R5L mutation led to both neuronal 
and glial pathology.
33
 G272V, K257T or L266V mutation in exon 9 exhibited phenotypic 
resemblance to PiD with Pick-body-like inclusions consisting of only 3R tau but without 
motor dysfunction.
34,35,36
 However, mutations and pathology are not clear cut. Clinical 
diagnoses of patients with P301L mutation in exon 10 ranged from PSP to CBD and PiD 
with narrow, twisted-ribbon structures of 4R-tau and little 3R-tau.
37
 Both P301L and P301S 
mutations led to neuronal and glial pathology.
38
 The N279K mutation typically led to PSP 
with dementia.
39
 ΔK280 in exon 10 displayed pathological features largely in the form of 
Pick-body-like bodies with some 4R-tau found in them.
40
 However, it is not clear if ΔK280 
is pathogenic. ΔN296, however, generated atypical PSP-like symptoms.41 K317M in exon 
11 led to degeneration of frontotemporal, corticospinal tract and substantia nigra without 
Lewy bodies causing Parkinsonism with motor neuron disease and FTD. Abnormal tau 
deposition was observed in both neuronal and glial tissues but no Pick-body-like inclusions 
were observed.
42
 Other mutations in exon 11, however, such as L315R led to memory loss 
and behavioral changes with neuronal and astrocytic tau inclusions while S320F mutation 
led to memory decline with neuronal inclusions and only rare coiled bodies found in 
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oligodendroglial cells.
43,44
 Unlike K317M, Pick-body-like inclusions were observed with 
the other two mutations in exon 11. Although three mutations in exon 12 (Q336R, E342V 
and K369I) all resulted in the development of Pick-like bodies, V337M produced 
widespread neurofibrillary tangles, both PHFs and straight filaments (SF), containing all six 
isoforms similar to AD.
45,46,47,48
 Recently, another mutation in exon 12, V363I, had been 
associated with progressive nonfluent aphasia.
49
 The G389R in exon 13 showed phenotypic 
variability resulting in FTD, corticobasal syndrome (CBS) or PiD without motor 
dysfunction with large number of Pick-body-like and axonal inclusions.
50
 
 
1.6  Molecular implications of tau protein mutations 
 
In P301L brains, there was selective aggregation of mutant tau in the deposits which 
were partly resistant to degradation as confirmed by pulse-chase experiments.
51
 In R406W 
brains, unlike P301L, there were equal amounts of wild-type (WT) and mutant tau present 
in the aggregated form. Hence, there was no selective aggregation of R406W tau 
isoforms.
52
 Although the same level of phosphorylation was seen in WT and R406W 
aggregated tau, soluble R406W was less phosphorylated than soluble WT tau at Ser-396 
and 404. This was probably due to a steric restriction imposed by the substitution. R406W 
mutant tau also led to the potential loss of phosphorylation at Thr-231 and Ser-235 by 
GSK3β compared to WT tau, implying long-range conformational effects.53 No differences 
in phosphorylation were seen between P301L and V337M compared to WT tau. In 
neuroblastoma cell culture experiments, P301L and V337M mutations led to decreased 
phosphorylation at the pathologically relevant Ser-202/Thr-205 site but R406W did not.
54
  
For Cdk5-dependent phophorylation, R406W mutant tau was less phosphorylated at Ser-
404 whereas no difference was seen with K257T, P301L/S mutant tau compared to WT 
tau.
55
 The reduction in Cdk5 phosphorylation was only seen with full-length R406W tau 
suggesting again long-range conformational changes. Upon binding to microtubules, more 
P301L, P301S and R406W tau were phosphorylated compared to WT tau, implying that the 
conformation change brought about by the mutations was negated by microtubule binding. 
JNK, activated in the mitotic phase, directly hyperphosphorylated R406W mutant tau at the 
PHF-1 site suggesting a functional role of R406W tau in mitotic cell.
56
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Effects on phosphorylation of tau are only half the picture. It had been shown that 
G272V, ΔK280, P301L, P301S, S305N, V337M, G389R and R406W mutations inhibited 
the binding of recombinant 3R- and 4R-tau to protein phosphatase 2A (PP2A) by 20-
95%.
57
 The reduction in binding was greatest with G272V, ΔK280 and V337M mutations. 
R406W and G389R mutations, however, showed isoform-specific inhibition of 3R-tau to 
PP2A compared to 4R-tau. 
 
Both P301L and P301S mutant recombinant tau were able to respond strongest to 
the stimulation of heparin-induced filament assembly in 4R-tau only.
58
 G272V mutation in 
exon 9 produced an increase in tau filaments in both 3R- and 4R-tau. However, V337M in 
exon 12 had a small stimulatory effect in 3R-tau while the ΔK280 mutation had no obvious 
effect on tau filament assembly. G272V and P301L mutations increased the rates of both 
filament nucleation and extension reactions whereas R5L and V337M increased the 
nucleation phase.
59
 Using tryptophan scanning mutagenesis, it was shown that both ΔK280 
and P301L led to enhanced propensity for β-structure where packing is tightest in 
filaments.
60
 Sf9 insect cells overexpressing G272V, P301L and R406W mutant tau were 
able to form filaments resembling PHFs.
61
 G272V, in both 3R- and 4R-tau, ΔK280 and 
P301L mutant tau, all exhibited significant reduction in their ability to regulate microtubule 
dynamic instability compared to WT tau.
62
 This meant they were less able to increase the 
amount of time microtubules were attenuated. R406W, however, had little effect on 
regulating microtubule dynamics, suggesting indirect biological effects. These mutational 
effects were reduced when cells were treated with lithium implicating a role for GSK3β. 
Largest effects on aggregation were observed with G272V and P301L tau mutations.
45
 
They were predicted to be highly sensitive to changes in free cytosolic tau concentration 
and their ability to aggregate at submicromolar concentrations. Both G272V and P301L 
mutations lie in segments adjacent to hexapeptide motifs involved in inducing cross-β-sheet 
structure in the repeat region. In hippocampal neurons, N279K potentiated the apoptotic 
effect of tau 151-421, the cleavage product of caspase-3.
63
 This probably was related to the 
N279K, and in a similar way, S305N tau’s ability to bind to microtubules with equal 
efficacy but compromised their abilities to regulate microtubule growth rate and 
catastrophe frequency.
64
 Microtubule effects of these mutations are summarized in Figure 
1.6.1.  
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Figure 1.6.1: Effects of FTDP-17 mutations on the tau fibrillization pathway. Ux 
represents tau in an assembly incompetent state while Uc represents an assembly competent 
tau. N represents the nucleus of fibrillization with tau as a dimer. Modified from
60
.  
 
1.7  Molecular implications of tau splicing mutations 
 
Besides affecting tau at the protein level, mutations in and around intron and exon 
10 contribute to changes in 4R:3R tau expression levels, most of which lead to an increase 
in 4R-tau. The 5’ and the 3’ exon 10 splice sites differ from the canonical sites by 4 and 1 
nucleotides respectively, making them weaker binding sites.
15
 Furthermore, exon 10 is 
flanked by two reasonably large introns, intron 9 (13.6 kb) and intron 10 (3.8 kb). The 5’ 
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splice site sequence contains three components: an invariant dinucleotide at the 5’ end of 
the intron separated from the branchpoint sequence (BPS) by a central polypyrimidine tract 
(PPT). The BPS consensus sequence is complementary to the U2 snRNA recognition 
sequence. At the 5’ end of exon 10, three exonic splicing enhancers (ESEs) have been 
identified: a SC35-like enhancer, a polypurine enhancer (PPE) and an AC-rich element 
(ACE).
65
 An exon splicing silencer (ESS) in exon 10 is sandwiched between these ESEs 
upstream and another ESE downstream, but still within the same exon.  
 
The 3’ splice site is located at the boundary between exon 10 and intron 10. This 
sequence is complimentary to and base-pairs with the 5’ end of U1 snRNA.66 The sequence 
located further down had been proposed to form a stable, folded stem-loop structure which 
acts as an intron splicing silencer (ISS).
67
 Two different structures have been proposed 
(Figure 1.7.1B).
68, 69
 Downstream of this ISS, an intron splicing modulator (ISM) from +19 
to +26 had been described. It had also been proposed that the +29 intron 10 mutation which 
led to decreased exon 10 (more 3R-tau) splicing might be due to a smaller double-stem 
loop structure (Figure 1.7.1C).
70
  
 
During the initial splicing pathway, the 65 kDa U2 auxiliary factor (U2AF65) 
interacts loosely with the PPT which is stabilized by U2AF35 binding to the dinucleotide of 
the 3’ splice site.71, 72 U1 snRNP then associates with the 3’ splice site and further stabilizes 
U2AF65 at the PPT. This leads to the strengthening of the recruitment of U2 snRNP to the 
BPS. This and all subsequent steps are energy dependent. SR factors bound to ESEs are 
important for the recruitment and stabilization of U2AF, U1 and U2 snRNPs (Figure 
1.7.1A). Exon 10 inclusion into mRNA is regulated by CDC2-like kinases (CLK1, 2, 3 and 
4) which phosphorylate serine-arginine-rich (SR) proteins which regulate pre-mRNA 
splicing.
73
 CLKs achieve this through releasing specific proteins from nuclear storage sites. 
Other proteins thought to bind to the intron 10 and contribute to splicing include RBM4, 
CELF3 and CELF4.
74,75 
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Figure 1.7.1: Model of tau exon 10 splicing. A. Position of cis-elements and related trans-
factors along MAPT that enhance or reduce exon 10 splicing. FTDP-17 mutations affecting 
exon 10 splicing are listed below. B. Two of the variant stem-loop structures proposed to 
form at the ISS. C. The secondary structure of +29 mutation predicted to form with the ISM 
highlighted in grey. Modified from
71,76,89
.
 
 
A 
C 
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A mutation in intron 9, -10, added an additional pyrimidine, strengthening the 
polypyrimidine tract by having more consecutive pyrimidines. This had been shown to 
strengthen the splice acceptor site and to promote the inclusion of exon 10.
77
 The N279K 
mutation (AAT to AAG) not only affected the peptide sequence but its location in the PPE 
created a purine-rich stretch (AAGAAGAAG) which made it more resemble an ESE 
consensus sequence.
78
 The ΔK280 mutation, however, abolished exon 10 splicing by 
removing an AAG.
79
 The PPE acts as a binding site for trans-acting factors such as 
SF2/ASF, Tra2β, SRp30c and SRp54.80 The silent mutation L284L increased the AC 
content of ACE which made it more effective as an ESE.
61
 Three mutations (N296H, 
N296N and ΔN296) within the ESS, disrupted this 18 nucleotide sequence which enhanced 
exon 10 splicing.
81
 The S305N mutation (AGT to AAT) and the +3 mutation occurred in 
the 5’ splice site and strengthened its binding to U1 snRNA.55,56 This mutation had been 
associated with Pick-body-like inclusions while S305S mutation was reminiscent of PSP. 
S305S disrupted the stem-loop structure without the predicted effect on U1 snRNA.
82
 A 
new mutation, S305I, had a morphological phenotype resembling AgD. It had a strong 
effect on exon 10 inclusion by substituting the complimentary binding partner of +16 and 
weakening the stem-loop structure.
83
 The +11, +12, +13, +14 and +16 mutations within the 
stem-loop structure of the ISS destabilized this structure and prevented it from acting as an 
ISS, leading to more 4R-tau. The +19 mutation, 3’ of the stem-loop, disrupted the ISM 
which acted to destabilize the effects of the ISS, resulting in more 3R-tau.
84
 
 
In myotonic dystrophy type 1 (DM1), patients suffer from degeneration of cortical 
neurons with reduced levels of exon 2-containing tau.
85
 Splicing of exon 2 in tau pre-
mRNA is regulated by CELF protein ETR-3.
86
 Inclusion of exon 6c in tau decreased in 
DM1 brains compared to control brains.
87
 This isoform of tau might be needed in neuronal 
differentiation and neurite extension and exon 6 splicing is aided by CELF-5 and -6. Figure 
1.7.2 illustrates the sequences involved in exon 2 and 3 splicing.  
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Figure 1.7.2: Model of tau exon 2/3 splicing. The exon splicing enhancers (ESEs), exon 
splicing silencers (ESSs), intron splicing silencer (ISS) and weak branch point (BP) for 
exons 2 and 3 are shown. Unspliced exons are coloured green, spliced exons are coloured 
orange and exons expressed in the peripheral nervous system are coloured grey. Modified 
from
88
.      
                                          
From all these studies, two models have been proposed for the regulatory elements 
in tau pre-mRNA: linear cis-element model and the stem-loop model.
5
 The stem-loop 
model, however, does not support the in vivo modulatory effect of the ISM. In the linear 
cis-element model, multiple weak interactions between factors binding to sequences inside 
intron 9, exon 10 and intron 10 act in a linear fashion to modulate the splicing of exon 10.  
 
Recently, a partial deletion of the MAPT gene (17.3 kb from exon 6 to 9) was 
detected in a patient with FTD.
89
 This meant that the first microtubule binding domain was 
absent. In vivo binding assays showed that this dramatically reduced binding to 
microtubules. 
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1.8  Complex architecture of the human tau gene locus 
 
The FTDP-17 candidate region had been studied and mapped extensively.
90
 The 
human MAPT locus spans 130,987 bp on chromosome 17 and has approximately one SNP 
for every 200 bp and an insertion or deletion every 1 kb. Two MAPT haplotypes with 8 
SNPs and the TG dinucleotide repeat have been described.
91
 H2 was characterized by a 238 
bp deletion in intron 9. Chromosome 17 is prone to recurrent inversions because the 
inversion breakpoints correspond to core duplications within the leucine-rich repeat 
containing (LRRC37) gene family.
92
 LCR A is located 250 kb centromeric to MAPT and 
inverted relative to LCRs B (which is 180kb telomeric to MAPT) and C (Figure 1.8.1). 
LCR D is located in the same orientation as LCR A but 19 Mb telomeric of MAPT. LCR A 
and B flank the extended H1 and H2 haplotypes that resulted from a historical inversion. 
H1 was assumed to be the ancestral sequence as most of sub-Saharan African haplotypes 
were of the H1 clade. However, H2 is the most likely great ape and human ancestral state. 
The divergence was estimated to be about 3 million years ago. The H2 is the minor 
haplotype in Caucasian populations but still accounted for 20% of the Caucasian compared 
to 10% of the Russian, 6% of the Guamanian Chamorros and 0% of the Japanese 
population.
93
 The distribution of the haplotype and analysis of the slippage of dinucleotide 
repeat markers within the haplotype suggested that it entered Homo sapiens populations 
between approximately 10,000 and 30,000 years ago when Homo neanderthalensis co-
existed.
94
  
 
Looking at the detailed BAC-based sequence assembly of the approximately 970 kb 
inverted human H2 haplotype and comparing it to the sequence structure and genetic 
variation of the corresponding region for the H1 human haplotype and that of chimpanzee 
and orangutan, provided evidence that the inversions occurred independently in 
chimpanzee and humans.
95
 
  
 34 
 
 
 
Figure 1.8.1: Inverted MAPT haplotypes at 17q21.31. Besides the inversion between H1 
and H2, there are also segmental duplications in both directions. Modified from
96
. 
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1.9  Tau gene haplotypes and disease 
 
Since 1997, the first reported genetic predisposition to sporadic PSP of the A0 allele 
of MAPT of a repeat polymorphism in intron 9 was made.
97
 The entire, fully extended H1 
haplotype was associated with PSP and CBD as a pathogenic locus.
98,99,100
 This locus was 
defined to at least 56 kb from rs242557 to rs2471738. The sole H2 derived haplotype was 
underrepresented in PSP and CBD. The H1/H1 genotype correlated the parkinsonism 
phenotype of FTDP-17 while the H1/H2 genotype correlated with the dementia 
phenotype.
101
 H2/H2 was found to be overrepresented in FFTD patients especially in 
APOE ε4 negative FFTD patients.102 This was also associated with reduced tau expression. 
From linear regression analysis, the H1/H1 genotype was associated with significantly 
earlier age at symptomatic onset (AAO) in patients with PSP and may contribute to earlier 
clinical expression of PSP-related pathology.
103
 In another study, H1 and H2 haplotypes 
were not found to associate with a significant difference in the risk of developing FTD.
104
  
 
The H1c subhaplotype was shown to be associated with increased risk of AD with 
the most likely region for a pathogenic variant lying between rs242557 (5’ of exon 1) and 
rs2471738 (in intron 9) of MAPT.
105
 However, there was no evidence of association 
between the H1c haplotype or rs242557 with late onset AD (LOAD).
106
 When gender and 
APOE4 status were taken into account, there was a suggestive association between 
rs242557 and LOAD.
107
 There was a slight increase in H1/H1 genotype in AD cases with 
AgD, suggesting a possibility of MAPT H1 as a risk factor for AgD.
108
 People with Down’s 
syndrome (DS) and the H1/H2 haplotype had a greater risk of developing dementia before 
45 years old compared to H1/H1.
109
 MAPT H1 subhaplotypes had been shown to be 
preferentially associated with PD even though there was no consistent association between 
the H1 haplotype and PD in three ethnically diverse populations.
110,111
 In the Serbian 
sample, however, there was significant evidence for an association between H1 and PD 
suggesting that this role might be ethnically dependent.
112
 More recently, H1-clade but not 
H1c was associated with increased risk of sporadic PD in single-locus associations.
113,114
 
However, the linkage disequilibrium did not extend beyond the MAPT haplotype to 
neighbouring genes.
115
 This indicated the probability of a different mechanism involved in 
PD compared to other pathologies.  
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H2 carriers, however, were associated with significant reductions of glucose 
utilization in the superior and medial frontal gyri in both hemispheres. Compared to H2/H2 
patients, H1 carriers showed up to 19% smaller grey matter volume in all the regions 
compared, frontal gyrus, insula, temporal and cerebellar lobes.
116
 These results might shed 
some light on pathology as FTD, PSP and CBD have some form of cerebral atrophy and 
reduced glucose metabolism. There was a detection of a relative decrease in MAPT H1 
expression with increased age in human brain. H1c was also associated with both 
Richardson’s syndrome and PSP-Parkinsonism compared to controls.117  
 
The H1 haplotype was also shown to express significantly more 4R-tau mRNA and 
protein in post-mortem tissue compared to H2 while the H2 haplotype was shown to 
express more 2N-tau compared to H1.
118,119
 This might suggest that the inclusion of exon 3 
might contribute to the protective effects of H2. 
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1.10  Molecular function of MAPT SNPs 
 
The rs242557 SNP falls within a 182 bp transcriptionally active region that is 
conserved in human, chimpanzee, mouse, dog and rat. It is 47 kb downstream from the core 
promoter and19 kb upstream of the first coding exon.
79
 Genotypes at rs2258689 interact 
with rs242557 to confer risk for Guam ALS/PDC and dementia.
120
 There was a significant 
association of the rs242557-A allele with AD.
121
 The H1 risk in young PSP patients could 
be explained by one SNP, rs242557 within the 22 kb regulatory region of intron 0.
122
 In 
two different human cell lines, H1 haplotype was more efficient at driving gene expression 
compared to H2.
92
 The reporter assay was consistent with the view that rs242557 was a key 
part of promoter variability and may underlie some of the association.
96, 123
 In the Chinese 
Han population, the 347 C/C promoter allele within the H1/H1 genotype was over-
represented in 252 sporadic AD patients compared to control.
124
 Promoter transcriptional 
activity of the 347 C/C genotype was significantly higher compared to 347 G/G genotype. 
Survival analysis of rs1880753, 160 kb and 50 kb upstream of tau and CRHR1 genes 
respectively, was consistently associated with disease risk and with AAO in PSP and 
CBD.
125
 It might act as a cis-element that regulates gene expression. Another 
polymorphism within the tau promoter region such as del-568Tins (a deletion at position    
-568 or an insertion of a T allele) was found to correlate with AAO in PD, suggesting 
variants within MAPT might modify the pathogenesis process of PD.
126
 A novel H1 
haplotype with rs1800547 was significantly associated with the risk of PD.
127
 
 
The general aim of this PhD was to gain an understanding of the regulation of the 
transcription of MAPT by identifying transcription factors (TF) and TF complexes that bind 
to the MAPT core promoter and its conserved regulatory domains. The specific aim was to 
test the hypothesis that the differential binding of TFs and TF complexes to the allelic 
variants of the SNPs in the MAPT promoter region forms the basis of the allele-specific 
differences in MAPT transcription that Dr. de Silva’s group has observed in vitro and in 
vivo. The identification of MAPT transcriptional machinery would provide the basis for 
therapeutic intervention and the individual TFs would be plausible candidates for analysis 
of genetic variants that exacerbate or reduce these differences. 
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2 Methods 
 
2.1 DNA and protein quantification 
 
DNA or protein quantity and quality was monitored using the Nanodrop™ ND-
1000 Spectrophotometer (Thermo Scientific). It is a full spectrum (220 – 750 nm) 
spectrophotometer that measures 1 µl samples with high accuracy and reproducibility 
without the use of cuvettes or the need for dilutions (between 2 – 3700 ng/µl for double-
stranded DNA or 0.1 – 100 mg/ml for protein) (Figure 2.1.1).128 
 
  
Figure 2.1.1: Upper and lower sampling arms of ND-1000. Adapted from
129
. 
 
 
The absorption at 260 nm indicated the concentration of nucleic acid in a sample. 
The approximate concentration of sample protein mixtures is calculated using the 
absorption at 280 nm while using the mass extinction coefficient of bovine serum albumin 
(BSA) which is 6.7 L·g
-1
cm
-1
 at 280 nm for a 10 mg/ml BSA solution.  
 
The ratio of absorption at 260 nm to 280 nm provides an indication of the purity of 
DNA in relation to protein contamination. A ratio of 1.8 is generally accepted as pure for 
DNA samples. The ratio of absorption at 260 nm to 230 nm provides an indication of DNA 
purity in relation to contamination by carbohydrates, peptides, urea, phenols and other 
aromatic compounds. A ratio of 2.0 is generally accepted as pure. For proteins, the ratio of 
absorption at 260 nm to 280 nm of 0.6 is generally accepted as pure for protein samples.  
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2.2 Polymerase chain reaction (PCR), Generation of concatamers & Annealing 
complimentary pairs of oligonucleotides 
 
Developed in 1984 by Kary Mullis, PCR is an in vitro method for the exponential 
amplification of a target DNA sequence within a DNA sample.
130
 This was aided by the use 
of temperature cycling. Knowing the target DNA sequence, designing the primers was done 
using the computer program Primer3 v. 0.4.0 (http://frodo.wi.mit.edu/). Having primers, 
heat-stable DNA polymerase and an excess of the four deoxynucleoside triphosphates 
(dNTPs) : deoxyadenosinetriphosphate (dATP), deoxycytidinetriphosphate (dCTP), 
deoxyguanidinetriphosphate (dGTP) and deoxythymidinetriphosphate (dTTP), and in 
permissive buffer conditions, the DNA polymerase will catalyze the synthesis of new 
complimentary DNA strands containing the target DNA sequence. With every temperature 
cycling, newly synthesized DNA strands from previous cycles will act as DNA templates 
for subsequent cycles. Thus, this chain reaction will continue until DNA strands containing 
the target DNA sequence predominate. After about 25 cycles of DNA synthesis, there will 
be about 10
5
 copies of PCR product with the target DNA sequence. 
 
The generation of concatamers of the region of interest through PCR was carried 
out using Platinum® Pfx DNA polymerase (Invitrogen). This uses a recombinant DNA 
polymerase from Thermococcus species strain KOD with proofreading (3’ to 5’ 
exonuclease) activity. Typical 50 μl reactions contained 1x Pfx amplification buffer, 1x 
PCR enhancer solution, 0.15 mM dNTPs, 1 mM magnesium sulfate, 7.5 nM of each 
forward and reverse primer, and 1 unit of Platinum® Pfx DNA polymerase. Designing 
primers that were tandem repeat and complimentary to each other negated the need for a 
separate DNA template.
131
 These primers form a partial duplex which act as the substrate 
for DNA polymerase (Figure 2.2.1). This was carried out using either an Eppendorf 
Mastercycler or Techne Touchgene. After an initial denaturing step at 94°C for 2 minutes, 
there were 25 cycles of denaturation at 94°C for 30 s, annealing step at 55°C for 30 s and 
extension step at 68°C for 1 minute. The PCR products were held at 4°C until collection. 
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Figure 2.2.1: Synthesis of concatamers using PCR and partially duplex 
oligonucletoides. Adapted from
132
. 
 
The process of annealing complimentary oligonucleotides was achieved using the 
thermocycling function of the PCR machine. After an initial denaturing step at 95°C for 5 
minutes, the temperature was reduced by 1°C per minute until the melting temperature (Tm) 
was reached. The reaction was held for 30 minutes at this temperature before reducing the 
temperature by 1°C per minute until the temperature reached 25°C. The annealed 
oligonucleotides were then held at 4°C until collection. 
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2.3 Agarose gel electrophoresis 
 
Agarose gels were used to analyze the PCR product sizes and quality. 1% w/v 
agarose gels were routinely used. Agarose powder (Sigma-Aldrich) was melted in Tris-
Acetate buffer (TAE) in a microwave oven for 2 minutes. Once the gel solution was hand-
warm, 5 μl SafeView nucleic acid stain (NBS Biologicals) was added to every 100 ml gel 
solution. This was then poured into a cast and a comb was used to form wells once the gel 
had set. After setting, the gel was submerged in an electrophoresis tank filled with TAE 
buffer. Samples were mixed with 5x gel loading dye before being loaded into the wells. 
Samples were electrophoresed for 20 minutes at 80 mV. The DNA bands were then 
visualized on a UV transilluminator and captured digitally using the EDAS Geldoc system 
(Labtech International). 
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2.4 Immunoblot analysis of proteins  
 
Immunoblot analysis of proteins is a separation of proteins according to their 
molecular weight using sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE), followed by immobilization onto a membrane before detection of specific proteins 
by enzyme conjugated antibodies. 
 
Equal masses of protein samples were mixed with 10x NuPAGE reducing agent 
(Invitrogen) to reduce any disulfide bonds, thus removing tertiary and quaternary structures. 
4x NuPAGE LDS sample buffer (Invitrogen) was then added to envelope the proteins in 
negative charges to denature the proteins as well as to weigh them down and act as a 
tracking dye. Samples were heated to 70°C for 10 minutes. To run SDS-PAGE gels, the 
NuPAGE (Invitrogen) system was used. This comprised of pre-cast polyacrylamide gels of 
defined concentrations. Samples were loaded into the wells and SeeBlue (Invitrogen) pre-
stained molecular mass markers were added to each end of the gel. Electrophoresis was 
carried out in either 2-(N-morpholino)-ethanesulfonic acid (MES) or 3-(N-morpholino)-
propanesulfonic acid (MOPS) buffer with NuPAGE antioxidant (Invitrogen) added. The 
gels were allowed to run at 200V until the dye front reached the foot of the gel. 
 
Gels were then removed from their casts and transferred to Hybond P membranes 
(Amersham Biosciences) using the electrophoresis blot method. The gels and membranes 
were sandwiched between filter paper (BioRad) and sponges (Invitrogen) and held together 
between two electrodes. 1x transfer buffer (Invitrogen) containing 20% methanol (VWR) is 
then added to complete the circuit. The apparatus was left to run at 30V for 1 hour.  
Successful blotting can be observed by the presence of pre-stained molecular mass markers 
on the membrane. 
 
Excess protein binding sites on the membranes were blocked by incubating them in 
5% fat-free milk powder (Premier Brands) dissolved in phosphate buffered saline (PBS, 
Roche) with 0.1% Tween-20 (Sigma-Aldrich) rocking for 1 hour. Primary antibodies 
against the proteins of interest were diluted at defined ratios in PBS with 0.1% Tween-20 
(PBS tween) and 5% fat-free milk and incubated with the membranes rocking for a defined 
period at 4°C. Membranes were then washed in PBS tween, once quickly followed by three 
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10 minute washes at room temperature. A secondary antibody (Santa Cruz Biotechnologies, 
supplied by Autogen Bioclear) against the primary antibody, conjugated to horseradish 
peroxidase (HRP), was then incubated with the membrane rocking for 1 hour at room 
temperature. They were diluted at defined ratios in PBS tween with 5% fat-free milk. This 
was followed by a similar set of washes with PBS tween.  
 
Presence of HRP was detected using the Super Signal West Pico kit (Perbio) which 
utilizes enhanced chemiluminescence (ECL). HRP reacts with luminol in the presence of 
hydrogen peroxide and an azine enhancer to emit light. ECL reagents were left to react with 
the blots for 5 minutes before exposing them to Kodak Biomax film (Sigma-Aldrich) for 1 
second or up to 1 hour, depending on the strength of the signal.  
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2.5 Nuclear and cytoplasmic fractionation  
 
Nuclear extracts from SH-SY5Y and M17 neuroblastoma cell lines were obtained 
using the NE-PER® nuclear and cytoplasmic extraction reagents (Pierce). These enabled 
stepwise separation of cytoplasmic and nuclear extracts. The reagents were derived from 
work done by Dignam and colleagues where optimum salt concentration of low ionic 
strength and alkaline pH was used to extract the nuclei.
132
 Before any extraction, fresh 
protease inhibitor pellets (Roche) were dissolved accordingly into the cytoplasmic and 
nuclear extraction reagents and kept on ice. Empty Eppendorfs were weighed so that weight 
of packed cells can be determined. Knowing this, it was then possible to scale-up or –down 
the extraction process. Addition of the first two reagents to the cell pellet results in the 
disruption of cell membranes and release of cytoplasmic contents. After recovering the 
intact nuclei through centrifugation at 16,000 x g for 5 minutes, the cytoplasmic 
supernatant was aliquoted immediately into prechilled Eppendorfs on dry ice before storing 
at -80°C. The remaining nuclei were lysed with a third reagent to yield the nuclear extract. 
After centrifugation, the nuclear extract was aliquoted into prechilled Eppendorfs on dry ice 
before storing at -80°C. Nuclear extracts obtained in this manner were compatible with a 
variety of downstream processes such as western blotting and gel shift assays. 
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2.6 Electrophoretic mobility shift assay (EMSA) 
 
EMSA (gel shift or gel retardation assay) has been used extensively for studying the 
interaction of DNA-binding proteins with their cognate DNA recognition sequence.
133
 This 
technique operates on the basis that DNA-protein complexes migrate slower compared to 
unbound DNA in a native polyacrylamide or agarose gel. This results in a shift in migration 
of the labeled DNA band (Figure 2.6.1).
134
 The LightShift® chemiluminescent EMSA kit 
(Pierce) uses a nonisotopic method to detect DNA-protein interactions.
135
 Biotin end-
labeled DNA containing the binding site of interest was incubated with nuclear extract 
before being subjected to gel electrophoresis on a native polyacrylamide gel and then 
transferred to a positively-charged nylon membrane (Sigma-Aldrich). The biotin labeled 
DNA was detected using streptavidin-HRP conjugate and a chemiluminescent substrate. 
Specificity of DNA binding was established using competition experiments with an 
unlabelled DNA of the same sequence.  
 
 
Figure 2.6.1: EMSA.  
The protein extract (•) and DNA probe (-) are incubated before loading them onto a 
native polyacrylamide gel. This separates the bound DNA probe from the unbound 
DNA probe. Only complexes bound to the DNA probe and unbound DNA are 
visualized. Adapted from
135
.  
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A typical 20 µl reaction volume consisted of 1x protein-binding buffer (Roche), 50 
ng/µl Poly(deoxyinosinic-deoxycytidylic) acid [Poly (dI.dC)] (Roche or Sigma Aldrich) to 
inhibit non-specific binding of proteins present in crude nuclear extracts, 5 ng/µl Poly L-
lysine (Roche or Sigma Aldrich) to stabilize protein-protein and protein-DNA 
interactions
136
, 8 pmol of unlabelled target DNA (Invitrogen, for competition reactions), 
H1c-A (5’-TTCGCCCAGGGTACACCAGGACA-3’), H1b-G (5’-
TTCGCCCAGGGTGCACCAGGACA-3’), 2.5 µl of nuclear extract from 2.5 and 20 fmol 
of biotin end-labeled target DNA (Invitrogen), H1c-A (5’-biotin- 
TTCGCCCAGGGTACACCAGGACA-3’), H1b-G (5’-biotin-
TTCGCCCAGGGTGCACCAGGACA-3’). The reagents have been listed in the order they 
should be added. Before the crude nuclear extract was added, the buffer, non-specific DNA 
and stabilizer were allowed to equilibrate for 15 minutes at room temperature. After the 
nuclear extract was added, the reaction was allowed to equilibrate on ice for 15 minutes. 
After the biotin end-labeled target DNA was added, the reaction was left on ice for 30 
minutes to allow for the formation of protein-DNA complexes. 
 
Loading buffer was then added before the reaction was loaded onto native 6% Tris-
Borate buffer (TBE) gels (Invitrogen). These gel matrices are effective in separating 
proteins from 15-500 kDa and 30-200 bp of DNA fragments. Current was set to 100V 
using Invitrogen’s NuPAGE® mini-gel system until the bromophenol dye migrated 
approximately ¾ of the gel. Sequence-specific interactions are transient and they are 
stabilized by the low ionic strength of 0.5x TBE used. 
 
Gels were then removed from their casts and transferred to BioBond™-Plus Nylon 
membrane (Sigma Aldrich) using the electrophoresis blot method. The gels and membranes 
were sandwiched between filter paper (BioRad) and sponges (Invitrogen) and held together 
between two electrodes. 0.5x TBE cooled with ice is then added to complete the circuit. 
The apparatus was left to run at 30V for 2 hours on ice.  When the transfer was completed, 
transferred DNA was cross-linked to the membrane on a transilluminator with 312 nm bulb 
for 15 minutes. 
 
Excess protein binding sites on the membranes were blocked by incubating them in 
Blocking buffer (Pierce) warmed to 45°C for 15 minutes with gentle shaking. 1:300 
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dilution of stabilized streptavidin-HRP conjugate (Pierce) in blocking buffer was then 
incubated with the membranes rocking for 15 minutes. Membranes were then washed in 1x 
wash solution warmed to 45°C, once quickly followed by four 5 minute washes. 
Membranes were then transferred to a new container and incubated in substrate 
equilibration buffer (Pierce) cooled to 4°C for 5 minutes with gentle shaking. 
 
Presence of HRP was detected using the chemiluminescent nucleic acid detection 
module (Pierce) which utilizes enhanced chemiluminescence (ECL). HRP reacts with 
luminol in the presence of hydrogen peroxide and an azine enhancer to emit light. ECL 
reagents were left to react with the blots for 5 minutes before exposing them to Kodak 
Biomax film (Sigma-Aldrich) for 1 second or up to 1 hour, depending on the strength of the 
signal.  
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2.7 Cell culture 
 
The SH-SY5Y (SKY5) and BE(2)-M17 (M17) human neuroblastoma cells were 
obtained from the European Collection of Cell Cultures (ECACC). The SKY5 cell line was 
a thrice-cloned sub-line originally derived from the SK-N-SH cell line from a bone marrow 
biopsy of a neuroblastoma patient in December 1970 (Figure 2.7.1).
137
 It has dopamine-β-
hydroxylase activity and converts glutamate to GABA.
138
 It also has a substrate-adherent 
phenotype and naturally grows processes in culture. The M17 cell line was twice-cloned 
sub-line isolated from the SK-N-BE(2) cell line which was from a bone marrow biopsy of 
another neuroblastoma patient in November 1972.
139
 These cells have tyrosine hydroxylase 
and dopamine-β-hydroxylase activity as well as specific uptake of noradrenalin. 
Intermediate filaments and vimentin were also expressed in M17 cells.  
 
 
Figure 2.7.1: Undifferentiated SKY5 cells.  
Roundish features with few short processes. Adapted from
140
. 
 
Both SKY5 and M17 cells were cultured in SKY5 culture medium (42% v/v Ham’s 
F12 nutrient mixture, 42% v/v Eagle’s minimum essential medium, 15% v/v fetal calf 
serum, 2 mM L-glutamine, 1% v/v non essential amino acids, 20 U/ml penicillin, 20 mg/ml 
 49 
streptomycin, 250 ng/ml amphotericin B) maintained at 37°C in 100% relative humidity 
and 5% carbon dioxide. The growth medium was changed every two to three days. 
 
Cells were subcultured by diluting (splitting) at a ratio between 1:4 and 1:100 after 
they reach 80% confluency, approximately seven days after subculture. Old culture 
medium was aspirated before rinsing the adherent cells with warmed 1x PBS solution 
(Sigma Aldrich) to remove any remaining culture medium. Cells are then detached by 
incubating them with a thin layer of trypsin-EDTA solution (Invitrogen) at 37°C for 5 
minutes. Fresh culture medium was then added to quench the reaction. Cells were harvested 
to remove the supernatant containing trypsin. Cell pellets were then resuspended in warmed 
fresh culture medium and diluted accordingly to further seed culture flasks.  
 
For medium term storage of cells, SKY5 and M17 cells were harvested by 
trypsinisation and pelleted by centrifugation at 800xg for 5 minutes and resuspending the 
cells in 1 ml of freezing medium. They were then transferred to polypropylene cryotubes 
and slowly frozen in a bath of isopropanol in a -80°C freezer. Long term storage of cells 
were placed in liquid nitrogen.  
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2.8 DNA-binding protein purification 
 
DNA-binding proteins were purified using the DNA-binding protein purification kit 
(Roche) (Figure 2.8.1). Streptavidin magnetic particles provided had been coupled to 
double-stranded 16mer (5’-GGAATTCGGATCCGCG-3’) oligonucleotide via a 3’-end 
labeled biotin at one site. The DNA region of interest, H1c-A (5’-
TTCGCCCAGGGTACACCAGGACATTCGCCCAGGGTACACCAGGACA-3’), H1b-G 
(5’-TTCGCCCAGGGTGCACCAGGACATTCGCCCAGGGTGCACCAGGACA-3’), 
control oligonucleotides, R2 (5’-
ATCAGTGGTAACCGTTAAATACCATCAGTGGTAACCGTTAAATACC-3’) and R3 
(5’-ATGCCTAGCAAGCAGTCGTTATA ATGCCTAGCAAGCAGTCGTTATA -3’) was 
concatamarized using a self-primed PCR technique described in section 2.2. The generated 
DNA with multiple DNA-binding protein binding sites of interest was then ligated to the 
tethered oligonucleotide on the magnetic particles using DNA ligase. Nuclear extracts was 
then added to the magnetic particles to allow the DNA-binding proteins of interest to be 
captured. Unspecific DNA-binding proteins were removed by the addition of poly (dI•dC). 
Specific DNA-binding proteins were eluted using a magnetic separator and elution buffer 
of high ionic strength. Next, the elution buffer was removed from the proteins by 
microdialysis and the proteins analyzed by SDS PAGE. 
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Figure 2.8.1: Principle behind the purification of the DNA-binding protein. 
Adapted from
141
. 
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2.9 Mass spectrometry 
 
As a general rule, protein bands that are visible with Coomassie stain have sufficient 
amount of protein to be analyzed by mass spectrometry (Figure 2.9.1). Proteins of interest 
purified using the method described in 2.8 were subjected to SDS-PAGE described in the 
beginning of 2.4.  
 
 
 
 
 
 
 
                     
 
 
                   
                                 
Figure 2.9.1: Amount of protein stained with Coomassie sufficient for mass 
spectrometry. Adapted from Dr. Kevin Mills’ protocol, R Coomassie was used. 
  
A clean scalpel was used to cut bands 2 mm long and 1 mm thick. The excised gel 
pieces were placed into silanised Eppendorfs (Sigma-Aldrich) and destained using 50% 
methanol (Sigma-Aldrich) containing 0.1% acetic acid (VWR) in a 37°C water bath. The 
gel pieces were then washed three times with 50 mM ammonium bicarbonate buffer, pH 
7.8 (Sigma-Aldrich).   
 
Proteins needed to be carboamidomethylated to prevent proteins from re-folding 
and to allow trypsin to digest the proteins efficiently. Before carboamidomethylation, any 
disulfide bridges needed to be broken using 1, 4-Dithioerythritol (DTE) (Sigma-Aldrich). 
First, the gel pieces were quickly dehydrated by shaking them in LC-MS grade acetonitrile 
(Sigma-Aldrich). For complete dehydration, they were placed in a centrifugal evaporator 
until gel pieces become brittle. Second, the gel pieces were then incubated in a 37°C water 
This is the level where you start seeing more keratin 
and peptide mass - mapping identification becomes more difficult. 
.  
Coomassie blue staining. 
. 
4.7  g 2.4  g 1.2  g 0.8  g 0.3  g 79n g 16ng 
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. 
. 
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bath with 50 mM ammonium bicarbonate buffer, pH 7.8 with 10 mM DTE for 1 hour. After 
washing them, 50 mM ammonium bicarbonate, pH 7.8 containing 55 mM iodoacetamide 
(Sigma-Aldrich) was then added and the gel pieces were left to incubate in the dark for 45 
minutes.  
 
-CH2-SH + I-CH2-CONH2         -CH2-S-CH2-CONH2         +               HI 
  Cystine     iodoacetamide       S-carboamidomethyl cystine          hydrogen iodide 
 
Trypsin (Sigma-Aldrich) extensively purified from porcine pancreas was used to 
digest the protein samples. Trypsin is a highly specific serine endoprotease that cleaves on 
the carboxyl side of arginine or lysine residues. The rate of hydrolysis is reduced when an 
acidic residue is next to the cleavage site and mis-cleavage might occur when a proline is 
on the carboxyl side. Reductive methylation of the lysine residues made trypsin resistant to 
autolysis while TPCK treatment removed the chymotryptic activity of the enzyme. Trypsin 
solution was added to the gel pieces and incubated overnight in a 37°C water bath.   
 
After digestion, the trypsin solutions were removed into new tubes. Hydrophilic 
peptides in the gel were extracted by the addition of 1% formic acid shaking for 20 minutes. 
Tryptic peptides were then extracted using 50% acetonitrile containing 1% formic acid 
shaking for 20 minutes. This was repeated once. All the extraction were then pooled 
together with the trypsin solution and freeze-dried.   
 
Peptide samples were resuspended in 0.1% trifluoroacetic acid (TFA) (Sigma-
Aldrich) to prevent peptides from associating with the tube walls. 1.5 μl of the sample was 
added to 1.5 μl of a U.V. absorbing co-matrix of α-cyano-4-hydroxycinnamic acid (CHCA) 
(Sigma-Aldrich) and 50 mM fucose (Sigma-Aldrich). Two 1.5 μl spots for each sample 
were then added to a clean mass spectrometry (MS) 96-well sample plate (Figure 2.9.2) to 
form a distinct drop. 
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Figure 2.9.2: MS 96-well sample plate.  
Samples are loaded onto the clear circles. Standards are loaded onto the shaded 
circles. Adapted from
142
. 
 
10 pmol/μl of protein standards such as glu-fibrinogen, 1570.6 Da (Sigma Aldrich) 
and bovine serum albumin (BSA) (Sigma-Aldrich), 66430 Da were used to calibrate the 
machine as well as polyethylene glycol (PEG) (VWR). The spots were allowed to dry 
before loading them into the MS machine. 
  
The biological MS centre houses a quadrupole time-of-flight (QTOF) mass 
spectrometer (Waters® Micromass® MALDI Q-TOF Premier™). It is fitted with an 
interchangeable matrix assisted laser desorption ionization (MALDI) and electrospray 
ionization (ESI) sources.  
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Figure 2.9.3: Camera picture of a spot of matrix and sample peptides. Adapted 
from
146
. 
 
Figure 2.9.4: Principle of MALDI ionization. (a) peptide and matrix spotted on a 
grid (b) Mixture allowed to dry (c) UV laser fired onto mixture to ionize. 
Adapted from Dr. Kevin Mills’ protocol. 
 
For MALDI, once the spots were housed in the ionization chamber (Figure 2.9.3), 
the energy of the laser was absorbed by the co-matrix and resulted in the ionization of the 
sample peptides (Figure 2.9.4). This was a soft ionization technique where matrix material 
absorbed the UV laser beam and became ionized. The ionized matrix then charges the 
protein molecules.  
 
r 
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Figure 2.9.5: Principle of ESI ionization. Peptides are mixed with a volatile 
organic compound. The aerosol is sampled into the chamber through a capillary. 
The charge droplets shrink and become unstable until they emit charged jets. 
Adapted from Dr. Kevin Mills’ protocol. 
 
Nanoflow high pressure liquid chromatography (HPLC) (Waters® nanoACQUITY) 
combined with ESI-QTOF allowed for greater separation of peptides as they enter the mass 
spectrometer and hence a greater number of peptides that will be sequenced resulting in a 
larger sequence coverage of the unknown protein. Charged peptide micelles were pumped 
through a small aperture at high pressure resulting in multiply charged peptides (Figure 
2.9.5). 
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Figure 2.9.6: Principle of a QTOF analyzer.  
Adapted from Dr. Kevin Mills’ protocol.  
 
Whether peptides were ionized through MALDI or ESI, they were then sequenced 
in the QTOF (Figure 2.9.6). A parent ion of a particular m/z value was selected in the first 
quadrupole section of the mass analyzer. Only this peptide was allowed into the collision 
cell where it was collided with inert argon gas resulting in several fragments of the peptide 
through collision-induced dissociation (CID). The masses of these fragment ions were then 
measured according to their time of flight.   
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nHPLC 
Quadrupole 
(MS1) 
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2.10 Bioinformatics 
 
The National Centre for Biotechnology Information (NCBI) 
(www.ncbi.nlm.nih.gov/) is a resource for molecular biology and genetics consisting of 
publicly available databases for nucleotide sequence data and polymorphism frequency data.  
 
The University of California Santa Cruz (UCSC) genome browser 
(http://genome.ucsc.edu/) is a useful resource for the visualization of an assembled 
reference human genome annotated with gene positions, polymorphic variation, repeats, 
cross-species conservation and structural variation. It also has programs for the 
identification of the location of nucleotide sequences on the genome (BLAT) and in silico 
PCR for the identification or PCR products generated of primer-pairs when using genomic 
DNA as a template.  
 
The Japanese DNA transcription factor binding site prediction program 
(TFSEARCH) (www.cbrc.jp/research/db/TFSEARCH.html) was written by Yutaka 
Akiyama in 1995. It searches sequence fragments against TFMATRIX transcription factor 
binding site profile database in TRANSFAC databases developed at GBF-Braunschweig, 
Germany.
143
 
 
MatInspector (http://www.genomatix.de/matinspector) is another software tool that 
uses a large library of matrix descriptions for transcription factor binding sites to locate 
matches in DNA sequences. It also assigns quality rating to the matches and allows for 
filtering and selection of matches.
144
 This avoids redundant and false-positive matches.
145
   
 
Mascot (www.matrixscience.com/mascot) is a search engine which uses mass 
spectrometry data to identify proteins from primary sequence databases. It carries out 
probability-based scoring based on Molecular Weight Search (MOWSE) score. Searches 
can be carried out using peptide mass fingerprint, sequence query or MS/MS ion search. 
Experimental mass values are compared with calculated peptide mass or fragment ion mass 
values from applying cleavage rules to the entries in a comprehensive primary sequence 
database. Such databases include MSDB, NCBInr, Swissprot and dbEST. Mascot is also 
able to consider multiple chemical modifications and missed cleavages.
146
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STRING (Search Tool for the Retrieval of Interacting Genes/Proteins) v8.0 
(http://string.embl.de) is a metaresource that pools most of the available information on 
protein-protein associations. There are more than 50 million stored interactions from 2.5 
million proteins from 630 organisms.
147
 It weighs and integrates information from 
experimental repositories, public text collections and computational prediction methods.
148
 
These resources include SMART, PDB, COG, Ensembl, Intact, RefSeq, Medline, 
Reactome, DIP, BioGRID, MINT, KEGG, SGD, FlyBase, SwissProt/UniProt, HUGO, 
OMIM, NCI/Nature PID, The Interactive Fly, HPRD, BIND, EcoCyc, NCI-Nature 
Pathway Interaction Database, Gene Ontology (GO) protein complexes and all abstracts 
from PubMed.
149
   
 
Reactome (http://www.reactome.org) is a manually curated resource for human 
pathway data. Every reaction comes from evidence in the biomedical literature with 
appropriate citations.
150
 This could either come from direct assays on human cells or 
indirectly from experiments or observations in non-human species. It has grown into a 
collaboration between the Ontario Institute for Cancer Research, Cold Spring Harbor 
Laboratory, New York University School of Medicine and The European Bioinformatics 
Institute.
151
 The SkyPainter, a tool used to map a user’s list of genes or proteins of interest 
into reaction pathways has now been updated and replaced by the Pathway Analysis tool.
152
 
The overrepresentation analysis allows for clustering of the data into pathways, the higher 
the degree of clustering, the higher the probability of the proteins involved.   
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2.11 Native Western blotting of EMSA 
 
Native Western blotting of proteins is the separation of protein complexes according 
to their native sizes and conformations using native polyacrylamide gel electrophoresis 
(native-PAGE), followed by immobilization onto a membrane before detection of specific 
proteins by enzyme conjugated antibodies. 
 
A typical 20 µl reaction volume consisted of 1x protein-binding buffer (Roche), 50 
ng/µl Poly(deoxyinosinic-deoxycytidylic) acid [Poly (dI.dC)] (Roche or Sigma Aldrich) to 
inhibit non-specific binding of proteins present in crude nuclear extracts, 5 ng/µl Poly L-
lysine (Roche or Sigma Aldrich) to stabilize protein-protein and protein-DNA 
interactions
137
, 2.5 µl of nuclear extract from 2.1.5 and 20 fmol of biotin end-labeled target 
DNA (Invitrogen). As controls, biotin end-labeled random DNA (Sigma) R2 (5’-biotin-
ATCAGTGGTAACCGTTAAATACC-3’) and R3 (5’-biotin-
ATGCCTAGCAAGCAGTCGTTATA-3’) were used instead. The reagents have been 
listed in the order they should be added. Before the crude nuclear extract was added, the 
buffer, non-specific DNA and stabilizer were allowed to equilibrate for 15 minutes at room 
temperature. After the nuclear extract was added, the reaction was allowed to equilibrate on 
ice for 15 minutes. After the biotin end-labeled target DNA was added, the reaction was left 
on ice for 30 minutes to allow for the formation of protein-DNA complexes. 
 
Loading buffer was then added before the reaction was loaded onto native 6% Tris-
Borate buffer (TBE) gels (Invitrogen). Current was set to 100V until the bromophenol dye 
migrated approximately ¾ of the gel. Sequence-specific interactions are transient and they 
are stabilized by the low ionic strength of 0.5x TBE used. 
 
Gels were then removed from their casts and soaked in 2x transfer buffer 
(Invitrogen) for 10 minutes to aid in the transfer of protein complexes onto Hybond P 
membranes (Amersham Biosciences) using the electrophoresis blot method. The gels and 
membranes were sandwiched between filter paper (BioRad) and sponges (Invitrogen) and 
held together between two electrodes. 1x transfer buffer containing 20% methanol (VWR) 
is then added to complete the circuit. The apparatus was left to run at 30V for 2 hours.   
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Native protein complexes were fixed onto the membrane by incubating the blots in 
8% acetic acid (VWR) for 15 minutes, rinsing in double distilled water and air-drying 
overnight. Before blocking, the membrane had to be re-wet with methanol and rinsed with 
double-distilled water. Excess protein binding sites on the membrane were blocked by 
incubating them in 5% fat-free milk powder (Premier Brands) dissolved in phosphate 
buffered saline (PBS, Roche) with 0.1% Tween-20 (Sigma-Aldrich) rocking for 1 hour. 
Primary antibodies against the proteins of interest were diluted at defined ratios in PBS 
with 0.1% Tween-20 (PBS tween) and 5% fat-free milk and incubated with the membranes 
rocking for a defined period at 4°C. Membranes were then washed in PBS tween, once 
quickly followed by three 10 minute washes at room temperature. A secondary antibody 
(Santa Cruz Biotechnologies, supplied by Autogen Bioclear) against the primary antibody, 
conjugated to horseradish peroxidase (HRP), was then incubated with the membrane 
rocking for 1 hour at room temperature. They were diluted at defined ratios in PBS tween 
with 5% fat-free milk. This was followed by a similar set of washes with PBS tween.  
 
Presence of HRP was detected using the Super Signal West Pico kit (Perbio) which 
utilizes enhanced chemiluminescence (ECL). HRP reacts with luminol in the presence of 
hydrogen peroxide and an azine enhancer to emit light. ECL reagents were left to react with 
the blots for 5 minutes before exposing them to Kodak Biomax film (Sigma-Aldrich) for 1 
second or up to 1 hour, depending on the strength of the signal.  
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2.12 Transfection & Luciferase assay 
 
All transfections of SH-SY5Y cell line were carried out using TransFast™ 
transfection reagent (Promega). It is comprised of a synthetic cationic lipid (+)-N,N-[bis(2-
hydroxyethyl)-N-methyl-N-[2,3-di(tetradecanoyloxy)propyl] ammonium iodide (Figure 
2.12.1) and the neutral lipid L-dioleoyl phosphstidylethanolamine (DOPE) (Figure 2.12.2). 
 
            
Figure 2.12.1: Structure of synthetic cationic lipid. Adapted from
153
. 
            
Figure 2.12.2: Structure of DOPE. From Sigma-Aldrich website. 
 
These lipids form liposomes with water and engulf nucleic acids probably via 
electrostatic interactions. These neutralized micelles are then able to approach closer to the 
negatively-charged cell membrane. Entry into the cell may either be via endocytosis or 
fusion with the plasma membrane.  
 
Before transfection, 1x10
4
 cells are seeded onto wells and grown overnight in SKY5 
media. On the day of transfection, plasmids (contructed and prepared by another PhD 
student) only transfection was carried out by adding 200 ng of endotoxin-free plasmid 
DNA to every 1.5 μl of Transfast™ transfection reagent with 50 ng of Renilla plasmid in 
SKY5 media without fetal bovine serum. The mixture was then incubated at room 
temperature for 10 minutes. The cell culture medium was removed and replaced with this 
mixture. The cells were then incubated at 37°C for 1 hour. The wells were then overlaid 
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with SKY5 culture medium and incubated for at least 24 hours. Co-transfections were 
carried out similarly by including 1µl of 2 µM siRNA desired into the mix. 
 
The Dual-Glo™ luciferase assay system (Promega) was used to quantify the action 
of specific DNA cis-elements on promoter transcriptional activity. A change in the 
transcription and translation of a reporter molecule can be tracked in a biological system as 
a marker for promoter activity. The promoter and regulatory sequences to be studied were 
inserted into the multiple-cloning site upstream of the reporter gene in the pGL4.10 reporter 
gene plasmid (Promega). This was then transfected into cell cultures. A gene from the 
firefly (Photinus pyralis) when translated, gives rise to the monomeric 61 kDa firefly 
luciferase enzyme. This acts as a reporter by catalyzing the oxidation of luciferin with 
ATP•Mg2+ as a cosubstrate which produces light in a linear relationship with enzyme 
activity (Figure 2.12.3). 
 
           
Figure 2.12.3: Bioluminescent reaction catalysed by firefly luciferase. Adapted 
from
154
. 
 
Readings were normalized by co-transfection with the pRL-CMV internal control 
plasmid which expresses the sea pansy (Renilla reniformis) luciferase. This monomeric 36 
kDa enzyme catalyzes the oxidation of coelenterate-luciferin (coelentrazine) to produce 
light (Figure 2.12.4). This allowed control for varying transfection efficiencies. 
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Figure 2.12.4: Bioluminescent reaction by Renilla luciferase.  
Adapted from
155
. 
 
Luciferase assays were carried out on mammalian cell cultures seeded onto opaque 
96-well plates (Greiner) in 200 μl of SKY5 media. 125 μl of the media was removed before 
75 μl of the Dual-Glo™ luciferase reagent was added. It lysed the cells and acted as a 
substrate for firefly luciferase which produced a luminescent signal that was stable for over 
2 hours. Luminescence was measured using a 96-well reader luminometer (Tecan GENios). 
The process was then repeated using 75 μl of the Dual-Glo™ Stop and Glo reagent to 
quench the firefly reaction and provide the substrate for the Renilla luciferase. 
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2.13 Chromatin Immunoprecipitation 
 
 Chromatin immunoprecipitation (ChIP) is a method that is performed over several 
days and prone to variability in results. It is powerful for analyzing the direct or indirect 
protein interaction with DNA. The technique is based on formaldehyde’s ability to form 
reversible Schiff’s base cross-linkages between protein and DNA or protein and protein or 
both (Figure 2.13.1 A and B). This can be done either by acid or by increased temperature. 
Variability is introduced through the specificity of the antibody, the crosslinking conditions 
and digestion conditions. Antibodies used must be able to recognize formalin-fixed 
epitopes. These variabilities need to be empirically determined.  
 
 The first step of ChIP is to crosslink DNA to associated proteins using 
formaldehyde (Figure 2.13.1 C). Next, the DNA-protein complexes are extracted from the 
cells. Thirdly, these complexes are fragmented with micrococcal nuclease. The fourth step 
involves immunoprecipitation of DNA fragments through the binding of antibodies to the 
DNA-associated proteins. The immunoprecipitated DNA-protein complexes are then de-
crosslinked in the fifth step. Lastly, the purified DNA fragments are then subjected to PCR 
with primers specific to the DNA regions of interest. It is important to use a large number 
of cells to improve the signal-to-noise ratio.  
 
 Sufficient quantity of 36.5% formaldehyde (Sigma F8775) was added to a flask of 
cells to obtain a final concentration of 1% formaldehyde. After mixing, the cells are left to 
incubate in the formaldehyde for ten minutes. 10x glycine solution (Pierce Agarose ChIP 
kit, cat no. 26156) was then added and left to incubate for five minutes to stop the reaction. 
After the media had been removed, the cells were washed twice with ice-cold PBS solution. 
The cells were then detached by scraping with ice-cold PBS along with protease and 
phosphatase inhibitor (Pierce Agarose ChIP kit). The cells were pelleted before proceeding 
to cell lysis and micrococcal nuclease digestion.
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Figure 2.13.1: Schematic of formaldehyde crosslinking step of chromatin immunoprecipitation (ChIP) and ChIP workflow. 
(A) Formaldehyde crosslinking chemistry. (B) Depending on the length of formaldehyde crosslinking, only direct DNA-protein 
interaction could be crosslinked (short fix – line: DNA and circles: proteins) or indirectly associated proteins could also be crosslinked 
(longer fix). (C) Six steps of a ChIP workflow. Adapted from
156,157,158
.
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 The cells were lysed according to the manufacturer’s instructions while the 
micrococcal nuclease digestion had been optimized previously. The digested chromatin was 
then immunoprecipitated with either the positive control antibody (anti-RNA polymerase 
II), or the negative control antibody (rabbit IgG) or the target specific antibody overnight. 
ChIP grade protein A/G plus agarose beads were then used to capture the 
immunoprecipitates. After washing, the beads were washed before elution. De-crosslinking 
was achieved by incubation in a 65°C water bath for 40 minutes before digesting the 
proteins using proteinase K. DNA fragments were then recovered using a DNA clean-up 
column before proceeding with PCR. 
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3 Chapter 1 Results  
 
3.1 Subcellular fractionation of nuclear and cytoplasmic extracts 
 
As a lot of the work involved DNA-binding proteins and SNP rs242557, a 
reproducible and effective means of isolating nuclear extracts from human neuroblastoma 
cell lines was needed. Obtaining nuclear extracts was carried out using a commercially 
available kit from Pierce (NE-PER® nuclear and cytoplasmic extraction kit). This ensured 
that there was little variation between the different batches of nuclear extracts. SH-SY5Y 
(SKY5) and BE3-M17 (M17) human neuroblastoma cell lines were used for their neuron-
like properties. To validate the purity of cytoplasmic and nuclear extracts derived from 
SKY5 and M17 cells, antibodies against glyceraldehyde-3-phosphate (GAPDH) and 
histone deacetylase 1 (HDAC1) were used, respectively.  All western blots were carried out 
in independent biological triplicate experiments as shown and the bands quantified using 
Bio-Rad’s Quantity One software. 
 
GAPDH is primarily located in the cytoplasm where it catalyses the reversible 
oxidative phosphorylation of glyceraldehyde-3-phosphate. During apoptosis, however, 
GAPDH translocates into the nucleus. Hence, as can be seen in Figure 3.1.1, even though 
there was more GAPDH in the cytoplasmic extract of both cell lines, this was 
approximately four (M17) to six (SKY5) as much as those seen in the nuclear extracts 
which was a significant (p<0.05) cytoplasmic protein enrichment. 
 
HDAC1 is a nuclear protein which catalyses the deacetylation of histones. This is 
associated with transcriptional silencing. In Figure 3.1.1, the nuclear extracts were enriched 
with three (M17) to nine (SKY5) times more HDAC1 as compared to the cytoplasmic 
extracts. Although there was no significant (p=0.08) enrichment of nuclear proteins with 
M17, SKY5 did show significant (p<0.05) and robust enrichment. This shows that the 
nuclear extraction kit is effective in fractionating and enriching the nuclear proteins from 
the cell line SH-SY5Y. 
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Figure 3.1.1: Western blot of undifferentiated SKY5 & M17 cytoplasmic (Cyt) and nuclear (Nuc) extracts with polyclonal 
cytoplasmic- (anti-GAPDH) and nuclear- (anti-HDAC) specific antibodies. These were done in triplicate, *: p<0.05, n.s.: non-
significant (Two-tailed T-test). 
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3.2 Chemiluminescent electrophoretic mobility shift assay (EMSA) 
 
Biotin-labelled 23-mer oligonucleotide probes containing the H1c-A and H1b/H2-G 
allelotypes of rs242557 were incubated with nuclear extracts of undifferentiated SH-SY5Y. 
Complexes containing the probe and DNA-binding proteins migrated slower through the 
native gel compared to the free probe. Non-specific binding was blocked using poly-(dI.dC) 
oligonucleotides. Specificity of binding between DNA-binding proteins and the probe 
containing rs242557 was demonstrated using unlabelled probe, which competed out 
binding to the labelled probe.  
 
The results in Figure 3.2.1 showed that the H1b/H2-G allelotype of rs242557 was 
able to recruit more DNA-binding proteins as compared to the A allelotype. On an average 
of five independent experiments, the H1b/H2-G allelotype pulled down four fold more 
nuclear proteins than the H1c-A allelotype normalised against the amount of free biotin 
probe (p<0.01). 
 
This result was promising as it demonstrated a potential biological significance of a 
SNP that has been associated with increased risk of sporadic PSP, CBD and AD. The next 
step was to characterize these DNA-binding proteins by identifying them and to investigate 
if there were any nuclear proteins that differentially bind to the H1c-A or H1b/H2-G 
allelotypes.
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Figure 3.2.1: EMSA of rs242557 H1c-A or H1b/H2-G variant.  
Biotin-labelled 23-mer oligonucleotides containing the A (H1c) and G (H1b & H2) allelotypes of rs242557 were incubated with 
nuclear extracts from undifferentiated SH-SY5Y cells. Incubation with unlabelled probe confirmed the specific interaction between 
probe and nuclear proteins. On average, the H1b/H2-G allelotype had 4-fold more blot density than the H1c-A allelotype. Five 
replicates were done. As replicate 3 was an outlier, only repliactes 1-2 and 4-5 were used for the average and standard deviation. *: 
p<0.01, two-tailed T-test.  
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3.3 Affinity purification of DNA-binding proteins 
 
To purify these DNA-binding proteins, much larger quantities of nuclear extracts 
were used. In order to maximize capture of the nuclear proteins of interests, concatamers of 
the 23-mer oligonucleotide binding site containing either the H1c-A or H1b/H2-G 
allelotype of rs242557 were created using PCR (see 2.1.2). These were ligated to DNA 
linkers that were biotin-streptavidin linked to magnetic beads using T4 DNA ligase and 
incubated with the nuclear extracts. The beads were washed thoroughly to remove unbound 
proteins and eluted with a 3.5 M potassium chloride salt elution.  
 
As illustrated in Figure 3.3.1, there was not much difference between the washes 
and the supernatants indicating that only a few specific proteins were bound to the probe. 
When the SDS-containing sample buffer was added to the elution, however, a SDS-soluble 
fraction (Figure 3.3.1) and a less SDS-soluble fraction formed. More SDS-containing 
sample buffer, heating and vortexing were needed to solubilise the less SDS-soluble 
fraction. Elution bands from both gels that were of sufficient intensity and/or of different 
intensity between H1c-A and H1b/H2-G were sliced with a clean scalpel and analysed by 
mass spectrometry (see 3.4).  
 
We were now able to observe in greater detail the allele-specific differences of 
discrete protein bands of promoter trapped DNA-binding proteins. Although the eluted 
proteins were spread across two gels, looking from the protein identification, only two 
proteins were common to both at the same gel band, poly ADP ribose polymerase 1 
(PARP1) and actin. Actin, however, had more of it bound to the H1b/H2-G allelotype of 
rs242557 for both gels and was identified as the only protein within those gel bands. Bands 
34 and 31 kDa (Histone H1.5 and fumarate hydratase as identified later) were similar to 
actin in being the only protein present in a band that could be identified and bound more 
strongly to H1b/H2-G. Other gel bands that had more than one protein identified made it 
difficult at this stage to decipher which protein was responsible for such allelic differences. 
Bands 95, 89, 64, 44, 42, 34, 32, 28 kDa, however, were bands like actin that had one 
protein confidently present in each band but unlike actin interacted with the H1c-A 
allelotype of rs242557 more strongly. These bands were subsequently identified (see 3.4) as 
DNA topoisomerase 1 (TOP1), nucleolin (NUCL), replication protein (RPA70), 
 73 
heterogeneous ribonucleoprotein D0 (ROD), nucleolar RNA helicase II (DDX21), H1 
histone (H1.2 or H1.4), high mobility group protein 2 (HMGB2). 
 
Thus, one SNP seems to have the ability to vary protein-DNA interaction subtlely 
as in the case of the HMG proteins or more pronouncedly as in the case of DDX21. How 
these proteins were identified and the significance of their identifications will be discussed 
in the following section. 
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Figure 3.3.1: SDS-PAGE gel of DNA-binding proteins purified using concatamerised probes of the region containing the H1c-A and 
H1b/H2-G allelotypes of rs242557 incubated with nuclear extracts of undifferentiated SH-SY5Y, less SDS-soluble fractions on the 
right. 
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3.4 Identification of DNA-binding proteins 
 
To identify the allele-specific binding of proteins to rs242557, as many discrete 
bands that were visible to the eye were cut carefully using a clean scalpel. A general guide 
for proteins with sufficient yield for MS sequencing was that they were visible on 
Coomassie stained protein gels. As these proteins had been separated on a 1-D gel, each 
protein band might include more than one protein of interest. Performing MALDI-QTOF 
on the bands characterized the most abundant protein within a band based on the molecular 
weight of the digests. Hence it was necessary to carry out ESI-QTOF/TOF sequencing the 
digested peptide fragments and was sensitive enough to characterize other proteins within 
the same protein gel band. MS data generated from the runs were translated into protein hits 
using the manufacturer’s software. In total, there were 43 protein hits from 22 protein bands, 
37 of which were unique (Table 3.4.1). Ten protein bands yielded single protein 
identifications while 11 protein bands yielded multiple protein identifications between two 
to five protein matches. One protein band did not have sufficient peptides for any positive 
identification. It was more difficult to positively identify some of the histone linker H1 
proteins as there were different isoforms and the peptides sequenced did not match to the 
unique regions of any isoforms (H1.2 – 1.4). The known molecular weights of most of the 
proteins identified matched well with the observed molecular weights of the gel bands from 
which they were identified from. The exceptions were the 20 kDa H1 proteins that were the 
only proteins identified in the 93 kDa band, the 80 kDa nucleolar RNA helicase II in the 
34.1 kDa band and the 55 kDa fumarate hydratase in the 30.7 kDa band. The smaller 
molecular weight proteins found in a larger gel band might be due to the different isoforms 
of H1 interacting with each other or multimers of the same isoform or they might be 
interacting with another protein that was not identified. A larger protein might have been 
truncated or fragmented or partially degraded that might have resulted in it being identified 
in a smaller molecular weight gel band. 
 
A positive identification of a protein depends on various factors: the abundance of 
protein within a gel band, the efficiency of the trypsin digestion, the condition of the 
peptide, the size and composition of the peptide. Waters analysis and scoring system, 
ProteinLynx Global Server (PLGS) used the selectivity of the exact mass measured data, 
the specificity of the analysis coupled with filtering and scoring routines to generate the 
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PLGS score. These were also manually verified to prevent mis-assignment of spectra. A 
score above 10 was usually considered as highly confident identification. For example, 
hnRNPU was identified from a one peptide that represented 2.2% of the protein while 
myosin heavy chain was identified from 55 peptides that accounted for 30.5% of the 
protein. Both were assigned a score of 11.6. The specificity and uniqueness of a peptide to 
protein match was significant regardless of protein coverage. Even 13 peptides that 
represented 44.5% coverage for actin was assigned a score of 8.4, possibly due to the poor 
fragmentation data for some of the peptides or the lack of specificity of the peptide match. 
 
A positive control was found with the identification of bacteriophage T4 DNA 
ligase. It was used to ligate the concatamers of the rs242557-containing oligonucleotides to 
the linker DNA attached to the magnetic beads. Twenty four peptides covering 46% of the 
protein with a PLGS score of 11.6 gave a confident identification for this protein. However, 
the fact that the ligase carried over could have led to spurious non-specific protein-protein 
interactions with some of the other proteins in the pull-down assay. 
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No Band 
ID 
(kDa) 
Accession 
no. 
Protein ID Gel bands were 
from / Abb. 
Theoretical  
MW (Da) 
Peptide sequence or % 
coverage 
PLGS 
score 
1 201.5 P35580 Myosin Heavy Chain 2 / MYH10 228796 30.5% coverage 11.6 
O75643 U5 snRNP 200 kDa helicase 2 / U5-200 194354 3.4% coverage 11.6 
P35579 Myosin  heavy chain nonmuscle A 2 / MYH9 226390 25.4% coverage 11.6 
P35749 Smooth muscle myosin heavy chain 2 / MYH11 227339 4.0% coverage 11.2 
2 109.4 P09874 Poly ADP ribose polymerase 1 / PARP1 112881 33.5% coverage 11.6 
3 103.5 P09874 Poly ADP ribose polymerase 2 / PARP1 112881 39.5% coverage 11.6 
O00159 Myosin 1c 2 / MY1C 117965 3.7% coverage 11.6 
Q00839 hnRNP U 2 / hnRNPU 90422 2.2% coverage 11.6 
Q9H9Y6 DNA directed RNA polymerase I 2 / PPOL 122058 2.4% coverage 11.6 
Q8IXJ3 U5 snRNP 116 kDa 2 / U5-116 95372 6.2% coverage 10.6 
4 95.4 P11387 DNA topoisomerase I 1 / TOP1 90668 See Figure 3.4.5 11.6 
P19338 Nucleolin Protein C23 1 / NUCL 76167 GLSEDTTEETLK 
GFGFVDFNSEEDAK 
10.2 
5 93 P16403 Histone H1.2 /H1d 2 / H1.2 21220 ASGPPVSELITK 
SGVSLAALK 
7 
P10412 Histone H1.4 /H1b 2 / H1.4 21720 
 6.9 
P16402 Histone H1.3 /H1c 2 / H1.3 22205 
 6.9 
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P16401 Histone H1.5 /H1a 2 / H1.5 22435 ATGPPVSELITK 10.8 
6 64 P27694 Replication protein A 70kDa 2 / RPA70 68095 25 % coverage 11.6 
7 59/57 N.A. Not enough peptides 1 / - N.A. N.A. N.A. 
8 55 Q15233 NONO 2 / NONO 54066 44.5 % coverage 11.6 
P26368 U2AF2 2 / U2AF2 53467 16.2% coverage 10.9 
P26599 PTBP1 2 / PTBP1 57185 4.3% coverage 10.2 
9 52.5 P08670 Vimentin 2 / VIM 53522 7.3% coverage 11.6 
P00970 DNA Ligase from Bacteriophage T4 2 / T4DNAL 55257 46 % coverage 11.6 
10 49/47 P35659 DEK protein 1 / DEK 42647 45.9 % coverage 11.6 
P04687 Tubulin a1 chain brain specific 1 / TUBA 50125 4.4% coverage 8.9 
11 48.3 P02570 Actin 2 / Actin 41709 44.5 % coverage 8.4 
12 44.5 P02570 Actin 1 / Actin 41709 36.3% coverage 10.0 
13 43.9 Q14103 hnRNP D0 1 / ROD 38410 DLKDYFSK 
FGEVVDCTLK 
IFVGGLSPDTPEEK 
11.6 
14 42.2 Q14103 hnRNP D0 1 / ROD 38410 IFVGGLSPDTPEEK 9.3 
15 34.3 P16401 Histone H1.5 /H1a 2 / H1.5 22435 ATGPPVSELITK 10.8 
16 34.1 Q9NR30 Nucleolar RNA helicase II 1 / DDX21 79607 APQVLVLAPTR 11.0 
17 31.6 P16403 Histone H1.2 /H1d 1 / H1.2 21220 SGVSLAALK 8.3  
 
8.3 
P10412 Histone H1.4 /H1b 1 / H1.4 21720 
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18 30.7 P07954 Fumarate Hydratase 2 / FUMH 54602 YAMT RIKAAMPR 11.6 
19 30.0 P09429 High mobility group protein 1 1 / HMGB1 24747 48.1% coverage 10.2 
Q92522 Histone H1x 1 / H1x 22473 5.6% coverage 11.6 
P12324 Tropomyosin cytoskeletal type 3 1 / TPMN 29014 13.3% coverage 10.9 
Q86V81 Thoc4/ALY 1 / ALY 26871 24.9% coverage 11.2 
Q8WU19 Tubulin  1B 1 / TUBA 37194 11.3% coverage 10.7 
20 28.2 P26583 High mobility group protein 2 1 / HMGB2 23887 48.1% coverage 10.5 
21 21.6 P29316 60S ribosomal protein L23a 2 / RL2B 17684 LAPDYDALDVANK 11.6 
P23284 Peptidyl prolyl cis trans isomerase E 2 / CYPB 22728 TVDNFVALATGEK 10.2 
22 16 P25111 40S ribosomal protein S25 1 / RS25 13733 LITPAVVSER 
AALQELLSK 
11.6 
P17096 High mobility group protein A1 1 / HMGA1 11538 KQPPVSPGTALVGSQK 10.9 
 
Table 3.4.1: List of protein hits from MS data.  
Proteins highlighted in green had been positively identified within the protein bands excised using PLGS. Those in yellow had the possibility 
of being present in the bands. It was possible for some of the 1-D protein bands to yield more than 1 protein identification. ProteinLynx 
Global Server (PLGS) was Waters analytical platform which matched MS spectra against those generated from proteins in the Swissprot and 
Uniprot databases and generated the PLGS score. The higher the score, the higher the confidence in the match.
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A closer look at the analysis of the peptide sequencing (Appendix, figures 3.4.2 – 
3.4.19) revealed that some of the matches were to exact sequences (coloured blue), partial 
match (coloured red), modified match (coloured green), partial modified match (coloured 
yellow). For those proteins that were identified that had extensive peptide coverage such as 
myosin (Appendix, figure 3.4.2), PARP1 (Appendix, figures 3.4.3 & 3.4.4), RPA70 
(Appendix, figure 3.4.8), Non-POU domain-containing octamer-binding protein (NONO) 
protein (Appendix, figure 3.4.9), actin (Appendix, figure 3.4.11), HMGB2 (Appendix, 
figure 3.4.17), the coverage for each protein was fairly evenly distributed across the protein 
sequence and not skewed.  
 
For the rest of the proteins without extensive peptide coverage, a closer look into 
the fragmentation patterns (b and y ions) was done. The b or y ions were formed from the 
most common cleavage site along the peptide backbone (CO-NH). Such a cleavage resulted 
in a neutral and a charged species. When the charge remained on the N-terminal fragment, 
b ions were generated while y ions were the result of the charge being on the C-terminal 
fragment. For most of these proteins such as DNA topoisomerase I (Appendix, figure 3.4.5), 
nucleolin (Appendix, figure 3.4.5 continued), hnRNPD0 (Appendix, figure 3.4.13), 
nucleolar RNA helicase II (Appendix, figure 3.4.14), 60S ribosomal protein L23a 
(Appendix, figure 3.4.18), peptidyl prolyl cis trans isomerise E (Appendix, figure 3.4.18 
continued) and 40S ribosomal protein S25 (Appendix, figure 3.4.19), they had well-defined 
y fragmentation pattern for each of the amino acids but their b fragmentation patterns were 
not as defined. H1.5 (Appendix, figure 3.4.6), H1.2/1.3/1.4 (Appendix, figure 3.4.7), T4 
DNA ligase (Appendix, figure 3.4.10), hnRNPD0 (Appendix, figure 3.4.12) and HMGB1 
(Appendix, figure 3.4.16), however, had both clearly defined b and y fragmentation 
patterns which yield more confidence in their protein prediction. Fumarate hydratase 
(Appendix, figure 3.4.15) and HMGA1 (Appendix, figure 3.4.19 continued) neither had 
good b and y fragmentation patterns and since fumarate hydratase was of a different 
molecular weight to the gel band, its protein identification might be less significant.
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3.5 Bioinformatics on DNA-binding proteins 
 
 To stratify the 36 unique proteins that had been previously identified through mass 
spectrometry into a hierarchy of manageable numbers of relevant proteins, several 
approaches were adopted. Besides the crude method of visually discriminating protein 
bands from Figures 3.3.1 and 3.3.1 (continued) for allelic effects, different bioinformatic 
tools such as Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) v 8.0 
which discerned proteins according to their known or predicted protein-protein interactions, 
Reactome which grouped proteins by the reaction pathways they were known to be 
involved in. Lastly, transcription factor prediction software was used to highlight the 
likelihood of transcription factors recognizing and binding to the rs242557-containing 
oligonucleotides used.  
   
In order to understand the functional interactions between these proteins, STRING 
was used to trawl through databases, text-mining, experiments and co-expression studies to 
identify functional networks amongst the protein hits. In doing so, it was possible to rank 
the hits according to how likely they are to form complexes as opposed to the false 
positives.  
  
Figure 3.5.1 is an example of how STRING v 8.0 displays its results, using the 
highest confidence set of proteins as an example. At such confidence, a 30% coverage of 
the proteins identified or 15 proteins fell into this category. Hence, in terms of validating 
these proteins, it was logical to validate the proteins of the highest confidence first. Most of 
these proteins formed a complex (U2AF2, PTBP1, hnRNPU, hnRNPD0, ALY/Thoc4, U5 
SNRNP 200). This complex is involved in splicing which might be important especially in 
light of the complex splicing pattern of tau. The rest of the proteins (nucleolin, DNA 
topoisomerase 1 and NONO) were important in DNA binding and transcription activation 
or silencing. Thus, these proteins suggested a possible coordination between chromatin 
remodeling and splicing. The rest were cytoskeletal proteins such as actin, tubulin, myosin, 
tropomyosin and vimentin. These could be contamination from the cytoplasm or relevant 
architectural proteins. 
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A slight reduction in confidence level to high confidence, Figure 3.5.2, (21 proteins, 
4% coverage) showed the possibility of the non-splicing proteins to interact with each other 
and with the aid of PARP1. Another HMG protein, HMGA1 and the association between 
the HMG proteins were also revealed.  DEK, an oncoprotein, was also shown to interact 
with the splicing complex.  
 
At the medium confidence level, Figure 3.5.3 (29 proteins, 58% coverage) although 
some of the proteins included such as  nucleolar RNA helicase II, RNA-dependent helicase, 
myosin 1C, and other members of the H1 family proved to be more of satellite interactors, 
not adding much more to the picture, it is interesting to note that H1c was shown to interact 
with both PARP1 and DNA topoisomerase 1.  
 
The result of the STRING analysis has been summarized in Table 3.5.5 have been 
colour-coded in such a way that the first set of proteins include those that have highest 
confidence in associating with each other.
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Figure 3.5.1: Highest confidence (0.9=P=1) protein-protein interactions 
amongst proteins identified through MS.  
Blue lines represent associations based on databases. Yellow lines represent 
associations based on text-mining. Grey lines represent associations based on co-
expression studies. Purple lines represent associations from co-
immunoprecipitation experiments. Light blue lines represent putative homologs 
interacting in other species. Obtained using String v. 8.0 (string.embl.de). Size of 
nodes and length of lines are arbitrary. 
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 Figure 3.5.2: High confidence (0.7=P=0.9) protein-protein interactions 
amongst proteins identified through MS.  
Blue lines represent associations based on databases. Yellow lines represent 
associations based on text-mining. Grey lines represent associations based on 
co-expression studies. Purple lines represent associations from co-
immunoprecipitation experiments. Light blue lines represent putative homologs 
interacting in other species. Obtained using String v. 8.0 (string.embl.de). Size 
of nodes and length of lines are arbitrary. 
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Figure 3.5.3: Medium confidence (0.4=P=0.7) protein-protein interactions amongst proteins identified through MS.  
Blue lines represent associations based on databases. Yellow lines represent associations based on text-mining. Grey lines represent 
associations based on co-expression studies. Purple lines represent associations from co-immunoprecipitation experiments. Light 
blue lines represent putative homologs interacting in other species. Obtained using String v. 8.0 (string.embl.de). Size of nodes and 
length of lines are arbitrary. 
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No Accession  UniProt 
Name 
Full Name, Gene Name, Chromosome 
Number 
(kDa) 
1 P26599 PTB_HUMA
N 
Polypyrimidine tract binding protein, PTBP1/PTB, 
Chr 19 
57.2 
2 P26368 U2AF_HUM
AN 
Splicing factor U2AF 65 kDa subunit U2 auxiliary, 
U2AF2, Chr 19 
53.5 
3 Q00839 ROU_HUMA
N 
Heterogeneous nuclear ribonucleoprotein U, 
HNRNPU/SAFA, Chr 1 
90.5 
4 Q14103 ROD_HUMA
N 
Heterogeneous nuclear ribonucleoprotein D0, 
HNRNPD/AUF1, Chr 4 
38.4 
5 Q86V81 THOC4_HU
MAN 
THO complex subunit 4, THOC4/ALY/BEF, Chr 17 26.9 
6 O75643 U520_HUM
AN 
U5small nuclear ribonucleoprotein 200kDa helicase, 
SNRNP 200, Chr2 
244.5 
7 Q8IXJ3 Q8IXJ3_HU
MAN 
small nuclear ribonucleoprotein component, SNRP 
116, Chr 17 
95.4 
8 P19338 NUCL_HUM
AN 
Nucleolin Protein C23, NCL, Chr 2 76.6 
9 Q15233 NR54_HUM
AN 
54 kDa nuclear RNA and DNA binding protein, 
NONO/NRB54, Chr X 
54.2 
10 P08670 VIME_HUM
AN 
Vimentin, VIM, Chr 10 53.7 
11 P11387 TOP1_HUM
AN 
DNA Topoisomerase I, TOP1, Chr 20 90.7 
12 P12324 TPMN_HUM
AN 
Tropomyosin cytoskeletal type 3, TPM3, Chr 1 32.8 
13 P35579 MYH9_HUM
AN 
Myosin heavy chain nonmuscle type A, MYH 9, Chr 
22 
226.5 
14 P35580 MYHA_HU
MAN 
Myosin Heavy Chain nonmuscle type B, MYH10, Chr 
17 
229.0 
15 P35749 MYH11_HU
MAN 
Smooth muscle myosin heavy chain, MYH11, Chr 16 121.9 
16 P35659 DEK_HUMA
N 
DEK protein, DEK, Chr 6 42.7 
17 P60709 ACTB_HUM
AN 
Actin, ACTB, Chr 7 41.7 
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18 P09429 HMG1_HUM
AN 
High mobility group protein, HMGB1/HMG1, Chr 13 24.9 
19 P26583 HMG2_HUM
AN 
High mobility group protein HMG2, HMGB2, Chr 4 24.0 
20 P09874 PPOL_HUM
AN 
Poly ADP ribose polymerase, PARP1/ADPRT/PPOL, 
Chr 1 
113.1 
21 P17096 HMGI_HUM
AN 
High mobility group protein, HMGA1/HMGIY, Chr 6 11.7 
22 Q92522 H1X_HUMA
N 
Histone H1x, H1FX, Chr 3 22.5 
23 P62750 RL2B_HUM
AN 
60S ribosomal protein L23a, RPL23A, Chr 17 17.7 
24 Q8WU19 Q8WU19_H
UMAN 
TUBA1B, TUBA1B, Chr 12 37.2 
25 P16403 H12_HUMA
N 
Histone H1.2 Histone 1d, HIST1H1C, Chr 6 21.4 
26 P16402 H13_HUMA
N 
Histone H1.3 Histone H1c, HIST1H1D, Chr 6 22.4 
27 O00159 MY1C_HUM
AN 
Myosin 1C, MYO1C, Chr 17 117.9 
28 Q9H9Y6 RPA2_HUM
AN 
DNA-directed RNA polymerase I 135kDa 
polypeptide, POLR1B, Chr 2 
128.2 
29 Q9NR30 DDX21_HU
MAN 
Nucleolar RNA helicase II, DDX21, Chr 10 87.4 
30 P27694 RFA1_HUM
AN 
Replication protein A 70 kDa binding subunit, 
RPA1/RPA70, Chr 17 
68.1 
31 P62851 RS25_HUM
AN 
40S ribosomal protein S25, RPS25, Chr 11 13.7 
32 P07954 FUMH_HUM
AN 
Fumarate Hydratase, FH, Chr 1 54.6 
33 P10412 H14_HUMA
N 
Histone H1.4 Histone 1b, HIST1H1E, Chr 6 21.9 
34 P16401 H15_HUMA
N 
Histone H1.5 Histone 1a, HIST1H1B, Chr 6 22.6 
35 Q71U36 TBA1_HUM
AN 
Tubulin alpha 1 chain brain specific, 
TUBA1A/TUBA3, Chr 12 
50.1 
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36 P23284 CYPB_HUM
AN 
Peptidyl prolyl cis trans isomerase E, PP1B/CYPB, 
Chr 15 
23.7 
Table 3.5.4: List of protein hits from MS data generated after STRING analysis.  
Proteins highlighted in green are of highest confidence of interacting with each other. 
Those in orange are of high confidence, red for medium confidence, purple for low 
confidence and uncoloured for those with no known interactions as indicated by STRING v. 
8.0.
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3.6 Further bioinformatics on DNA-binding proteins 
 
While STRING was useful in shedding some light on the proteins identified, their 
interactions with each other and providing a rough framework to choose candidate proteins 
to carry through, it is still one bioinformatics tool rooted in protein-protein interactions. 
 
 Another bioinformatics tool, Reactome, took the list of submitted proteins and 
allocated them based on the reaction event(s) they are known to be involved in according to 
a database of curated reaction pathways. Each reaction event could consist of a few 
molecules to hundreds of molecules. For example, in Figure 3.6.1 (A) – (D), pathways 
involved in gene expression are highlighted by a series of arrows, each representing a 
particular event within the pathway. More specific events such as formation and maturation 
of mRNA transcript, processing of capped intron-containing pre-mRNA and mRNA 
splicing constitute smaller pathways within gene expression.  
 
 Once a list of protein identifiers was submitted, the skypainter tool displayed all the 
curated reactions and ‘painted’ or allocated the proteins to their respective reaction event. 
The more proteins that cluster around the same reaction event, the warmer the colour. As 
can be seen from Figure 3.6.1, most of the proteins (7 proteins) have functions within the 
mRNA splicing pathway. As it was a manually curated database, Reactome’s strength lies 
on the extensiveness of their database. Hence, 20 proteins (40% coverage) compared to 
STRING’s 88% coverage of proteins identified was to be reasonably expected.  
 
 A breakdown of each reaction event within mRNA splicing in which the proteins 
were involved in is illustrated in Table 3.6.2. The proteins first involved at the very 
beginning of the mRNA splicing pathway are hnRNPU, hnRNPD0 and PTBP1. This could 
possibly suggest that of all the proteins identified, these were the most likely direct 
interactors with DNA and/or mRNA. However, the reaction event that had the highest 
probability was the formation of the spliceosomal complex B. This was the earliest event 
within the mRNA splicing pathway that incorporated seven of the proteins identified. 
Subsequent downstream events were singled out as well since they involved the same seven 
proteins. However, it was harder to differentiate when a protein was recruited into a 
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complex from when it executed its function within a complex from remaining in the 
complex after its execution. 
 
 Other less represented pathways included the U12-dependent splicing pathway as 
well as the cleavage of mRNA at the 3’ end and polyadenylation, Table 3.6.2 continued.
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 Figure 3.6.1: Reactome over-representation analysis using Skypainter.  
All annotated reaction pathways are indicated as arrows and laid out. (A) Reactome clusters the proteins of interests into the reaction 
pathways they act upon. (B) Specifically, most of the proteins are involved in mRNA splicing with the warmer colours indicating more of 
the submitted proteins being involved in a reaction pathway. Numbered reactions elaborated in Figure 3.9. Obtained from 
www.reactome.org.  
(A) 
(B) 
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No. 
False 
discovery 
rate 
Un-adjusted 
probability of 
seeing N or more 
genes in this Event 
by chance 
Number of 
genes in your 
query which 
map to this 
Event 
Total 
number of 
genes 
involved in 
this Event 
Identifier of this 
Event Name of this Event 
Submitted identifiers mapping to this 
Event 
1 - 0.000391869 3 34 REACT_1877 Formation of pre-mRNPs hnRNPU, hnRNPD0, PTBP1 
2 - 7.12E-06 5 66 REACT_222 
Formation of the 
Spliceosomal E complex 
hnRNPU, THOC4, hnRNPD0, U2AF2, 
PTBP1 
3 - 2.34E-05 5 84 REACT_788 
Formation of the 
Spliceosomal A Complex 
hnRNPU, THOC4, hnRNPD0, U2AF2, 
PTBP1 
4 - 9.97E-08 7 97 REACT_48 
Formation of the 
Spliceosomal B Complex 
hnRNPU, U2AF2, U5 SNRNP200, PTBP1, 
hnRNPD0, THOC4, U5 SNRNP116 
5 - 2.24E-07 7 109 REACT_625 
Formation of an 
intermediate Spliceosomal 
C complex 
hnRNPU, U2AF2, U5 SNRNP200, PTBP1, 
hnRNPD0, THOC4, U5 SNRNP116 
6 - 1.73E-07 7 105 REACT_1554 
Formation of the active 
Spliceosomal C complex 
hnRNPU, U2AF2, U5 SNRNP200, PTBP1, 
hnRNPD0, THOC4, U5 SNRNP116 
7 - 1.85E-07 7 106 REACT_1935 
Lariat Formation and 5'-
Splice Site Cleavage 
hnRNPU, U2AF2, U5 SNRNP200, PTBP1, 
hnRNPD0, THOC4, U5 SNRNP116 
8 - 2.10E-07 7 108 REACT_774 
Formation of Exon Junction 
Complex 
hnRNPU, U2AF2, U5 SNRNP200, PTBP1, 
hnRNPD0, THOC4, U5 SNRNP116 
9 - 2.10E-07 7 108 REACT_1331 
Cleavage at the 3'-Splice 
Site and Exon Ligation 
hnRNPU, U2AF2, U5 SNRNP200, PTBP1, 
hnRNPD0, THOC4, U5 SNRNP116 
 
Table 3.6.2: List of reactome events over-represented by proteins of interest. 
Proteins of interest were matched to the reaction events they participated in. The events have been ordered according to the reaction pathway 
they follow, refer to Figure 3.8 (G). The warmer the colour, the higher the probability of the proteins involved in the reaction event. 
Un-adjusted probability refers to no correction for multiple testing. Probability was carried out using the hypergeometric test.
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No. 
False 
discovery 
rate 
Un-adjusted 
probability of seeing 
N or more genes in 
this Event by chance 
Number of genes 
in your query 
which map to this 
Event 
Total number 
of genes 
involved in this 
Event 
Identifier of this 
Event Name of this Event 
Submitted identifiers mapping 
to this Event 
10 - 0.014680417 2 43 REACT_1253 
Formation of AT-AC B 
Complex U5 SNRNP116, U5 SNRNP200 
11 - 0.014680417 2 43 REACT_1615 
Formation of AT-AC C 
complex U5 SNRNP116, U5 SNRNP200 
12 - 0.014680417 2 43 REACT_2241 
ATAC spliceosome mediated 
Lariat formation,5' splice site 
cleavage U5 SNRNP116, U5 SNRNP200 
13 - 0.014680417 2 43 REACT_1494 
ATAC spliceosome mediated 
3' splice site cleavage, exon 
ligation U5 SNRNP116, U5 SNRNP200 
14 - 0.009337753 2 34 REACT_1914 
Cleavage of mRNA at the 3'-
end THOC4, U2AF2 
15 - 0.005950512 2 27 REACT_1162 mRNA polyadenylation THOC4, U2AF2 
 
Table 3.6.2 continued: List of reactome events over-represented by proteins of interest. 
Proteins of interest were matched to the reaction events they participated in. The events have been ordered according to the reaction pathway 
they follow, refer to Figure 3.8 (G). The warmer the colour, the higher the probability of the proteins involved in the reaction event. 
Un-adjusted probability refers to no correction for multiple testing. Probability was carried out using the hypergeometric test.
 94 
3.7 In silico prediction of transcription factors binding to rs242557 region 
 
 Apart from the de novo identification of DNA-binding proteins that interact with the 
sequences for H1c-A and H1b-G flanking the rs242557 polymorphism – the same sequence 
used for the EMSA experiment (Figure 3.2.1) and pull-down / mass spectrometry 
experiment (Figure 3.3.1), was analysed by software such as MatInspector and Transfac to 
predict potential transcription factor binding sites and this yielded potentially promising 
leads.  
 
 First, MatInspector (Table 3.7.1) predicted less transcription factors compared to 
Transfac (Table 3.7.2) with differential binding to H1c-A and H1c-G. Only one protein, the 
erythroid krueppel like factor (EKLF) protein, was predicted to bind to the positive strand 
of H1c-A, stretching across 74% of the sequence. However, EKLF is also predicted to bind 
to H1b-G suggesting that this binding is not dependent on alleles. Selenocysteine tRNA 
gene transcription activating factor (Staf) protein is predicted to bind to H1b-G but not 
H1c-A. MatInspector, had Staf with the lowest confidence score even though it had a 100% 
coverage of the input sequence. Transfac had also predicted that Staf would bind to H1b-G 
more than it would bind to H1c-A, however unlike MatInspector, it had assigned Staf with 
the highest score for H1b-G. 
 
   The next transcription factor suggested binding to H1b-G more than H1c-A by 
both MatInspector and Transfac was CP2. It had an 83% sequence coverage. What made 
CP2 different to the other proteins was that it was predicted to bind to the negative strand of 
the sequence used. This could possibly explain why Transfac had lower confidence in 
predicting CP2 over Staf whereas MatInspector had more confidence in CP2 over Staf.  
 
 Lastly, MatInspector predicted Hypermethylated in cancer 1 (HIC1) with the 
highest score to bind to 57% of the input sequence. Although it was the smallest coverage, 
the motif which the protein recognized was where rs242557 resided. Since multiple binding 
sites are required for optimal binding, it made it harder to ascertain the relevance of this 
prediction. It was also probably why HIC1 did not feature in Transfac’s prediction.  
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No. H1c-A Position 
from 
Strand Score Sequence 
1 EKLF (Erythroid krueppel 
like factor) 
2-18 + 0.896 
tcgcccaGGGTacacca 
 
No. H1b-G Position 
from 
Strand Score Sequence 
1 STAF (Se-Cys tRNA gene 
transcription activating 
factor) 
1-23 + 0.803 ttcgCCCAgggtgcaccagg
aca 
2 EKLF (Erythroid krueppel 
like factor) 
2-18 + 0.925 tcgcccaGGGTgcacca 
3 CP2 [LBP-1c (leader-
binding protein-1c), LSF 
(late SV40 factor), CP2, 
SEF (SAA3 enhancer 
factor)] 
3-21 - 0.843 tCCTGgtgcaccctgggcg 
4 HIC1 (Hypermethylated in 
cancer 1, transcriptional 
repressor containing five 
Krüppel-like C2H2 zinc 
fingers, for optimal binding 
multiple binding sites are 
required.) 
7-19 + 0.937 cagggTGCAccag 
 
Table 3.7.1: List of predicted transcription factors to bind to H1c-A and H1b-G 
according to MatInspector. 23 base pair sequences for H1c-A 
(TTCGCCCAGGGTACACCAGGACA) and H1b-G 
(TTCGCCCAGGGTGCACCAGGACA) were submitted to MatInspector and a list of 
potential transcription factors that could bind was then generated. 
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No. H1c-A Score H1b-G Score No. H1c-A Score H1b-G Score 
1 Ik-3    74.9 Staf    75.0 21 GATA-2 65.2 C/EBPa 63.3 
2 deltaE  71.9 deltaE  71.9 22 c-Rel   64.5 Egr-1  63.0 
3 E47  71.2 c-Ets-  71.6 23 NF-kap  64.2 CdxA   62.9 
4 Lyf-1   70.1 USF    71.1 24 GATA-1  64.1 ZID     62.5 
5 Ik-1  69.9 C/EBPb 70.4 25 XFD-3   63.9 CP2     62.5 
6 Staf    69.6 Lyf-1  70.1 26 v-Myb   63.6 COUP-T 62.1 
7 USF     69.1 AhR/Ar  69.8 27 Evi-1   63.0 NGFI-C 61.9 
8 N-Myc   68.9 MZF1   68.7 28 Arnt    63.0 STATx  61.5 
9 AML-1a  68.8 Egr-3  68.6 29 C/EBPb  62.9 CHOP-C 61.1 
10 MZF1    68.7 N-Myc  67.5 30 CdxA    62.9 GR     60.6 
11 VBP     68.6 AML-1a  67.4 31 MyoD    62.8 NF-kap 60.5 
12 HLF     68.4 ARP-1  66.7 32 E4BP4   62.3 MyoD   60.5 
13 Egr-2   67.4 GATA-1 66.1 33 COUP-T  62.1 p300   60.4 
14 Egr-3  67.3 Egr-2  64.8 34 STATx   61.5 HLF    60.3 
15 Ik-2    66.7 E47    64.4 35 CREB    61.4 Arnt    60.1 
16 ARP-1  66.7 Ik-3   64.3 36 RREB-1  61.2 GATA-2  60.1 
17 Egr-1   66.6 NF-E2  64.2 37 CP2     60.4   
18 c-Ets-  65.7 AP-1   63.8 38 GATA-X  60.2   
19 NGFI-C  65.5 v-Myb  63.6      
20 p300   65.3 Elk-1  63.4      
 
Table 3.7.2: List of predicted transcription factors to bind to H1c-A and H1b-G 
according to Transfac. 23 base pair sequences for H1c-A 
(TTCGCCCAGGGTACACCAGGACA) and H1b-G 
(TTCGCCCAGGGTGCACCAGGACA) were submitted to Transfac and a list of potential 
transcription factors that could bind was then generated. 
 
 To probe CP2, HIC1 and Staf further, a high confidence STRING analysis was done 
to ascertain their most probable protein-protein interactions. CP2 was shown to interact 
with other transcription factors such YY1, GATA1 as well as HDAC1 and amyloid beta A4 
precursor protein-binding family B member 1 (APBB1) or Fe65 protein. HIC1 like CP2 
interacted with HDAC1 and as its name suggested, proteins involved in cell cycle and 
cancer such as p53, the cell cycle dependent transcription factor E2F-1, the NAD-
dependent protein deacetylase sirtuin 1 as well as the DNA-helicase/exonuclease WRN. 
Staf or the zinc finger protein 143 (ZNF143) was shown to interact with the RNAPII/III 
transcription factor complex SNAPc, RNAPIII transcription factor 
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BRF2/TFIIIB50, POU2F1/Oct-1. Besides playing a role in the transcription of RNAPII and 
III, Staf was also able to interact with RNAPII/III as well as the TATA-binding protein 
(TBP). 
 
 
Figure 3.7.3: High confidence (0.7<P<0.9) protein-protein interactions for CP2, Staf 
and HIC1 proteins.  
(A) Protein-protein interactions for transcription factor CP2 (TFCP2) (B) Protein-protein 
interactions for HIC1 (C) Protein-protein interactions for Staf or Zinc Finger protein 143 
(ZNF143). Blue lines represent associations based on databases. Yellow lines represent 
associations based on textmining. Red lines represent associations based on gene fusion. 
Grey lines represent associations based on coexpression studies. Purple lines represent 
associations from experiments. Light blue lines represent homology based association.  
Obtained using String v. 8.0 (string.embl.de). 
(A) 
(B) (C) 
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3.8 Discussion on DNA-binding proteins identified and bioinformatics analyses 
 
 Since the advent of genome-wide association studies (GWAS), this approach has 
helped create a deeper and more subtle understanding of complex diseases such as 
tauopathies, Alzheimer’s disease and Parkinson’s disease. The results of such extensive 
studies have led to genes previously not immediately associated with disease to be 
highlighted as well as single nucleotide polymorphisms (SNPs) adding a more complex 
picture in well-studied genes such as MAPT. In one of the more recent PSP GWAS, the 
conditional analysis still supported the relevance of rs242557 with disease.
159
 As rs242557 
is located within a conserved region within the MAPT promoter region (Region C), 
downstream of the core promoter, its location would suggest that it might exert its effect on 
the transcription or splicing machinery or even epigenetically by influencing chromatin 
dynamics. It is important to remember that in physiological conditions, genes are not linear 
strands of DNA but highly regulated conformational DNA. Furthermore, there exists a 
robust cross-talk between the transcription and splicing machinery as well as with their 
epigenetic environment that surrounds them. Most studies have focused on the carboxy-
terminal heptad repeat domain (CTD) of RNA polymerase II (RNAPII) being a key 
platform for gene expression. When the CTD was truncated in vivo, splicing 3’ end 
processing and termination were all inhibited.
160
  More specifically, phosphorylation at 
serine sites within a repeated heptameric sequence within the CTD couples processes 
within gene expression.
161
 
 
The approach taken in this work to elucidate the functionality of a disease-
associated SNP had been applied to various other SNPs within neurology to decipher their 
contribution to disease. The -258 T/G SNP located within the parkin gene was shown, 
through EMSA and dual-luciferase assay, to be the first functional evidence that it affected 
gene transcription.
162
 In delayed onset of Alzheimer’s disease, the PIN1 (Peptidyl-prolyl 
cis-trans isomerase NIMA-interacting 1) SNP rs2287839 was shown using EMSA, 
promoter luciferase assay and chromatin immunoprecipitation (ChIP) to affect the binding 
of AP4 to its promoter.
163
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In sporadic Alzheimer’s disease, the -1314C/T polymorphism was again 
investigated using a luciferase reporter assay and EMSA as to its functional relevance.
164
 
This methodological trend was seen across the breadth of neurology such as the G protein 
receptor kinase 3 (GRK3) gene in bipolar disorder, the tryptophan hydroxylase 2 (TPH2) 
gene in neuropsychiatric conditions, NOS1AP gene in schizophrenia, Dlx homeobox genes 
in neurodevelopmental disorders, DYX1C1 gene in dyslexia, the δ-opoid receptor (OPRD1) 
gene in addiction and guanine nucleotide exchange factor 10 (ARHGEF10) gene in 
atherothrombotic stroke.
165,166,167,168,169,170,171
   
 
 The model that we worked on throughout this work were the undifferentiated 
human neuroblastoma cell lines. These cells, in their undifferentiated form, still had 
neuronal characteristics such as dopamine-β-hydroxylase activity and converting glutamate 
to GABA. Between the SH-SY5Y and BE(3)-M17 neuroblastoma cell lines, however, SH-
SY5Y was the only cell line that showed significant nuclear extract enrichment using 
HDAC1 as a nuclear extract marker. The HDAC1 nuclear protein was enriched 
approximately ten-fold in the SH-SY5Y nuclear extracts compared to SH-SY5Y 
cytoplasmic extracts. Although genotyped human brain samples were available, it would 
have been premature to work on nuclear protein extracts from these as limited patient 
sample were available for use that would also be needed for other projects, the protein 
integrity would vary and it would not be a practical system to probe for protein-DNA 
interaction, protein identification or protein manipulation. 
 
 Once a reproducible method of enriching nuclear proteins was established, it was 
then possible to test the hypothesis that the effect previously reported that rs242557 had in 
dual-luciferase promoter assays was due to changes in protein- or protein complex-DNA 
interactions. EMSA is a native method which allows any differences in binding between 
alleles and nuclear proteins to be investigated, resulting in the labelled DNA probe to be 
retarded due to the proteins binding to it. To probe the protein binding affinity of rs242557, 
a minimal stretch of 23 base-pairs containing rs242557 as the only SNP was used. 
Repetitive stretches of DNA were used to sequester any non-specific protein-DNA binding 
while excess unlabelled DNA of interest was used to demonstrate the specificity of the 
interaction through competition. The result was the first evidence of rs242557 as having a 
functional allelic control on DNA-protein interaction. While previous dual-luciferase 
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promoter assays had shown that the risk allele, rs242557-A (H1c), increased the promoter 
strength, EMSA however showed less protein binding to rs242557-A. This was about four-
fold less protein binding compared to the protective allele, rs242557-G (H1b/H2), Figure 
3.2.1. This suggested that altered DNA-binding protein binding may account for the 
differences in allelic expression. It could be that the proteins recruited to rs242557 act 
primarily to repress the MAPT promoter. Since EMSA is a relatively crude method, it was 
not possible to infer how similar or different the proteins that made up the protein 
complexes around rs242557-A or –G. What was unexpected from the experiment was 
another larger complex that seemed to bind in the same allele-specific manner albeit less 
pronounced. This could have been an artefact as we were not able to compete it out even 
with a 400-fold excess of unlabelled competition probe.    
 
 We used mass spectrometry (MS) to identify the DNA-binding proteins involved 
with rs242557 region. Nuclear proteins that were affinity purified using allelic probes were 
separated on a 1-D SDS gel. Since we did not have our own mass spectrometry set up, we 
collaborated with the core proteomics unit of the UCL Institute of Child Health. We 
decided that it would not have been cost effective to divide the gel lanes into regular 
intervals and analyse each gel band. Instead, our focused approach was to target specific 
pairs of bands that from visual inspection showed differences in band intensity between 
rs242557-A and –G. Also, as a rule-of-thumb, the mass spectrometer was only likely to 
give a much more confident identification of a protein band that was visible to the naked 
eye by Coomassie staining. Hence, a targeted approach was pursued rather than a 
permissive approach of cutting the whole lane into equal segments and analysing each band.  
 
Although 37 unique proteins were identified, 21 of these showed considerable 
differences in band intensity in the 1-D gels. However, as these were 1-D gels, there could 
have been other proteins with similar molecular mass within the same band. Even though 
the mass spectrometer in most cases could only positively identify one protein in a band, 
usually the most abundant or most amenable to digestion and mass spectrometry, various 
non-abundant proteins could still accumulate to give the impression that one band is more 
intense than another. Hence, different bioinformatics approaches were employed to further 
stratify these results. One was based on protein-protein interactions (STRING) while 
another was based on proteins that were involved in the same biological events (Reactome). 
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STRING is a metasource that weighs and integrates protein-protein information from 
experimental repositories, public text collections and computational prediction methods. 
This is different to Reactome which is a manually curated resource for human pathway data. 
While the results of STRING demonstrated that 23 of the 37 proteins could potentially 
interact with one or more proteins identified with high confidence, the results of Reactome 
showed that 20 such proteins were involved in manually curated biological events. These 
have been summarised in Table 3.8.2. 
 
Consolidating all these different analyses revealed that ten proteins were repeatedly 
highlighted, eight proteins were common to both STRING and Reactome, five were 
common to both visual inspection and STRING while there was only one protein common 
to both visual inspection and Reactome. Looking at Table 3.8.2, eleven of the shortlisted 
proteins were mostly structural proteins such as myosins, ribosomal proteins, tubulin, 
vimentin, small nuclear ribonucleoproteins and high mobility group proteins. These were 
not highlighted as compared to the rest of the shortlisted proteins that had more dynamic 
roles in splicing and chromatin remodelling. Most of the splicing and chromatin 
remodelling proteins were common to all of the different analyses (seven out of the ten 
proteins), making them the more probable candidate binding proteins. Following this trend, 
six other possible candidate proteins have been highlighted amongst the shortlisted proteins. 
In total, about half (13 out of 24) of the shortlisted proteins were pursued further. These 
were PTBP1, U2AF2, hnRNPD0, hnRNPU, HMGB2, histone H1, actin, THOC4/ALY, 
DEK, PARP1, NONO, nucleolin and RPA70.  
 
A brief overview of what is currently known about each of these proteins follows. 
The scope of this PhD not only revolves around the tau gene but also transcriptional 
regulation. Hence, these identified proteins will be discussed in the context of 
transcriptional regulation and where possible a neuronal or neurological context as well. 
This brief literature research for each protein allows for not only a better understanding of 
these proteins but also an independent validation for the relatedness of these proteins either 
through direct interaction or similar function. Besides the binding proteins we 
experimentally identified, three proteins (CP2, HIC1 and ZNF43) were predicted in silico 
to bind to the rs242557 region. Hence, these proteins will be discussed in brief too.   
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No. Visual differences from 
gel bands 
STRING Reactome Proteins of interest 
shortlist 
1 PTBP1 PTBP1 PTBP1 PTBP1 
2 U2AF2 U2AF2 U2AF2 U2AF2 
3 hnRNPD0 hnRNPD0 hnRNPD0 hnRNPD0 
4 hnRNPU hnRNPU hnRNPU hnRNPU 
5 HMGB2 HMGB2 HMGB2 HMGB2 
6 Histone H1 Histone H1 Histone H1 Histone H1 
7 U5 snRNP 116 U5 snRNP 116 U5 snRNP 116 U5 snRNP 116 
8 40S Ribosomal protein 
S25 
40S Ribosomal protein 
S25 
40S Ribosomal 
protein S25 
40S Ribosomal 
protein S25 
9 Actin Actin Actin Actin 
10 Tubulin α1 brain-specific Tubulin α1 brain-
specific 
Tubulin α1 brain-
specific 
Tubulin α1 brain-
specific 
11 - HMGB1 HMBG1 HMBG1 
12 - THOC4/ALY THOC4/ALY THOC4/ALY 
13 - U5 snRNP 200 U5 snRNP 200 U5 snRNP 200 
14 DNA topoisomerase I Vimentin Vimentin Vimentin 
15 Myosin 1c MYH 9 MYH 9 MYH 9 
16 Nucleolar RNA Helicase 
II 
MYH10 MYH10 MYH10 
17 Fumarate hydratase MYH11 MYH11 MYH11 
18 PPOL 60S ribosomal protein 
L23a 
60S ribosomal 
protein L23a 
60S ribosomal 
protein L23a 
19 DEK DEK Elongation factor 1 
beta 
DEK 
20 PARP1 PARP1 - PARP1 
21 NONO NONO - NONO 
22 HMGA1 HMGA1 - HMGA1 
23 Nucleolin Nucleolin - Nucleolin 
24 RPA70 - RPA70 RPA70 
Table 3.8.2: Summary of bioinformatics analyses of identified proteins. A visual 
inspection of band intensity from the gel bands used to identify the proteins was compared 
against the results of protein-protein interactions generated through STRING as well as 
protein function through Reactome. Orange – proteins common to all three analyses, green 
– proteins common to String / Reactome, yellow – proteins common to visual / String, blue 
– proteins common to visual / Reactome, purple – proteins shortlisted to follow through. 
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3.8.1 Polypyrimidine tract binding protein (PTBP1 / hnRNPI) 
 
PTBP1 was first discovered as a protein that specifically bound to the 
polypyrimidine tract of introns.
172
 It was shown that PTBP1 represses neuron-specific 
splicing events in rat cerebellum.
173, 174
 A brain-specific isoform of PTBP1 was discovered 
that inhibits Nova activation of exon selection in neurons in addition to many others.
175, 176, 
177
 There are many ways that PTBP1 repress splicing. One way was that it competed and 
sterically impeded the binding of U2AF65 to polypyrimidine tracts.
178, 179
 However, it was 
also possible that PTBP1 promoted exon inclusion by occluding U2AF binding as was 
shown in calcitonin mRNA.
180
 Other ways PTBP1 hindered splicing was through looping 
via multimerization or interfering with U1 snRNP interactions (Figure 3.8.1.1).
181
 Ma, S. et. 
al. also showed that the tau mRNA also contained the conserved consensus PTBP1 binding 
site in its neurite localization signal.
182
 
 
 
Figure 3.8.1.1: Models of PTB repression. (a) PTB competes with U2AF2 for binding. 
(b) A series of PTB proteins mask an exon. (c) Looping as a result of binding sites flanking 
an exon. (d) PTB prevents U1 at N1 to form productive binding with U2AF2. (e) PTB 
protein binds to an exon-splicing silencer (ESS) and prevents U1 from interacting with 
U2AF2. Adapted from
170
.  
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3.8.2 Splicing factor U2AF 65 kDa subunit U2 auxiliary (U2AF65) 
 
The large subunit of splicing factor U2AF (U2AF65) binds to the polypyrimidine 
tract (PPT) and directs contacts with the branch site.
183,184
 It is also essential for the 
assembly of the pre-splicing complex A by forming a short helix between the U2 snRNA 
and the branch site.
185
  
 
3.8.3 High Mobility Group 2 (HMG2) protein 
 
HMG-2 belongs to a family of non-histone chromatin proteins that regulate 
transcription, replication, recombination and DNA repair.
186,187
 A mechanism for their 
action in priming the nucleosome is illustrated in Figures 3.8.3.1.
188
 The low level 
expression of HMG-2 in normal human brain and significant upregulation in glioblastoma 
tissue has been utilized to develop a glioblastoma gene therapy.
189
 Genome-wide linkage 
analysis and genome-wide expression analysis pointed to HMG-2 being differentially 
expressed in schizophrenia in postmortem dorsolateral prefrontal cortex.
190
 HMG-2 was 
shown to interact with huntingtin and ataxin 1 protein and repressing the genotoxic stress 
signals induced in these polyglutamine diseases. 
Figure 3.8.3.1: General model for HMG-2 function. HMG-2 protein bound at the 
entry/exit site induces increased DNA access while less accessible conformation of the 
nucleosome is stabilized by H1 proteins. Modified from
183
. 
 
3.8.4 Histone proteins (H1.2 – 1.5, H1x) 
 
The ten human H1 histones are small basic proteins, consisting of a highly 
conserved globular domain with variable hydrophilic N- and C-terminal tails.
191
 These 
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proteins are also extensively post-translationally modified.
192
 They not only have an 
essential architectural role of sealing off nucleosomes but also play a role in transcriptional 
regulation.
193
 
 
3.8.5 Heterogeneous nuclear ribonucleoprotein D0 (hnRNPD / AUF1) 
 
Splicing of AUF1 results in four isoforms: a 37 kDa core protein (p37), a 40 kDa 
protein (p40) with an N-terminal insertion of exon 2, a 42 kDa protein (p42) with a C-
terminal insertion of exon 7 and a 45 kDa protein (p45) containing both insertions.
194
 They 
differ in stabilities, ubiquination and A+U-rich element (ARE)-RNA binding characteristics. 
ARE in the mRNA 3’-untranslated region (UTR) aids in its degradation. It was found that 
Kd of ARE binding of AUF1 correlated with the efficiency of an ARE to direct degradation 
of mRNA.
195
  
 
3.8.6 Heterogeneous nuclear ribonucleoprotein U (hnRNPU / scaffold attachment 
factor / SAF-1) 
 
hnRNPU binds actin through its C-terminal domain and also associates with the 
phosphorylated C-terminal domain (CTD) of RNA polymerase II (RNAPII).
196
 It also 
could inhibit CTD phosphorylation by binding to TFIIH and repress transcription 
elongation.
197
 It is also a component of ribonucleoprotein (RNP) particles besides being 
associated with the transcription activator CBP/p300 and scaffold / matrix attachment 
regions (S/MAR) on chromosomes coupled to histone acetylation.
198, 199
 
 
3.8.7 THO complex 4 (Ally of AML-1 and LEF-1 proteins / RNA and export factor 
binding-I / bZIP enhancing factor / Aly) 
 
The human Aly protein is ubiquitously expressed in the nucleus. It was originally 
associated with a role in the activation of the T-cell receptor α gene.200 It could also act as a 
chaperone by interacting with the basic region-leucine zipper (bZIP) TFs and enhancing 
their DNA-binding.
201
 It was also part of the exon junction complex (EJC) which aided in 
nuclear export and the robustness of mRNA.
202
 Lastly, Aly is able to bind directly to some 
exons but also introns, 5’ end of genes near promoters.203  
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3.8.8 Actin 
 
In 1969, the first suggestion of the possibility of nuclear actin was made.
204
 Since 
then, nuclear actin had been implicated in chromatin re-modeling (Figures 3.8.8.1), 
transcriptional regulation, RNA processing and nuclear export.
205,206,207,208
 Actin is also 
required for all three classes of eukaryotic RNAPs.
209, 210, 211
 During transcription, actin 
interacts with RNAPII including the CTD.
196, 212 
It was also found to participate in 
transcriptional elongation.
213
  
 
  
Figure 3.8.8.1: Models of actin involved in RNAPI and II transcription. Left, actin and 
hnRNPU may recruit the co-activators, histone acetyl transferases (HATs). Right, actin and 
nuclear myosin recruits the chromatin re-modeling complex. Modified from 
214
 
 
3.8.9 DEK 
 
 In a specific subtype of acute myeloid leukemia, the chromosome translocation 
between chromosome 6 and chromosome 9 leads to the fusion of the DEK gene 
(chromosome 6p22.3) and the CAN (NUP214) gene (chromosome 9q34).
215
 This was the 
first identification of the 375 amino acids, 43 kDa, largely acidic DEK protein.
216
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A scan of brain tumours also showed that DEK was associated with tumour formation.
217
 
From DNase, RNase and micrococcal nuclease treatment, most of the DEK in the cell was 
found to be associated with chromatin with only about 10% associated with RNA.
218
  
Along with DNA topoisomerase I, DEK was able to induce positive supercoils in 
minichromosomes.
219
   
 
Besides DNA-binding, DEK also has an intimate role in splicing. The spliceosome 
deposits a 335 kDa complex which includes DEK, ALY and the splicing coactivator 
SRm160, 20-24 nucleotides upstream of exon-exon junctions, protecting eight nucleotides 
of mRNA .
220,221
   
 
3.8.10 Poly [ADP-ribose] polymerase 1 (PARP1 / NAD(+) ADP-ribosyltransferase 1 
or ADPRT1 / Poly[ADP-ribose] synthase 1) 
 
 PARP1 is an abundant nuclear enzyme (1 per 50 nucleosomes) that transforms 
nicotinamide adenine dinucleotide (NAD
+
) and ATP into poly-(ADP)-ribose (PAR), up to 
200 units, and adds it to various acceptor proteins via glutamic acid residues. It binds to 
DNA through its DNA-binding domain consisting of two zinc fingers while catalyzing the 
PAR reaction through its C-terminal catalytical domain. Between these domains lie an 
auto-modification domain where phosphorylation by extracellular signal-regulated kinases 
1/2 (ERK1/2) and AMP-activated kinase (AMPK) result in modification of PARP1 
activation.
222,223 
Although as previously mentioned, PARP1 is able to repair DNA under 
mild or moderate stress, severe stress, however, can lead to the overactivation of PARP1. 
This would then lead to cell death, both necrosis and apoptosis.
224
 Knowing PARP1’s 
involvement in cell death is especially important in the 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) model of Parkinson’s disease. The PARP1 inhibitor, benzamide, 
was able to reduce the MPTP-induced neurotoxicity.
225,226
 Furthermore, PARP knocked out 
mice showed that the dopamine containing neurons of the subtantia nigra were spared from 
the MPTP toxicity.
227
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 3.8.11 54 kDa nuclear RNA and DNA binding protein (p54nrb / Nono) 
 
NONO is an abundant nuclear factor. NONO was implicated in the formation of 
paraspeckles and was able to bind to DNA and regulate gene transcription.
228, 229 
It was 
implicated in transcriptional regulation, splicing, DNA unwinding, viral RNA processing, 
cell proliferation and circadian rhythm.
230, 231
 NONO was also shown to be one of the major 
interacting-proteins with DJ-1 in dopaminergic neuronal cells and blocked oxidative stress 
as well as α-synuclein-induced cell death.232 
 
3.8.12 Transcription factor CP2 
 
 CP2 also known as leader-binding protein (LBP)-1c or late simian virus 40 factor is 
a transcription factor that was first identified to bind to the promoter of the murine α-globin 
and that the murine CP2 was 96.4% identical to the human CP2 protein.
233
 Analysis of the 
CP2 protein domains highlighted that it shares certain motifs with that of the histone linker 
protein H1 amongst other DNA-binding proteins and that it recognises a fragmented 
sequence motif spanning one DNA helix turn.
234
 It falls under the neurogenic element 
binding transcription factor (NTF)-like family of transcription factors including LBP1a. 
When CP2 knockout mice were generated, however, very little effect was seen suggesting 
that LBP1a or other compensatory mechanisms might have taken over.
235
  
 
In British and French populations with sporadic Alzheimer’s disease, an association 
with a non-coding polymorphism in the 3’ untranslated region of CP2 was found with a 
trend seen with the north American population.
236
 This might be due to a decrease in 
binding to other nuclear proteins. This association was confirmed in another British cohort, 
two different north American cohorts as well as an Italian cohort.
237,238,239,240 
Extensive in 
vitro work had subsequently shown that the phosphorylation of the amyloid precursor 
protein intracellular domain (AICD) led to the formation of a ternary complex with Fe65 
and CP2 which induced the expression of glycogen synthase kinase-3β.241,242 Furthermore, 
CP2 regulates the expression of transferrin by binding to its promoter region and that this 
regulation is modulated by Aβ1-42 and Aβ25-35.
243
 Hence, because of its association of with 
Alzheimer’s disease both on the genetic and protein level, this makes CP2 a highly 
promising predicted transcription factor. In Figure 3.8.12.1, besides interacting with 
(C) 
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GATA-1 and Fe65 (APBB1) that had been highlighted, STRING also suggested that CP2 
can associate with the shortlisted proteins through HDAC1 and the transcription factor YY1. 
The HDAC1-CP2-YY1 interaction was obtained through the National Cancer Institute’s 
Pathway Interaction Database. 
 
3.8.13 Transcription factor Staf or ZNF143 
 
 Staf or selenocysteine tRNA gene transcription activation factor, was first 
identified in Xenopus laevis as a transcription factor which binds to and activates the 
selenocysteine tRNA gene using its zinc fingers.
244,245
 The human ortholog zinc finger 
protein 143 (ZNF143) was chromosomally fine-mapped to 11p15.3-p15.4.
246
 ZNF143 was 
predicted by STRING to associate with the list of shortlisted proteins through protein 
subunits common to the RNA polymerase complexes. This was derived from Reactome’s 
curated pathway which highlighted ZNF143’s involvement in transcription via RNA 
polymerase III (Figure 3.8.13.1). 
 
3.8.14 Transcription factor HIC1 
 
Hypermethylated in cancer 1 (HIC1) was first identified as a candidate tumour 
suppressor gene activated by p53.
247
 From its name, HIC1 was hypermethylated in multiple 
tumour types as well as gliomas.
248
 Its genomic structure consists of alternative promoters 
that lead to various isoforms, the two main isoforms termed 1a and 1b. This gene encodes a 
sequence-specific transcriptional factor with an N-terminal BTB/POZ (Broad complex, 
Tramtrack and Bric a brac/Poxviruses and Zinc Finger) protein dimerization domain as well 
as a C-terminal sequence specific DNA-binding domain consisting of five Krüppel-like 
C2H2 zinc fingers.
249,250
 This protein also has a central region which interacts with the co-
repressor protein CtBP (C-terminal binding protein) and a SUMOylation/acetylation switch 
motif controlled by the deacetylases HDAC4 and SIRT1 (Figure 3.8.14.1 B). HIC1 was 
also known to be post-translationally modified by O-GlcNAc glycosylation.
251
 Although 
this modification did not have any effect on the full-length protein, it did have an effect on 
the N-terminal truncated protein. It was plausible that HIC1 could associate with the list of 
proteins identified through HDAC1 (same as CP2) and p53 as shown in Figure 3.8.14.2.
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Figure 3.8.12.1: High confidence (0.7<P<0.9) protein-protein interactions for CP2 protein with shortlisted proteins of interest. 
(A) STRING analysis of CP2 and its interactors with shortlisted proteins highlighted in pink from Figure 3.8.1. (B) STRING analysis of CP2 
and its interactors with all of the shortlisted proteins from Figure 3.8.1. Blue lines represent associations based on databases. Yellow lines 
represent associations based on textmining. Red lines represent associations based on gene fusion. Grey lines represent associations based on 
coexpression studies. Purple lines represent associations from experiments. Light blue lines represent homology based association.  Obtained 
using String v. 8.0 (string.embl.de). 
(A) 
(B) 
 111 
 
Figure 3.8.13.1: High confidence (0.7<P<0.9) protein-protein interactions for Staf (ZNF143) protein with shortlisted proteins of 
interest. (A) STRING analysis of Staf and its interactors with shortlisted proteins highlighted in pink from Figure 3.8.1. (B) STRING 
analysis of Staf and its interactors with all of the shortlisted proteins from Figure 3.8.1. Blue lines represent associations based on databases. 
Yellow lines represent associations based on textmining. Red lines represent associations based on gene fusion. Grey lines represent 
associations based on coexpression studies. Purple lines represent associations from experiments. Light blue lines represent homology based 
association.  Obtained using String v. 8.0 (string.embl.de).
(A) (B) 
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Figure 3.8.14.1: High confidence (0.7<P<0.9) protein-protein interactions for HIC1 protein with shortlisted proteins of interest. 
(A) STRING analysis of HIC1 and its interactors with shortlisted proteins highlighted in pink from Figure 3.8.1. (B) STRING analysis 
of HIC1 and its interactors with all of the shortlisted proteins from Figure 3.8.1. Blue lines represent associations based on databases. 
Yellow lines represent associations based on textmining. Red lines represent associations based on gene fusion. Grey lines represent 
associations based on coexpression studies. Purple lines represent associations from experiments. Light blue lines represent homology 
based association.  Obtained using String v. 8.0 (string.embl.de).
(A) 
(B) 
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3.9 Conclusions from analyses of proteins identified 
 
Understanding how genes function requires an appreciation of the dynamic nuclear 
architecture. The results discussed so far are promising in highlighting the relationship 
between the risk associations of a SNP with neurological diseases and how a SNP 
influences the biology and subsequently the pathology of a neurological disease. The 
literature and evidence on the most likely proteins involved with rs242557 substantiate the 
most confident interactions highlighted by the STRING and Reactome programs. The 
hypothesis now seems to be that the region containing rs242557 is either occupied by 
histone proteins probably during a transcriptionally repressed state or is bound to a range of 
factors involved in the regulation of transcription, splicing and post-transcriptional 
activities. Also, of all the predicted transcription factor binding proteins, CP2 seems like a 
very promising candidate protein that should be included with the other experimentally 
shortlisted proteins and pursued further. 
 
The effects of the individual DNA-binding proteins will have to be rigorously 
studied. First, the proteins of interest highlighted need to be verified using antibodies and 
applied to the pull-down experiment. Other more stringent experiments to illustrate proteins 
binding to the region of interest such as chromatin immunoprecipitation (ChIP) or gel shift 
assays will be done on nuclear extracts of human neuroblastoma cells. Carrying out these 
experiments will shed some light on how these proteins influence the transcription and/or 
splicing of the human tau gene and how this varies with different genotypes.  
 
Furthermore, TFs that regulate MAPT transcription will also be candidates for 
genetic studies in order to ascertain if polymorphisms are associated with the MAPT H1c 
risk variant and lead to disease pathogenesis in AD and PSP. It is also important to 
remember that rs242557 lies within a 182-bp conserved region and looking at this region 
more closely might shed more light on the effects of rs242557 on MAPT. 
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4 Chapter 2 Results 
 
4.1 Validation of DNA binding proteins of interest identified affinity binding  
assay 
 
 To validate the 13 shortlisted proteins as well as one predicted binding protein and a 
control protein, we analysed these interactions with antibodies raised against these proteins 
(Table 4.1.1). HDAC1 had been predicted through the bioinformatics tool STRING to be 
able to interact with hnRNPD0 from the shortlisted proteins as well as vimentin and brain 
specific tubulin from the rest of the proteins identified. Hence, a subunit of the replicative 
S-phase helicase MCM complex, MCM2, was used as a nuclear control protein instead. In 
the first place, since mostly untested, we had to optimise the conditions of these 
commercially available antibodies for correct dilutions as well as to assess the specificity of 
the antibodies.   
 
 Figure 4.1.1, shows the optimization of nine of the antibodies (PARP1, PTBP1, 
NONO, U2AF2, DEK, actin, hnRNPD0, ALY, HMGB2) at different antibody dilutions and 
illustrates the specificity of the antibodies. hnRNPD0 is produced in human cell lines as 
four main isoforms. The rest of the shortlisted antibodies (hnRNPU, nucleolin, RPA70 and 
H1) titrated fairly satisfactorily except that they had varying levels of background with anti-
H1 antibody having the worst background. The antibody against the predicted protein CP2 
not only titrated well but had minimal background as well. Lastly, the antibody against the 
control nuclear protein MCM2 was not as specific compared to the other antibodies but was 
sufficient for the purpose of a control protein.
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No. Antibody Supplier Cat. No. 
1 Monoclonal mouse anti-human PARP1 BD Pharmigen 556494 
2 Monoclonal mouse anti-human MCM2 Abcam Ab6153 
3 Monoclonal mouse anti-human hnRNPU Abcam Ab10297 
4 Monoclonal mouse anti-human Nucleolin Abcam Ab13541 
5 Polyclonal rabbit anti-human RPA70 Abcam Ab12320 
6 Monoclonal mouse anti-human PTBP1 Abcam Ab30317 
7 Polyclonal rabbit anti-human CP2 Abcam Ab42973 
8 Polyclonal rabbit anti-human NONO Abcam Ab70335 
9 Polyclonal rabbit anti-human U2AF2 Abcam Ab37483 
10 Monoclonal mouse anti-human DEK BD Biosciences 610948 
11 Monoclonal rabbit anti-human Actin Sigma A2066 
12 Polyclonal rabbit anti-human hnRNPD0 Millipore 07-260 
13 Monoclonal mouse anti-human ALY ImmuQuest IQ221 
14 Monoclonal mouse anti-human HMGB2 Abcam Ab11354 
15 Monoclonal mouse anti-human H1 Abcam Ab11079 
 
Table 4.1.1: List of antibodies used.
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Figure 4.1.1: Antibody titrations for proteins of interest.  
Different antibody concentrations such as 1:100, 1:200, 1:500 and 1:1000 were tested on SH-SY5Y nuclear extracts. Extracts were run on a 
1-well gel before a 14-slot press was used so sparing amounts of antibodies were used
1:100 1:200 1:500 1:1000 
PARP1 (113 kDa) MCM2 (102 kDa) hnRNPU (91 kDa) Nuc (77 kDa) RPA70 (68 kDa) PTBP1 (57 kDa) CP2 (57 kDa) 
NONO (54 kDa) U2AF2 (53 kDa) DEK (43 kDa) Actin (42 kDa) hnRNPD0 (38 kDa) ALY (27 kDa) HMGB2 (24 kDa) H1 (23 kDa) 
1:100 1:200 1:500 1:1000 
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Once the antibodies had been tested and optimised, a much smaller-scale affinity 
pull-down experiment similar to that described in Chapter 3.3 was carried out. This was 
because the Western blot analysis that the fractions were subject to is more sensitive than 
the Coomassie protein staining. Eight of the 13 shortlisted proteins (U2AF2, hnRNPU, 
ALY, PTBP1, hnRNPD0, HMGB2, DEK, and PARP1) and the predicted transcription 
factor CP2 yielded reproducible results for their supernatant fractions (Figure 4.1.2) as well 
as their elution fractions (Figures 4.1.3 – 4.1.6). The supernatant fraction refers to all the 
proteins that remained in the cell lysate after incubation with the DNA concatamers of the 
rs242557 region and the elution fraction refers to all the proteins that are eluted after 
washing. Although nucleolin, RPA70, NONO, actin and H1 had reproducible staining in 
their supernatant fractions (Figure 4.1.2 continued), their elution fractions however, were 
not as reproducible and hence they were not included. None of the wash fractions were 
included as they were of a larger volume, and hence none of the proteins could be detected 
because they were present at a very low concentration either due to the dilution effect or 
tight binding to the DNA concatamers.  
 
MCM2 was chosen as the nuclear control protein as HDAC1 might be involved 
with some of the proteins mentioned previously. No MCM2 was detected in the elution 
fractions. In the supernatant fraction, the intensity of the MCM2 bands were fairly even 
except for the R2 (randomly designed control concatamers 2) pull down which had the least 
intense band. Taking into account this Western blot profile of the control protein for the 
supernatant, most of the proteins probed for in the supernatant had fairly even intensities 
for the various pull downs. The only marked difference was U2AF2. The pull downs with 
H1c-A and H1b-G for U2AF2 in the supernatant were markedly reduced compared to the 
randomly designed control concatamer probes R2 and R3 consistently and as low as the 
beads only pull down for two out of the three replicates.   
 
For those protein pull-downs with beads only i.e. those that did not have any 
concatamers ligated to them and still resulted in a high background, this is probably not just 
due to non-specific binding to the beads but also probably due to binding to the linker DNA 
attached to those beads.
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Figure 4.1.2: Supernatant fractions of rs242557 pull-down assay.  
SH-SY5Y nuclear extracts were incubated with concatamers or rs242557-containing oligonucleotides attached to magnetic beads (H1c-A, 
H1b-G, R2 & R3 – random sequences, B – magnetic beads only). Supernatant fractions were probed with antibodies against the proteins of 
interest (that were detected in the eluates too) as well as control nuclear protein. These were done in triplicate. 
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Figure 4.1.2 continued: Supernatant and wash fractions of rs242557 pull-down assay.  
These proteins of interest were grouped together as subsequent elution fractions for these proteins did not yield any detectable signal or 
reproducible bands even though their supernatant profiles were fairly similar. 
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Looking at the Western blots of the elution fractions (Figures 4.1.3 – 4.1.6) and 
starting with the shortlisted proteins with the highest confidence (Figure 4.1.3a) first, it can 
be seen that all the proteins exhibited more binding to the H1c-A concatamer compared to 
the H1b-G concatamer. They did differ, however, on the binding to the random 
concatamers R2 and R3 and control beads only pull down as well as the ratio of binding to 
H1c-A compared to H1b-G.  
 
 The protein that showed the most specific binding to the rs242557 region, H1c-A or 
H1b-G, or in other words, the proteins that had the least non-specific interaction with the 
random probes and the beads was PTBP1 (Figure 4.1.3c). This was closely followed by 
hnRNPD0, U2AF2, hnRNPU, HMGB2 and ALY. Taking into account their respective non-
specific interactions, the protein that had the largest difference in binding between H1c-A 
and H1b-G was U2AF2 (Figure 4.1.3b) where the H1c-A band had almost double the 
intensity (approximately 1.75x) of the H1b-G band. This was closely followed by hnRNPU 
and ALY which were very similar (approximately 1.6x). PTBP1 had a ratio of 
approximately 1.45x while hnRNPD0 had the smallest difference of about 1.2x. HMGB2 
which was not directly predicted to interact with the rest of the proteins came in at a ratio of 
about 1.5x but had the largest standard deviation.  
 
 DEK protein in Figure 4.1.4a, was one of the shortlisted proteins that had been 
predicted to interact with the other proteins when the confidence level was relaxed from 
highest to high (refer to Chapter 3.5). The level of the protein in the eluate, however, was 
very low. Although DEK, like the rest of the shortlisted proteins, was easily detected in the 
supernatant fraction, levels of bound protein in the eluate were very low, even with increase 
in concentration of detection antibody (Figure 4.1.4c). Nevertheless, the interaction appears 
specific to the rs242557 probe with no detectable bands with the random probes, R1 and R2 
and beads only. However, with the weak intensity, it is possible that non-specific 
interaction, if present, could not be detected. In any case, density analysis revealed the 
largest difference in allele-specific binding to the rs242557 probes (Figure 4.1.4b). 
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Figure 4.1.3: Elution fractions of rs242557 pull-down assay U2AF2 – HMGB2.  
SH-SY5Y nuclear extracts were incubated with concatamers of rs242557-containing oligonucleotides attached to magnetic beads (H1c-A, 
H1b-G, R2 & R3: random sequences, B: magnetic beads only). Eluates were probed with antibodies against the proteins of interest. (A) This 
set of proteins was shown by STRING to be of highest confidence in protein-protein interactions. (B) Plot of the ratio of band intensity of 
H1c-A against H1b-G after taking account of non-specific binding for each protein of interest. (C) Western blot analysis of eluates fractions 
in triplicate, n = 3.
(A) 
(B) 
(C) 
 122 
Figure 4.1.4: Elution fractions of rs242557 pull-down assay DEK.  
SH-SY5Y nuclear extracts were incubated with concatamers of rs242557-containing oligonucleotides attached to magnetic beads (H1c-A, 
H1b-G, R2 & R3: random sequences, B: magnetic beads only). Eluates were probed with antibodies against the proteins of interest. (A) This 
set of proteins was shown by STRING to be of high confidence in protein-protein interactions. (B) Plot of the ratio of band intensity of H1c-
A against H1b-G after taking account of non-specific binding for each protein of interest. (C) Western blot analysis of eluates in triplicate, 
n=3
(A) 
(B) 
(C) 
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The last of the shortlisted proteins that could be reproducibly detected was PARP1 
(Figure 4.1.5). It was, however, the least reliably reproducible protein blot with the largest 
standard deviation. It also had substantial non-specific binding to the random probes and 
beads (Figure 4.1.5c). Even though unlike the rest of the proteins, PARP1 seemed to favour 
binding to H1b-G, this difference is not reliable when the level of background is considered.  
 
 Lastly, CP2, the transcription factor not found in our interactor hunt but predicted in 
silico to bind to the rs242557 region was probed for in the eluate (Figure 4.1.6). It showed 
specific binding to the rs242557 probes and very little non-specific binding (Figure 4.1.6c). 
Like most of the shortlisted proteins tested, there appeared to be allelic binding to rs242557 
favouring H1c-A by about 1.5x (Figure 4.1.6b).  
 
Looking at the summary of Western blot density analysis in Figure 4.1.6, apart from 
PARP1, the rest of the proteins in this denaturing pull-down experiment seem to exhibit the 
same allelic preferential binding and at approximately to the same extent. Whether these 
results will hold in the native condition will still need to be elucidated. A direct method is 
to probe the proteins as they natively associate with the DNA probes as they would do in an 
EMSA experiment. 
 124 
 
Figure 4.1.5: Elution fractions of rs242557 pull-down assay PARP1.  
SH-SY5Y nuclear extracts were incubated with concatamers or rs242557-containing oligonucleotides attached to magnetic beads (H1c-A, 
H1b-G, R2 & R3 – random sequences, B – magnetic beads only). Elution fractions were probed with antibodies against the proteins of 
interest. (A) Theses set of proteins were shown by STRING to be of medium confidence in protein-protein interactions. (B) Plot of the ratio 
of band intensity of H1c-A against H1b-G after taking account for non-specific binding for each protein of interest. (C) Western blot bands 
of elution fractions in triplicate, n=3. 
(A) 
(B) 
(C) 
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Figure 4.1.6: Elution fractions of rs242557 pull-down assay CP2.  
SH-SY5Y nuclear extracts were incubated with concatamers or rs242557-containing oligonucleotides attached to magnetic beads (H1c-A, 
H1b-G, R2 & R3 – random sequences, B – magnetic beads only). Elution fractions were probed with antibodies against the proteins of 
interest. (A) Theses set of proteins were shown by STRING to be of medium confidence in protein-protein interactions with CP2. (B) Plot of 
the ratio of band intensity of H1c-A against H1b-G after taking account for non-specific binding for each protein of interest. (C) Western 
blot bands of elution fractions in triplicate, n=3.
(A) 
(B) 
(C) 
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4.2 Validating proteins of interest binding in native conditions 
 
Before the shortlisted and predicted proteins can be probed for in their native 
conditions interacting with the DNA region of interest, the Western blotting protocol had to 
be adapted to allow for the transfer of large protein complexes in their native conditions 
from native gels to PVDF membranes. A titration experiment using the cytoplasmic extract 
from SH-SY5Y cells was separated on native gels and visualized with both silver staining 
and Coomassie staining. An unstained native protein ladder from 1236 kDa to 66 kDa was 
used too. The range of protein extract used from 270 ng to 3 ng tested the limits of both 
silver and Coomassie stainings.  
 
Two different approaches for transferring native proteins onto PVDF membranes 
were tested. A gentle, SDS-free method where the native gel was soaked in 2x transfer 
buffer was compared to a method involving 0.1% SDS. The blot was then stained with 
Coomassie to visualize the proteins transferred as silver staining did not work on PVDF 
membranes. The gels after native Western blotting were then stained with both silver and 
Coomassie stains to see how much of the proteins were left on the gels. The gentler 
approach was able to transfer protein complexes around 200 kDa even when using 9 ng of 
starting cytoplasmic extract while protein complexes around 720 kDa were transferred 
down to 18 ng of starting material. Even complexes as big as 1048 kDa were detected on 
the membrane when using 44 ng or more of cytoplasmic extracts. The stained gels after 
transfer lacked the protein complex bands seen before blotting. Thus, the gentler approach 
would fit for the purpose of this experiment. 
 
 Of all the highest confidence shortlisted protein, U2AF65 was the only protein 
stained by its antibody on a native blot (Figure 4.2.1) i.e. without having to denature the 
blot. This meant that the U2AF65 antibody epitope was accessible in the native condition 
when it was part of a complex approximately greater than 1000 kDa. Since this was a 
native EMSA-like experiment, there was a certain amount of non-specific binding to 
random probes R2 and R3. Also, as U2AF65 was one of the main components of the major 
splicing pathway, it appears that within the nuclear extract, it could be present in various 
complexes. As the gel run was optimized to visualize protein complexes, it was not 
possible to see the levels of individual proteins within the same blot as they would have run 
 127 
out of the gel if they were detectable as individual proteins in native nuclear extracts. As a 
further control, the DNA probes on their own without the nuclear extracts but with all the 
EMSA reagents used [(A) & (G)] were not able to create any false positive bands when 
exposed to the native Western blotting procedure. From the high level of non-specific 
binding to R2 and R3, it is hard to make any judgment on allele-specific binding. 
 
 The only other protein that responded to the experiment was hnRNPD0. However, 
its antibody could not detect the epitope in the native complex. After denaturing the blot 
briefly with 6M guanidine hydrochloride, however, the epitope was sufficiently exposed for 
the blot to work. Like U2AF65, hnRNPD0 displayed a reverse in allelic preference in the 
native condition from H1c-A to H1b-G. The level of non-specific binding was higher than 
U2AF65 but was similar to the denaturing version of the experiment (Figure 4.1.3) and 
very little of it existed in the complex form without any DNA input. Again, from the high 
level of non-specific binding to R2 and R3, it is hard to make any judgment on allele-
specific binding. 
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Figure 4.2.1: Native Western blotting of U2AF65 and hnRNPD0.   
Biotin-labelled 16-mer oligonucleotides containing the A (H1c) & G (H1b) allelotypes of rs242557 were incubated with nuclear extracts 
from undifferentiated SH-SY5Y cells. Incubation with randomised probes (R2 & R3) highlighted the specificity of the interaction between 
probe and nuclear proteins, U2AF65 and hnRNPD0. Other controls included the nuclear extract without any probes (cell), the H1c-A and 
H1b-G probes without any nuclear extracts [(A) & (G)]. hnRNPD0 is highlighted in red as the blot had to be treated with 6M guanidine 
hydrochloride before antibody treatment while U2AF65 did not require this pre-treatment. The pairs of allele-specific binding were done in 
triplicates.
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We could not identify the rest of the shortlisted proteins, hnRNPU and PTBP1, H1 
and HMBG2 (Figure 4.2.2), ALY, DEK and PARP1 on the native Western blots either 
without denaturing or denaturing the blots. This did not necessarily mean that these 
proteins were not present in the native complex. One possibility is that the antibody 
epitopes are obscured within the complex and that the denaturation was not sufficient to 
expose these epitopes. The nature of this native method makes the results less clear to 
interpret and should be cautiously analysed and taken into consideration with the rest of the 
results in this thesis.     
 
During the course of this work, our group members were also investigating the 
protein TDP43 which they showed influences MAPT transcription by binding to the 
upstream core promoter region of the gene (Roberto Simone; personal communication). As 
a control, we assessed the binding of TDP-43 to a probe (T) representing the predicted GC-
rich binding domain of the MAPT promoter and random probes R2 and R3. Our STRING 
analysis also showed that TDP-43 interacts with the shortlisted protein hnRNPD0 through 
ubiquitin  although this might not be applicable in this case. Even under such native 
condition, there was no significant preferential binding above binding to random 
oligonucleotides. 
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Figure 4.2.2: Native Western blotting of H1 and HMGB2.   
Biotin-labelled 16-mer oligonucleotides containing the A (H1c) & G (H1b) allelotypes of rs242557 were incubated with nuclear extracts 
from undifferentiated SH-SY5Y cells. Incubation with randomised probes (R2 & R3) highlighted the specificity of the interaction between 
probe and nuclear proteins. Other controls included the nuclear extract without any probes (cell), the H1c-A and H1b-G probes without any 
nuclear extracts [(A) & (G)]. Treating the blots with 6M guanidine hydrochloride (in red) did not have any effect compared to without (in 
green). They were done in triplicates.  
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Three of the rest of the shortlisted proteins, nucleolin, actin and RPA70 and the 
predicted transcription factor, CP2 (Figure 4.2.3) were much easier to be probed for in the 
native blots without the blots needing to be denatured.  
 
CP2 and nucleolin like U2AF65 and hnRNPD0 that were previously discussed, had 
showed greater binding to H1c-A compared to H1b-G. Although nucleolin was present as a 
complex in the nuclear extract on its own and some binding was seen with the random 
oligonucleotides, it was interesting to note that in a native blot, no CP2 was seen in the 
nuclear extract on its own, no binding to the random probe R2 and very little binding to R3. 
Actin and RPA70 were the only proteins observed in the native blots to show a difference 
in allelic binding with greater binding to H1b-G rather than H1c-A. RPA70 was like CP2 in 
that it had specific binding to the DNA probes of interest compared to the random probes 
and nuclear extract alone whereas actin had a basal level of non-specific binding. 
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Figure 4.2.3: Native Western blotting of CP2, nucleolin, actin and RPA70.   
Biotin-labelled 16-mer oligonucleotides containing the A (H1c) & G (H1b) allelotypes of rs242557 were incubated with nuclear extracts 
from undifferentiated SH-SY5Y cells. Incubation with randomised probes (R2 & R3) highlighted the specificity of the interaction between 
probe and nuclear proteins, CP2, nucleolin, actin, RPA70. Other controls included the nuclear extract without any probes (cell), the H1c-A 
and H1b-G probes without any nuclear extracts [(A) & (G)]. All these blots did not need 6M guanidine hydrochloride treatment. They were 
done in triplicates. 
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4.3 Discussion on validating shortlisted DNA-binding proteins 
 
 In the work described in this chapter, we aimed to verify the proteins that had been 
predicted by the mass spectrometry data through the use of antibodies. Besides identifying 
these proteins through the pull-down assays, they were also probed in native gels that were 
blotted onto PVDF membranes to assess the association of the proteins with a complex that 
binds to the rs242557 region. It was also the intention to have used chromatin 
immunoprecipitation (ChIP) to validate these proteins. However, after many trials of 
optimisation and the time constraints, it was not possible to do so. The work that had been 
done on ChIP will be discussed further in the conclusion under future work.  
 
In summary, we confirmed 8 out of 13 of the shortlisted interacting proteins by pull-
down experiment followed by denaturing gel electrophoresis as described section 4.1. 
However, analysis of the interactions on native, non-denaturing gels that would keep the 
DNA-protein complex intact was largely difficult.  While some proteins were observed to 
bind non-specifically to the random probes, with certain allelotypes, the binding seen were 
still stronger compared to those random probes. Five of the same shortlist were able to be 
studied in the native Western blots, understandably due to the nature of conformational 
changes and protein-protein interactions that come about in native conditions. Only two 
proteins from the shortlist, U2AF65 and hnRNPD0, were common to both experiments. 
The predicted transcription factor, CP2 was also common to both denaturing and non-
denaturing experimental conditions. Three proteins, actin, nucleolin and RPA70, which had 
not been able to be reproducibly studied in the denaturing pull-down experiment, were 
probed with greater ease in the native Western blots. All of these are illustrated in Figure 
4.3.1.  
 
It was interesting to note that when the complexes were formed natively before 
being denatured, more epitopes for the antibodies against U2AF2, hnRNPD0 and CP2 were 
seen with rs242557 H1c-A compared to H1b-G but the reverse was true without any 
denaturation. This could be due to the different nature of the native complexes formed 
around the oligonucleotides where H1c-A recruited more U2AF2, hnRNPD0 and CP2 as 
seen when the complexes were denatured but were less exposed or had their epitopes more 
buried within the complex compared to H1b-G. Of these three proteins, hnRNPD0 and CP2 
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had approximately a two-fold difference between the denaturing and non-denaturing 
experiments while U2AF2 had a four-fold difference. 
 
The fact that under native conditions, different proteins such as actin and RPA70 
behaved differently to U2AF2, hnRNPD0 and CP2 toward H1c-A and H1b-G raised the 
possibility that some of the proteins within the complex might act as coordinators of 
varying downstream events between the different allelotypes whiles others served as core 
recognition binding proteins. A more extensive and detailed study would be needed to 
elucidate this.
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Figure 4.3.1: Density plot of Western blot bands of proteins of interest.   
Plot of the ratio of band intensity of H1c-A against H1b-G after taking account for non-specific binding for each protein of interest. Density 
plots from Western blots arising from native gels are represented in blue while those arising from denaturing gels are represented in orange. 
Each was done in triplicate. Error bars represent standard deviation. Shades of colour have no significance.  
 136 
4.4 Transactive Response DNA-binding protein-43 (TDP-43) 
 
 In 2006, it was shown that in some frontotemporal lobar degeneration (FTLD) cases, 
the characteristic ubiquinated inclusions are composed of transactive response DNA-
binding protein-43 (TDP-43).
252
 Brains of FTLD cases with mutations in progranulin also 
showed ubiquitin/TDP-43 inclusions as well as tau pathology.
253
 It had been shown that 
mutations in the TDP-43 gene on chromosome 1p36.2 cause familial and sporadic 
amyotrophic lateral sclerosis (ALS) and are thus sufficient to cause neurodegeneration.
254
  
 
The full extent of the function of the 43-kDa protein, TDP-43, is still being 
deciphered. TDP-43 is 414 amino acids long and encoded by six exons with two noncoding 
exons.
255
 TDP43 is an hnRNP protein consisting of two RNA recognition motifs, RRM1 
and 2, and a C-terminal glycine-rich region.
256
 Most of the 38 dominant mutations are 
localized in the glycine-rich region (Figure 4.4.1 top). TDP-43 was initially identified as a 
transcriptional repressor that bound to the transactive response (TAR) DNA region in HIV-
1.
257
 TDP-43 was shown to be highly conserved amongst human, Drosophila and C. 
elegans in terms of their nucleic acid binding specificity while exon recognition and 
splicing regulation were conserved between human and Drosophila.
258
 It was also shown 
that the protein could bind to the 3’ UTR of mRNA such as the low molecular weight 
neurofilament (NFL) and regulate its mRNA dynamics such shuttling and translation.
259
 
This gene like numerous other genes have been found to be functionally and directly 
affected by TDP-43 (Figure 4.4.1 bottom).
260
 It is unsurprising then that mutations, 
mislocalization and protein post-translational modifications would lead to various losses of 
function and gains in toxic function in cells that would lead to neurodegeneration (Figure 
4.4.2 left).  
 
Since it was shown that TDP-43 was found in inclusions in FTLD, there are now a 
growing number of disorders with similar inclusions (Figure 4.4.2 right). Because of the 
growing significance of this protein and the lack of understanding of it, TDP-43 was 
included in the study, especially for the next stage of functional knockdown promoter 
luciferase assays in order to see if TDP-43 could have a role in MAPT expression.
 137 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4.1: TDP-43 protein domains, mutations and effects of TDP-43 on genes.  Top, schematic representation of the full-length 
TDP-43 protein. There are two RNA recognition motifs (RRM1, RRM2), the nuclear localization signal (L) and the nuclear export signal (E) 
and the C-terminal glycine-rich region where most of the mutations lie. Bottom, genes directly controlled by TDP-43 either at the 
transcription level or exon recognition level other processes.
385,38
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Figure 4.4.2: Functional effects of TDP-43 in disease and list of pathological conditions showing TDP-43 inclusions. Left, in disease 
state, TDP-43 is ubiquinated, cleaved and phosphorylated. It accumulates as insoluble aggregates in the cytoplasm. Right, these TDP-43 
inclusions can be found in a growing number of pathological conditions including polyglutamine diseases, Huntington’s disease and 
spinocerebellar ataxia (not shown).
385,389
 
 139 
4.5 Conclusions from validation of proteins identified 
 
 Probing the proteins pulled-down with the rs242557 probes and control probes 
using antibodies validated some of the proteins identified by mass spectrometry. The 
proteins that showed specificity to the rs242557 probes over the control probes from the 
denaturing pull-down assays were U2AF2, hnRNPU, PTBP1, hnRNPD0 and CP2. This 
experiment also showed that these proteins bound more strongly to the H1c risk allele 
rs242557-A which was similar to the 1-D gel bands that these proteins were identified from 
except for CP2. The validation of these proteins under native conditions was less 
straightforward. Although U2AF2, hnRNPD0 and CP2 were identified by the same 
antibodies under native conditions, the effects observed were different with the protective 
H1b/H2 allele, rs242557-G. These proteins were seen to bind slightly more to the 
protective allele. While hnRNPU and PTBP1 could not be identified under native 
conditions, this did not mean they were not present as more parameters were at play during 
native experiments such as protein dynamics. Given the extensive research that had been 
carried out on hnRNPU and PTBP1 as seen from the literature and the results seen from the 
denaturing pull-down, there was still enough evidence to warrant these proteins to be 
scrutinized further with functional assays. 
 
 Since starting my PhD, the research into TDP-43 has intensified. Having explained 
its significance, it also made sense to investigate the potential functional role on the MAPT 
promoter. In the following sections, we investigated the six proteins U2AF2, hnRNPU, 
PTBP1, hnRNPD0, CP2 and TDP43 by specific knock down using siRNA and their effects 
on MAPT promoter activity using promoter-luciferase reporter assays in neuroblastoma cell 
cultures. 
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5 Chapter 3 Results 
 
5.1 Optimisation of plasmid and siRNA cotransfection functional assay 
 
 To be able to investigate the functional effects of the candidate proteins in relation 
to the haplotype effects of the MAPT promoter, luciferase promoter assays were combined 
with protein knockdown through transient transfections with siRNA. The luciferase 
promoter assays were the system to be initially used to show the haplotype effects of 
rs242557 on the promoter strength of pGL4.10.
124
 However, since then, more refined 
plasmid constructs with more extensive coverage of putative regulatory regions of the 
MAPT promoter region had been created by another PhD student, Victoria Kay. This 
allowed not only a more extensive and systematic analysis of the promoter region, but also 
coupling the promoter reporter assays with gene knockdown allowed for a greater 
understanding of how each downregulated protein specifically exerted their effects.  
 
 Before any functional assay could be started, work had to be done to establish the 
optimal conditions for combined transfections of both plasmid and siRNA. However, both 
transfection protocols utilized different transfection reagent formulation (Transfast and 
RNAiMax respectively). Whether one reagent could work for both transfections had to be 
ascertained. Alternatively, if no one reagent would work for the co-transfection 
experiments, then a serial assay would have to be set up with either the plasmids or siRNAs 
transfected first according to their specific protocols followed by the other. The difficulty 
with the latter approach would be finding the optimized lag time between the two 
transfections such that there would be sufficient plasmids transfected to yield high enough 
readings as well as sufficient siRNA and enough time for them to exert a reproducible 
effect without too much cell death.  
 
Hence, eight different co-transfection conditions were tested. Transfections of both 
plasmid and siRNA simultaneously using Transfast transfection reagent which was 
designed for plasmid transfections, were carried out according to the transfection protocol 
provided by the manufacturer for Transfast (this condition was abbreviated as Transfast in 
Figure 5.1.1). Transfections of both plasmid and siRNA simultaneously using RNAiMax 
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transfection reagent, which was designed for siRNA transfections were carried out 
according to the transfection protocol provided by the manufacturer for RNAiMax (this 
condition was abbreviated as RNAiMAx in Figure 5.1.1). Serial co-transfections of plasmid 
and siRNA could be done either with the plasmid or the siRNA transfections first with 
varying time intervals (6, 12 or 24h) between the two transfections. Plasmid transfections 
followed by siRNA transfections after 6, 12 or 24 hour intervals are abbreviated as 
plasmid/si_6h, plasmid/si_12h and plasmid/si_24h. Transfections with siRNA followed by 
plasmid after 6, 12 or 24 hour intervals are abbreviated as si/plasmid_6h, si/plasmid_12h 
and si/plasmid_24h. 
 
After the different experimental conditions had been established, a reliable 
experimental model had to be established. The ideal condition would include a promoter 
construct that gave a strong luciferase read-out. Also, a siRNA that would target the vector 
regardless of the construct and elicit a gene knockdown to similar levels with the negative 
controls had to be done. This would consist of cells being treated to the same experimental 
conditions but with a scrambled sequence of siRNA as well as without any plasmid 
constructs or siRNA. At the first instance, the reporter plasmid used for optimization had to 
be a strong promoter giving robust readings with the luciferase assay. Work by Victoria 
Kay had showed that the pGL4.10 vector containing the core promoter of MAPT, B1, gave 
the highest luciferase reading of all the constructs she made. Strong luciferase activity from 
the B1 plasmid enables us to observe the effect of direct siRNA targeting of the plasmid by 
pGL4si. Hence the model was to observe the luciferase read-out of B1 alone (this was 
abbreviated as B1 in Figure 5.1.1) and compare it with the co-transfection of B1 plasmid 
with pGL4si (this was abbreviated as B1&pGL4si in Figure 5.1.1). As a negative, we 
employed a scrambled siRNA (neg ctrl si) which was co-transfected with the B1 plasmid 
(this was abbreviated as B1&neg ctrl si in Figure 5.1.1). This should have little effect on 
the luciferase read-out of the B1 plasmid construct. Lastly, another negative control 
included untransfected naïve cells (this was abbreviated as “cells only” in Figure 5.1.1). 
 
The right optimized co-transfection condition would have a high luciferase reading 
for B1 plasmid on its own, a low luciferase reading for cells only transfected without any 
plasmids or siRNA, a low luciferase reading close to the negative control (cells only) for 
the co-transfection of the B1 plasmid with the pGL4si siRNA (B1&pGL4si) and a high 
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luciferase reading close to the B1 plasmid alone for the co-transfection of the B1 plasmid 
with the negative control siRNA (B1&neg ctrl si). From Figure 5.1.1, the conditions 
RNAiMax, plasmid/si_6h, si/plasmid_6h, plasmid/si_12h, si/plasmid_12h and 
plasmid/si_24h did not meet these criteria. Although the negative control of cells only 
worked as they should, most of the conditions did not yield any significant difference 
between B1 and B1&pGL4si. Although the experimental condition si/plasmid_6h was an 
exception, there was no recovery of the luciferase reading with B1&neg ctrl si which 
should not affect the luciferase reading of the B1 plasmid very much. 
 
 Two experimental conditions, however, Transfast and si/plasmid_24h, 
(Figure 5.1.1 continued) did meet these criteria. Carrying out the co-transfection of plasmid 
and siRNAs simultaneously with Transfast was slightly better than carrying out the siRNA 
transfection first for twenty-four hours before the plasmid transfection. Although the 
luciferase readings varied similarly for both conditions (approximately 80% reduction of 
B1 when compared to B1&pGL4si), Transfast alone had higher relative luminescence 
compared to si/plasmid_24h, allowing for a greater window for the actual experiments. 
Also, two-tailed T-tests revealed that Transfast alone was slightly more significant which 
again supported the larger experimental window that this condition provided. Using one 
reagent and adding all the plasmids and siRNAs together at the beginning simplifies the co-
transfection experiment which meant less technical errors could be introduced.
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Figure 5.1.1: Time course optimization assay of unsuccessful plasmid and siRNA co-transfections.   
Co-transfection was trialed by transfecting plasmid constructs and siRNAs together with  siRNA transfection reagent (RNAiMax) only or 
plasmid constructs were transfected first with Transfast for 6, 12 and 24 hours before siRNAs were transfected using RNAiMax or siRNAs 
were transfected first with RNAiMax for 6 and 12 hours before plasmid constructs were transfected with Transfast. B1 is a pGL4.10 plasmid 
MAPT promoter-luciferase construct with strong luciferase activity. pGL4si is a siRNA targeting the core promoter of pGL4.10, neg ctrl si is 
a scrambled siRNA. Each experiment was done in triplicate. Error bars represent standard deviation. 
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Figure 5.1.1 (continued): Time course optimization assay of successful plasmid and siRNA co-transfection.   
Co-transfection was trialed by transfecting plasmids and siRNAs together with plasmid transfection reagent (Transfast) only or siRNAs were 
transfected first with RNAiMax for 24 hours before plasmid constructs were transfected with Transfast. B1 is a pGL4.10 plasmid MAPT 
promoter-luciferase construct with strong luciferase activity. pGL4si is a siRNA targeting the core promoter of pGL4.10, neg ctrl si is a 
scrambled siRNA. Each experiment was done in triplicate. Error bars represent standard deviation.
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Before the plasmid constructs and siRNA co-transfection experiments could 
proceed, the siRNAs to be used had to be tested and verified for efficacy of targeted gene 
knockdown. We carried this out on the human neuroblastoma cell line SH-SY5Y. The 
siRNAs against U2AF2, PTBP1, hnRNPU, hnRNPD0, CP2 and PAX8 were purchased 
commercially. For each gene, three different siRNAs had been pre-designed to target 
different parts of the gene. The siRNA against TDP43, as in the case of the siRNA against 
pGL4.10, was custom designed to target the upstream promoter region and made-to-order 
(personal communication with Roberto Simone). PAX8 was chosen as a more stringent 
transcription factor-specific negative control. Knocking down a known transcription factor 
not known to be involved and observing no effect on the experiment would be more 
demonstrative of any specific effects seen with the rest of knockdowns than simply using a 
scrambled negative control siRNA not known to interact with any human DNA sequence. 
 
 SH-SY5Y cells were either transfected without any siRNA (abbreviated as Cells or 
Cells only in Figures 5.1.2 – 5.1.7), or negative control siRNAs (two were commercially 
available, Neg ctrl 1 or Neg ctrl 2). Both negative control siRNAs were random sequences 
not known to interact with any human sequences. The neuroblastoma cells were also 
transfected with either one of the three commercially available target siRNAs alone (#1, #2 
or #3) or in combination (#1&2, #1&3 or #2&3). After transfection, cells were lysed and 
their protein content normalized before separation by SDS-PAGE and identification by 
Western blotting. Actin was used as an endogenous housekeeping protein for normalisation. 
 
 In Figure 5.1.2, taking into account of the levels of actin, there was no significant 
difference (p=0.2) between transfection without any siRNA and transfection with negative 
control 1 siRNA. This made negative control 1 a better negative control siRNA than 
negative control 2 siRNA which had a significance of p<0.0005 when compared to 
transfection without any siRNA (Cells only) using a two-tailed T-test. This result was also 
reflected in Figures 5.1.3 – 5.1.7 where negative control 1 proved to be a better negative 
control and hence would be adopted as the negative control siRNA to be used in the co-
transfection assays.  
 
When it came to analyzing which target siRNA singly or in combination would 
provide the highest level of protein knockdown, there was variation amongst the different 
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target proteins. Although for all the target proteins, a combination of two siRNAs appeared 
to provide the most protein knockdown, the level of this knockdown varied from one target 
protein to the next. The exception was TDP43, Figure 5.1.7, which had a custom designed 
siRNA that led to a 63% reduction in TDP43 protein expression level compared to cells 
transfected with negative control 1 siRNA (p<3.5x10
-4
, two-tailed T-test). The largest 
amount of protein knockdown that was also the most significant for U2AF2 was a 70.4% 
reduction (Figure 5.1.2, p<5.4x10
-3
), for hnRNPU, it was a 84.7% reduction (Figure 5.1.3, 
p<9.62x10
-5
),
 
for PTBP1, it was a 93.2% reduction (Figure 5.1.4, p<1.1x10
-4
), for 
hnRNPD0, it was a 89.1% (Figure 5.1.5, p<8.13x10
-6
), for CP2 , it was a 79.6% reduction 
(Figure 5.1.6, p<0.0025).  
 
 While for most of the protein knockdowns, a combination of two different siRNAs 
yielded the largest amount of protein reduction, they were not always significantly different 
when compared to single siRNA transfections. hnRNPU siRNA knockdowns, however, 
stood out in that the siRNA#2&3 combination had significantly less hnRNPU when 
compared to negative control 1 siRNA and any of the siRNAs on their own (Figure 5.1.3). 
PTBP1 siRNA #1&3 was similar to hnRNPU with respect to having significantly less 
protein when compared to negative control 1 siRNA and any of the siRNAs on their own, 
but it also had significantly less protein when compared to another double siRNA 
knockdown #1&2 (Figure 5.1.4). This observations gave more confidence in using a 
combination of two siRNAs to knockdown a gene for these proteins of interest. 
 
 After all the different aspects of the co-transfection assay had been optimized with 
confidence, this assay could now be proceeded with to analyse the effects each protein 
knockdown on different aspects of the MAPT promoter.
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Figure 5.1.2: siRNA optimization assay for target protein U2AF2.   
SH-SY5Y cells were transfected with two different scrambled siRNAs (neg ctrl 1 and 2) or three different target siRNAs (#1, #2 and #3) or a 
combination of two target siRNAs (#1&2, #1&3 and #2&3). Top: Visualisation of target protein siRNA knockdown through Western blots 
using actin as a housekeeping protein. Bottom: Western blot density plot of target bands normalized against respective housekeeping bands, 
represented as a fraction of cells only.  Each was done in triplicate. Error bars represent standard deviation. *: p<0.0066, **: p<0.0064, ***: 
p<0.0054 (two-tailed T-test).
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Figure 5.1.3: siRNA optimization assay for target protein hnRNPU.   
SH-SY5Y cells were transfected with two different scrambled siRNAs (neg ctrl 1 and 2) or three different target siRNAs (#1, #2 and #3) or a 
combination of two target siRNAs (#1&2, #1&3 and #2&3). Top: Visualisation of target protein siRNA knockdown through Western blots 
using actin as a housekeeping protein. Bottom: Western blot density plot of target bands normalized against respective housekeeping bands, 
represented as a fraction of cells only.  Each was done in triplicate. Error bars represent standard deviation. *: p<0.00018, **: p<0.00015, 
***: p<9.62x10
-5
, *1: p<0.034, **1: p<0.012, ***1: p<0.0018, **2: p<0.032 / p<0.033, ***2: p<0.010 / p<0.022 (two-tailed T-test). 
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Figure 5.1.4: siRNA optimization assay for target protein PTBP1.   
SH-SY5Y cells were transfected with two different scrambled siRNAs (neg ctrl 1 and 2) or three different target siRNAs (#1, #2 and #3) or a 
combination of two target siRNAs (#1&2, #1&3 and #2&3). Top: Visualisation of target protein siRNA knockdown through Western blots 
using actin as a housekeeping protein. Bottom: Western blot density plot of target bands normalized against respective housekeeping bands, 
represented as a fraction of cells only.  Each was done in triplicate. Error bars represent standard deviation. *: p<0.00019, **: p<0.00018, 
***: p<0.00011, *1: p<0.0025 / 0.0050, **1: p<0.0016 / 0.0027, ***1: p<0.00059 / 0.0014, ***2: p<0.048, ***3: p<0.017 (two-tailed T-test).
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Figure 5.1.5: siRNA optimization assay for target protein hnRNPD0.   
SH-SY5Y cells were transfected with two different scrambled siRNAs (neg ctrl 1 and 2) or three different target siRNAs (#1, #2 and #3) or a 
combination of two target siRNAs (#1&2, #1&3 and #2&3). Top: Visualisation of target protein siRNA knockdown through Western blots 
using actin as a housekeeping protein. Bottom: Western blot density plot of target bands normalized against respective housekeeping bands, 
represented as a fraction of cells only.  Each was done in triplicate. Error bars represent standard deviation. *: p<0.0349, **: p<0.00421, ***: 
p<0.00213 (two-tailed T-test). 
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Figure 5.1.6: siRNA optimization assay for target protein CP2.   
SH-SY5Y cells were transfected with two different scrambled siRNAs (neg ctrl 1 and 2) or three different target siRNAs (#1, #2 and #3) or a 
combination of two target siRNAs (#1&2, #1&3 and #2&3). Top: Visualisation of target protein siRNA knockdown through Western blots 
using actin as a housekeeping protein. Bottom: Western blot density plot of target bands normalized against respective housekeeping bands, 
represented as a fraction of cells only.  Each was done in triplicate. Error bars represent standard deviation. *: p<0.045, **: p<0.018, ***: 
p<0.029 (two-tailed T-test).
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Figure 5.1.7: siRNA optimization assay for target protein TDP43.   
SH-SY5Y cells were transfected with two different scrambled siRNAs (neg ctrl 1 and 2) or custom-designed target siRNAs (custom). Top: 
Visualisation of target protein siRNA knockdown through Western blots using actin as a housekeeping protein. Bottom: Western blot 
density plot of target bands taking into account respective housekeeping bands, represented as a fraction of cells only.  Each was done in 
triplicate. Error bars represent standard deviation.  ***: p<0.00035 (two-tailed T-test).
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5.2 Effects of shortlisted protein siRNA knockdowns on transcriptional activity of 
MAPT core promoter domains 
 
After establishing the assay protocol, the efficacy of the siRNAs against the proteins 
of interest, the co-transfection functional assays could proceed. The MAPT core promoter 
plasmid constructs to be used in these assays were created by Victoria Kay and had been 
tested and sequenced extensively. These promoter plasmid constructs were based on the 
MAPT promoter region (Figure 5.2.1). The 1,398 bp core promoter region is 47,370 bp 
upstream of the C and D regions and it is in the C region where rs242557 resides. Of 
multiple haplotypes in the H1 clade, the H1c sub-haplotype drives the association with PSP 
and CBD, suggesting that it carries the pathogenic variation leading to increased risk of 
these largely sporadic disorders. 
 
Hence, to fully investigate the effects of gene knockdown of the proteins of interest, 
various different promoter plasmid constructs were made. Although the underlying impetus 
for this work was based on the rs242557 SNP located in the C region, it was important to 
not only study the effect of the proteins of interest on the C region but also on the various 
different aspects of the MAPT promoter region and how they relate and interact to the 
different gene knockdowns. This would shed as much light on the in vivo system ex vivo. 
These plasmid constructs, also shown in Figure 5.2.1, were the core promoter B1, an 
extended core promoter region termed B1+B2, the downstream promoter region, C, where 
rs242557 resided (hence the different haplotypes, C-H1b and C-H1c), a combination of the 
core promoter B1 with the different haplotypes of the C region (B1+C-H1b and B1+C-H1c), 
the core promoter B1 with an extended sequence of the downstream promoter region 
(termed B1+D+C-H1b and B1+D+C-H1c) as well as the extended downstream promoter 
regions on their own (D+C-H1b and D+C-H1c). 
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Figure 5.2.1: Organization of the MAPT promoter region and promoter plasmid constructs derived from it.   
1. Schematic of the MAPT promoter region showing the relation of the core promoter with its downstream element. 2. Various promoter 
constructs inserted to the pGL4.10 vector. 
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U2AF2 
 
The first protein to be knocked down in the co-transfection assay was U2AF2  
(Figure 5.2.2). Before any analysis can begin, checks on whether the co-transfection assay 
had worked had to be done. The pGL4 siRNA was co-transfected with the plasmid 
construct containing the B1 core promoter which was the strongest plasmid construct 
amongst all the other plasmid constructs on their own in a luciferase assay. Compared to 
the B1 plasmid construct on its own, the co-transfection of the B1 plasmid construct with 
pGL4 siRNA did manage to knock it down by 84.1%, similar to the 80% seen during the 
optimization experiment. Next, co-transfection of the B1 plasmid construct with negative 
control 1 siRNA was compared to transfection with plasmid only to observe whether there 
was any difference between the two conditions. Out of the ten plasmid constructs used, 
only two plasmid constructs that had been co-transfected with negative control 1 siRNA 
(B1+C-H1b and B1+D+C-H1b), did show significant reductions of around 25%.  
 
After ascertaining that the co-transfection assay had largely worked as it should, 
analysing the effect of knocking down U2AF2 was done by expressing the knock down 
effect relative to the same plasmid construct co-transfected with negative control 1 siRNA. 
This would allow any non-specific effects of siRNA transfection on plasmid transfection to 
be taken into account (bottom panel of Figures 5.2.2 and 5.2.2 continued) and any 
comparison to co-transfection with negative control 1 siRNA was similar to comparisons to 
the plasmid constructs on their own. The first observable effect of reducing the level of 
U2AF2 in the cell was that regardless which MAPT plasmid construct was used, all of them 
performed less effectively. The largest effect of knocking down U2AF2 was on the core 
promoter, B1, and the extended core promoter, B1+B2, both of which had their functions 
reduced by about 70%.  
 
The region of most interest was the downstream promoter region, C, where 
rs242557 resides. C-H1b was significantly more sensitive to the reduction of U2AF2 levels 
than C-H1c with a 60% reduction in transcription compared to a 50% reduction 
respectively (p<0.01). When the core promoter, B1, was included upstream to the C region 
however, the allelic effect seen before was abolished. Both plasmid constructs B1+C-H1b 
and B1+C-H1c were not significantly different from each other with a reduction in 
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promoter strength of about 50% but were significantly less affected than B1 alone (70%). 
The extended downstream promoter region D+C, had the opposite effect in that the allelic 
effect was significantly exacerbated (p<0.01). Although D+C-H1b with reduced levels of 
U2AF2 varied similarly to C-H1b, which was a 60% reduction in the luciferase assay, 
D+C-H1c was less sensitive to the effects of low levels of U2AF2 (30% reduction) than the 
50% reduction with C-H1c. 
 
It was interesting to note that when the different strands of the MAPT promoter were 
put together: the core promoter B1 and the extended downstream promoter region D+C 
(B1+D+C – the most extensive promoter construct used), the largest and most significant 
(p<0.001) rs242557 allelic effect was seen. Of all the H1b plasmid constructs used, siRNA 
knockdown of U2AF2 had the least effect on B1+D+C-H1b. This was still a 40% reduction 
and significantly less than U2AF2 knockdown with B1 alone (70% reduction). No 
significant effect was seen with U2AF2 knockdown on B1+D+C-H1c . Hence, the 
reduction of U2AF2 had very little if any effect on the function of B1+D+C-H1c but 
negatively affected B1+D+C-H1b ten-fold more. Another interesting note was that even 
though no allelic effect was seen with B1+C, it was only when the D region was included 
that the full allelic effect was observed. Thus, it was not only important to study the 
different components of a promoter but also the cumulative effects of these components. 
All these results seemed to suggest that U2AF2 was required for the normal functioning of 
MAPT promoter except maybe in the case of B1+D+C-H1c.
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Figure 5.2.2: Effects of U2AF2 siRNA knockdown on various regions of MAPT core promoter plasmid constructs.   
SH-SY5Y cells were transfected with negative control 1 siRNA (neg ctrl 1) or target siRNAs (#1&2) along with luciferase reporter plasmids 
for six different combinations of MAPT promoter regions (B1, B1+B2, C, B1+C, B1+D+C and D+C), four of which were from a H1b or 
H1c background (C, B1+C, B1+D+C and D+C). Top: Relative luminescence for each transfection condition with pGL4 siRNA as a positive 
control knockdown of B1. Bottom: Representation of target siRNA cotransfection as a fraction of their respective negative control 1 siRNA 
cotransfection. Each was done in triplicate. Error bars represent standard deviation.  *: p<0.01, **: p<0.001 (two-tailed T-test).   
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Figure 5.2.2 (continued): Effects of U2AF2 siRNA knockdown on various regions of MAPT core promoter plasmid constructs.   
SH-SY5Y cells were transfected with negative control 1 siRNA (neg ctrl 1) or target siRNAs (#1&2) along with luciferase reporter plasmids 
for two different combinations of MAPT promoter regions (C and D+C), from a H1b or H1c background. Top: Relative luminescence for 
each transfection condition with pGL4 siRNA as a positive control knockdown of B1. Bottom: Representation of target siRNA 
cotransfection as a fraction of their respective negative control 1 siRNA cotransfection. Each was done in triplicate. Error bars represent 
standard deviation.  *: p<0.01 (two-tailed T-test). Different scale to previous graph. 
 159 
hnRNPU 
 
Before any analysis can begin, checks on whether the co-transfection assay had 
worked had to be done. The pGL4 siRNA was co-transfected with the plasmid construct 
containing the B1 core promoter which was the strongest plasmid construct amongst all the 
other plasmid constructs on their own in a luciferase assay. Compared to the B1 plasmid 
construct on its own, the co-transfection of pGL4 siRNA with B1 plasmid construct did 
manage to knock it down by 81.0%, similar to the 80% seen during the optimization 
experiment (Figure 5.2.3). Next, co-transfection of negative control 1 siRNA with plasmid 
constructs were compared to transfections with plasmids only to observe whether there was 
no significance difference between the two conditions. Out of the ten plasmid constructs 
used, only two plasmid constructs that had been co-transfected with negative control 1 
siRNA (B1+B2 and B1+D+C-H1b), did show significant reductions of around 30% and 
20% respectively. 
 
The first observable effect of reducing the level of hnRNPU in the cell was that 
unlike U2AF2, the relationship with protein knockdown and MAPT promoter region was 
less straightforward. The largest effect of knocking down hnRNPU was not only on the 
core promoter, B1, and the extended core promoter, B1+B2, both of which had their 
transcriptional activity reduced by about 60% but also on B1+D+C-H1b which had its 
activity increased by about 60%.  
 
The region of most interest was the downstream promoter region, C, where 
rs242557 resided. Although the reduction of hnRNPU level did not affect the C region 
much, it had an opposing effect depending on the allelotype. C-H1b was significantly less 
sensitive to the reduction of hnRNPU levels than C-H1c with a 10% gain in promoter 
strength compared to a 20% reduction respectively (p<0.001). When the core promoter, B1, 
was included with the C region however, the allelic effect seen before was substantially 
exacerbated (p<0.0001). While B1+C-H1b had a slight reduction in the gain of promoter 
strength (4%), B1+C-H1c had a three-fold reduction in promoter strength (60%). Hence, 
although B1+C-H1b was hardly affected by the reduction of hnRNPU, C- H1b abolished 
any effect the lack of hnRNPU had on B1 (reduction of 60%). The opposite was true for 
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B1+C-H1c which showed similar results to the core promoter, B1 affected by hnRNPU 
knockdown.   
 
The extended downstream promoter region D+C, was differently influenced by the 
rs242557 alleles (p<0.01) on hnRNPU knockdown. Although D+C-H1b had similar gains 
of about 10% luciferase activity like the C-H1b and B1+C-H1b, D+C-H1c was more 
sensitive to the effects of hnRNPU knockdown (40% gain in function) than the 20% or 
60% reduction with C-H1c and B1+C-H1c respectively. Thus, from these results, it seemed 
that hnRNPU had very little effect on the H1b haplotype of the C region even with the core 
promoter or an extended C region. It did, however, have an increased opposing effect on 
the H1c haplotype depending on whether it was paired with the core promoter or the 
extended downstream region. 
 
It was interesting to note that when the different domains of the MAPT promoter 
were put together: the core promoter B1 and the extended downstream promoter region 
D+C (B1+D+C – the most complete promoter construct used), no significant rs242557 
allelic effect was observed. While the rest of the H1b plasmid constructs were hardly 
affected by the reduction of hnRNPU levels, B1+D+C-H1b had the largest gain (60%) in 
promoter strength with hnRNPU knockdown. Since very little effect was seen either with 
B1+C-H1b or D+C-H1b, this result hinted at a possible synergistic effect of combining the 
core promoter and the extended downstream promoter. The 50% gain in promoter strength 
with B1+D+C-H1c which was not significant when compared to B1+D+C-H1b might 
suggest that the haplotype effect is abolished by this synergistic effect. Hence, the reduction 
of hnRNPU had no haplotype effect on the function of B1+D+C. Another interesting 
observation was that even though no allelic effect was seen with B1+D+C, it was only 
when the D region was included to B1+C-H1c or C-H1c that similar, non-significant 
effects were observed. Thus, it was not only important to study the different components of 
a promoter but also the cumulative effects of these components. All these results seemed to 
suggest that hnRNPU had a complex repressive effect on the MAPT promoter, largely 
brought about by the D region which otherwise masked any haplotype effect.
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Figure 5.2.3: Effects of hnRNPU siRNA knockdown on various regions of MAPT core promoter plasmid constructs.   
SH-SY5Y cells were transfected with negative control 1 siRNA (neg ctrl 1) or target siRNAs (#1&2) along with six different MAPT core 
promoter regions (B1, B1+B2, C, B1+C, B1+D+C and D+C), four of which were from a H1b or H1c background (C, B1+C, B1+D+C and 
D+C). Top: Relative luminescence for each transfection condition with pGL4 siRNA as a positive control knockdown of B1. Bottom: 
Representation of target siRNA cotransfection as a fraction of their respective negative control 1 siRNA cotransfection. Each was done in 
triplicate. Error bars represent standard deviation.  *: p<0.01, **: p<0.001, ***:p<0.0001 (two-tailed T-test).
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Figure 5.2.3 (continued): Effects of hnRNPU siRNA knockdown on various regions of MAPT core promoter plasmid constructs.   
SH-SY5Y cells were transfected with negative control 1 siRNA (neg ctrl 1) or target siRNAs (#1&2) along with two different MAPT core 
promoter regions (C and D+C), from a H1b or H1c background. Top: Relative luminescence for each transfection condition with pGL4 
siRNA as a positive control knockdown of B1. Bottom: Representation of target siRNA cotransfection as a fraction of their respective 
negative control 1 siRNA cotransfection. Each was done in triplicate. Error bars represent standard deviation.  *: p<0.01, **: p<0.001 (two-
tailed T-test).
 163 
PTBP1 
 
Before any analysis can begin, checks on whether the co-transfection assay had 
worked had to be done. The pGL4 siRNA was co-transfected with the plasmid construct 
containing the B1 core promoter which was the strongest plasmid construct amongst all the 
other plasmid constructs on their own in a luciferase assay. Compared to the B1 plasmid 
construct on its own, the co-transfection of B1 plasmid construct with pGL4 siRNA did 
manage to knock it down by 60.1%, not as much as the 80% seen during the optimization 
experiment (Figure 5.2.4). Next, co-transfection with negative control 1 siRNA was 
compared to transfection with plasmid only to observe whether there was no significance 
difference between the two conditions. Out of the ten plasmid constructs used, only two 
plasmid constructs that had been co-transfected with negative control 1 siRNA (B1 and 
D+C-H1b), did show significant reductions of around 30%.  
 
The first observable effect of knockdown of PTBP1 in the cells was that like 
U2AF2 this caused reduction in transcriptional activity for most of the MAPT plasmid 
construct variants. The largest was on the core promoter and the H1c haplotype of the 
downstream C region, B1+C-H1c, with reductions in transcriptional activity by about 70%. 
This was a 50% greater reduction that PTBP1 knockdown had on the core promoter, B1, 
alone. PTBP1 knockdown had the strongest effect on the extended core promoter, B1+B2, 
with 65% greater reduction in transcriptional activity compared to B1 alone. 
 
Based on the initial premise of this project, the region of greatest interest was the 
downstream promoter region, C, where rs242557 resided. Although the reduction of 
PTBP1 level did not affect the C region much, it had an opposing effect depending on the 
allelotype. C-H1b was significantly more sensitive to the reduction of PTBP1 levels than 
C-H1c with a 40% reduction in promoter strength compared to a 15% gain respectively 
(p<0.01). When the core promoter, B1, was included with the C region however, the allelic 
effect seen before was eliminated. Both plasmid constructs B1+C-H1b and B1+C-H1c were 
not significantly different from each other with a reduction in promoter strength of about 
65% like with to B1 alone. The extended downstream promoter region D+C, had a similar 
effect as B1+C in that the allelic effect was abolished. The effect was less pronounced as 
there was no significant difference between the activities of D+C-H1b and D+C-H1c, with 
 164 
a reduction in promoter strength of about 30%. Unlike B1+C where there were significant 
effects of the core promoter on both haplotypes of the C region, the D region did not have 
any significant effect on C-H1b but rather only on C-H1c. 
 
It was interesting to note that when the different domains of the MAPT promoter 
were put together –  the core promoter B1 and the extended downstream promoter region 
D+C (B1+D+C – the most extensive promoter construct used), there was still a significant 
(p<0.05) allelic effect of rs242557. However, B1+C and D+C did not show any allelic 
effect, demonstrating the complex and synergistic effects of the different elements of the 
MAPT promoter.  
 
Compared to the other plasmids representing the H1b sub-haplotype, B1+D+C-H1b 
had a very similar reduction (40%) in promoter activity with PTBP1 knockdown, similar to 
the effect on B1 alone. Of all the H1c sub-haplotype variants, the transcription of B1+D+C-
H1c was the least affected by PTBP1 knockdown with only a 2% reduction compared to a 
50% reduction seen with B1 alone. Hence, PTBP1 knockdown had very little if any effect 
on the function of B1+D+C-H1c but caused a 20-fold greater reduction of B1+D+C-H1b 
transcriptional activity. It is also of interest that with PTBP1 knockdown, the effect on H1c 
haplotype promoter variants varied widely: there was a gain in allelic effect seen with C-
H1c alone, a moderate reduction in allelic effect with the D+C-H1c and a substantial 
reduction in allelic effect with B1+C-H1c whereas B1+D+C-H1c was not affected. Thus, it 
was not only important to study the different components of a promoter but also the 
cumulative interactions of these components. All these results seemed to suggest that 
PTBP1 has an intimate and significant relationship with the H1c risk haplotype of MAPT 
promoter
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Figure 5.2.4: Effects of PTBP1 siRNA knockdown on various regions of MAPT core promoter plasmid constructs.   
SH-SY5Y cells were transfected with negative control 1 siRNA (neg ctrl 1) or target siRNAs (#1&2) along with six different MAPT core 
promoter regions (B1, B1+B2, C, B1+C, B1+D+C and D+C), four of which were from a H1b or H1c background (C, B1+C, B1+D+C and 
D+C). Top: Relative luminescence for each transfection condition with pGL4 siRNA as a positive control knockdown of B1. Bottom: 
Representation of target siRNA cotransfection as a fraction of their respective negative control 1 siRNA cotransfection. Each was done in 
triplicate. Error bars represent standard deviation. 
+
: p<0.05, *: p<0.01 (two-tailed T-test). 
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Figure 5.2.4 (continued): Effects of PTBP1 siRNA knockdown on various regions of MAPT core promoter plasmid constructs.   
SH-SY5Y cells were transfected with negative control 1 siRNA (neg ctrl 1) or target siRNAs (#1&2) along with two different MAPT core 
promoter regions (C and D+C), from a H1b or H1c background. Top: Relative luminescence for each transfection condition with pGL4 
siRNA as a positive control knockdown of B1. Bottom: Representation of target siRNA cotransfection as a fraction of their respective 
negative control 1 siRNA cotransfection. Each was done in triplicate. Error bars represent standard deviation. *: p<0.01 (two-tailed T-test).  
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hnRNPD0 
 
Before any analysis can begin, checks on whether the co-transfection assay had 
worked had to be done. The pGL4 siRNA was co-transfected with the plasmid construct 
containing the B1 core promoter which was the strongest plasmid construct amongst all the 
other plasmid constructs on their own in a luciferase assay. Compared to the B1 plasmid 
construct on its own, the co-transfection of B1 plasmid construct with pGL4 siRNA did 
manage to knock it down by 73.9%, close to the 80% seen during the optimization 
experiment (Figure 5.2.5). Next, co-transfection of plasmid constructs with negative control 
1 siRNA was compared to transfection with plasmid only to observe whether there was no 
significance difference between the two conditions. Out of the ten plasmid constructs used, 
only two plasmid constructs that had been co-transfected with negative control 1 siRNA 
(B1+B2 and B1+C-H1c), did show significant reduction of around 30% and gain of 20% 
respectively.  
 
The first observable effect of reducing the level of hnRNPD0 in the cell was that it 
had a close and complex relationship with the various MAPT promoter variants. The largest 
effect of knocking down hnRNPD0 was on the core promoter, B1, and the H1c haplotype 
of the extended downstream promoter region, D+C-H1c and extended promoter, B1+D+C-
H1c, all of which had about 100% increases in transcriptional activity. The extended core 
promoter, B1+B2, however, was significantly unaffected with only a slight reduction of 6% 
(p<0.001). 
 
Based on the initial premise of this project, the region of greatest interest was the 
downstream promoter region, C, where rs242557 resided. Although hnRNPD0 knockdown 
did not affect the C region much, it had an opposing effect depending on the allelotype. C-
H1b was significantly more sensitive to hnRNPD0 knockdown than C-H1c with a 30% 
gain in promoter strength compared to a 60% reduction respectively (p<0.01). When the 
core promoter, B1, was included with the C region however, the allelic effect was reduced 
and B1 seemed to not affect the C region much. B1+C-H1b was unaffected by the 
knockdown of hnRNPD0 (reduction of 1%) which was similar to B1+B2 while B1+C-H1c 
was less affected (reduction of 40%).  
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Knockdown of hnRNPD0 had the opposite allelic effect on downstream promoter 
region D+C (p<0.01). D+C-H1b and C-H1b activity had 30% reduction and 30% increase 
respectively. Knockdown of hnRNPD0 had the strongest allele-specific on D+C-H1c 
promoter activity (100% increase) whereas the C-H1c variant had a 60% reduction in 
activity.  
 
When the different domains of the MAPT promoter were put together: the core 
promoter B1 and the extended downstream promoter region D+C (B1+D+C – the most 
extensive promoter construct used), a significant (p<0.01) rs242557 allelic effect was still 
seen. Of all the H1b plasmid constructs used, B1+D+C-H1b had a similar gain in promoter 
strength as C-H1b (30%) with hnRNPD0 knockdown. B1+D+C-H1c unlike B1+D+C-H1b 
had the greatest increase in promoter activity of all the H1c plasmid constructs, a 135% 
gain. Hence, hnRNPD0 knockdown had a moderate effect on the function of B1+D+C-H1b 
but caused a four-fold increase in B1+D+C-H1c activity. Another interesting note was that 
even though no knockdown effect was seen with B1+C-H1b, it was only when the D region 
was included that the full allelic effect was restored. The D region also had an overriding 
effect on B1+C-H1c. Thus, it was not only important to study the different components of a 
promoter but also the cumulative effects of these components. All these results seemed to 
suggest that hnRNPD0 had a haplotypic effect on the various components of the MAPT 
promoter but had an overall repressive haplotypic effect on the MAPT promoter.
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Figure 5.2.5: Effects of hnRNPD0 siRNA knockdown on various regions of MAPT core promoter plasmid constructs.   
SH-SY5Y cells were transfected with negative control 1 siRNA (neg ctrl 1) or target siRNAs (#1&2) along with six different MAPT core 
promoter regions (B1, B1+B2, C, B1+C, B1+D+C and D+C), four of which were from a H1b or H1c background (C, B1+C, B1+D+C and 
D+C). Top: Relative luminescence for each transfection condition with pGL4 siRNA as a positive control knockdown of B1. Bottom: 
Representation of target siRNA cotransfection as a fraction of their respective negative control 1 siRNA cotransfection. Each was done in 
triplicate. Error bars represent standard deviation.  *: p<0.01, **: p<0.001 (two-tailed T-test)
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Figure 5.2.5 (continued): Effects of hnRNPD0 siRNA knockdown on various regions of MAPT core promoter plasmid constructs.  
SH-SY5Y cells were transfected with negative control 1 siRNA (neg ctrl 1) or target siRNAs (#1&2) along with two different MAPT core 
promoter regions (C and D+C), from a H1b or H1c background. Top: Relative luminescence for each transfection condition with pGL4 
siRNA as a positive control knockdown of B1. Bottom: Representation of target siRNA cotransfection as a fraction of their respective 
negative control 1 siRNA cotransfection. Each was done in triplicate. Error bars represent standard deviation.  *: p<0.01 (two-tailed T-test).
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CP2 
 
Before any analysis can begin, checks on whether the co-transfection assay had 
worked had to be done. The pGL4 siRNA was co-transfected with the plasmid construct 
containing the B1 core promoter which was the strongest plasmid construct amongst all the 
other plasmid constructs on their own in a luciferase assay. Compared to the B1 plasmid 
construct on its own, the co-transfection of B1 plasmid constructs with pGL4 siRNA did 
manage to knock it down by 72.3%, similar to the 80% seen during the optimization 
experiment (Figure 5.2.6). Next, co-transfection of all plasmid constructs with negative 
control 1 siRNA was compared to transfections with plasmids only to observe whether 
there was no significance difference between the two conditions. Out of the ten plasmid 
constructs used, only two plasmid constructs that had been co-transfected with negative 
control 1 siRNA (C-H1c and D+C-H1c), did show significant reductions of around 30%.  
 
The first observable effect of CP2 knockdown was that it was allele specific and had 
a moderate effect on most of the MAPT promoter variants. The largest effect was on the 
H1c haplotype of the downstream C region and the extended downstream region, C+D, 
both had substantial gains in activity of 150% and 200% respectively. This was sharply 
contrasted with the 57% and 13% reduction in activity of the core promoter, B1 and the 
extended core promoter, B1+B2.  
 
Based on the initial premise of this project, the region of greatest interest was the 
downstream promoter region, C, where rs242557 resided. C-H1b was significantly less 
responsive to CP2 knockdown than C-H1c with an 8% and 150% gains in promoter activity, 
respectively (p<0.001). This was the largest allelic effect seen with almost a twenty-fold 
difference between the risk and non-risk associated haplotype. Hence, CP2 would exert a 
much more repressive effect on the risk haplotype. When the core promoter, B1, was 
included with the C region however, the extreme allelic effect seen before was abolished. 
Both plasmid constructs B1+C-H1b and B1+C-H1c were not significantly different from 
each other with a reduction in promoter strength of about 50%, not dissimilar to that seen 
with B1 alone.  
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The extended downstream promoter region D+C, had the opposite effect in that the 
allelic effect was significantly exacerbated (p<0.001). D+C-H1b with CP2 knockdown 
varied moderately compared to C-H1b which had a 36% gain in the luciferase assay. D+C-
H1c was more affected by CP2 knockdown (200% gain) than the 150% gain with C-H1c.  
 
When the different domains of the MAPT promoter were put together: the core 
promoter B1 and the extended downstream promoter region D+C (B1+D+C – the most 
extensive promoter construct used), CP2 knockdown resulted in the smallest significant 
(p<0.001) rs242557 allelic effect and the differences were in the opposite direction 
compared to the previous results with CP2. Of all the H1b plasmid constructs used, there 
was little influence on promoter activity and, B1+D+C-H1b like D+C-H1b had a 30% gain 
in promoter strength with low levels of CP2. Although B1+D+C-H1c like B1+D+C-H1b 
promoter activity was least affected of all the H1c plasmid constructs, it was much more 
dramatic as it was a 50% reduction compared to a gain, but comparing to B1+C-H1c, there 
was little change. This was a big change from the 150 and 200% gain seen with C-H1c and 
D+C-1c. Hence, the CP2 knockdown had a very modest haplotype effect (two and half-fold 
difference) on B1+D+C-H1 but of opposing effect. Also of interest was that even though no 
allelic effect was seen with B1+C, it was only when the D region was included that the full 
allelic effect was observed and this was completely different from either B1+C or D+C. 
Thus, it was not only important to study the different components of a promoter but also the 
cumulative effects of these components. All these results seemed to suggest that CP2 has a 
highly specific role in the downstream MAPT promoter region of C and D+C but this is 
attenuated by the presence of the core promoter B1.  
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Figure 5.2.6: Effects of CP2 siRNA knockdown on various regions of MAPT core promoter plasmid constructs.   
SH-SY5Y cells were transfected with negative control 1 siRNA (neg ctrl 1) or target siRNAs (#1&2) along with six different MAPT core 
promoter regions (B1, B1+B2, C, B1+C, B1+D+C and D+C), four of which were from a H1b or H1c background (C, B1+C, B1+D+C and 
D+C). Top: Relative luminescence for each transfection condition with pGL4 siRNA as a positive control knockdown of B1. Bottom: 
Representation of target siRNA cotransfection as a fraction of their respective negative control 1 siRNA cotransfection. Each was done in 
triplicate. Error bars represent standard deviation.  *: p<0.01, **: p<0.001 (two-tailed T-test).
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Figure 5.2.6 (continued): Effects of CP2 siRNA knockdown on various regions of MAPT core promoter plasmid constructs.  SH-
SY5Y cells were transfected with negative control 1 siRNA (neg ctrl 1) or target siRNAs (#1&2) along with two different MAPT core 
promoter regions (C and D+C), from a H1b or H1c background. Top: Relative luminescence for each transfection condition with pGL4 
siRNA as a positive control knockdown of B1. Bottom: Representation of target siRNA cotransfection as a fraction of their respective 
negative control 1 siRNA cotransfection. Each was done in triplicate. Error bars represent standard deviation.  **: p<0.001 (two-tailed T-
test).
 175 
TDP43 
 
Before any analysis can begin, checks on whether the co-transfection assay had 
worked had to be done. The pGL4 siRNA was co-transfected with the plasmid construct 
containing the B1 core promoter which was the strongest plasmid construct amongst all the 
other plasmid constructs on their own in a luciferase assay. Compared to the B1 plasmid 
construct on its own, the co-transfection of the B1 plasmid construct with pGL4 siRNA did 
manage to knock it down by 84.8%, very similar to the 80% seen during the optimization 
experiment (Figure 5.2.7). Next, co-transfection of plasmid constructs with negative control 
1 siRNA was compared to transfections with plasmids only to observe whether there was 
no significance difference between the two conditions. Out of the ten plasmid constructs 
used, three plasmid constructs that had been co-transfected with negative control 1 siRNA 
(B1+C-H1c, B1+D+c-H1b and B1+D+C-H1c), did show significant reductions of around 
50%, 20% and 30% respectively.  
 
The first observable effect of TDP43 knockdown was that only those promoter 
variants containing the core promoter domain, B1, were affected with the strongest effect 
on the B1, B1+B2, B1+C-H1b, B1+C-H1c, B1+D+C-H1b, B1+D+C-H1c variants. In all 
cases, TDP43 knockdown resulted in a range of increases in promoter activity (from 170% 
for B1+D+C-H1b to 240% for B1+D+C-H1c with non-significant differences) between 
variants under a two-tailed T-test. The rs242557 allelotype did not have any modulatory 
effect on the changes caused by TDP43 knockdown as seen with B1+C and B1+D+C. 
Furthermore, plasmid constructs without the core promoter, B1, element (C and D+C) were 
not affected by the knockdown of TDP43. This demonstrated that TDP43 specifically acted 
on the core promoter of MAPT to repress its activity. 
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Figure 5.2.7: Effects of TDP43 siRNA knockdown on various regions of MAPT core promoter plasmid constructs.   
SH-SY5Y cells were transfected with negative control 1 siRNA (neg ctrl 1) or target siRNAs (#1&2) along with six different MAPT core 
promoter regions (B1, B1+B2, C, B1+C, B1+D+C and D+C), four of which were from a H1b or H1c background (C, B1+C, B1+D+C and 
D+C). Top: Relative luminescence for each transfection condition with pGL4 siRNA as a positive control knockdown of B1. Bottom: 
Representation of target siRNA cotransfection as a fraction of their respective negative control 1 siRNA cotransfection. Each was done in 
triplicate. Error bars represent standard deviation.
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Figure 5.2.7 (continued): Effects of TDP43 siRNA knockdown on various regions of MAPT core promoter plasmid constructs.   
SH-SY5Y cells were transfected with negative control 1 siRNA (neg ctrl 1) or target siRNAs (#1&2) along with two different MAPT core 
promoter regions (C and D+C), from a H1b or H1c background. Top: Relative luminescence for each transfection condition with pGL4 
siRNA as a positive control knockdown of B1. Bottom: Representation of target siRNA cotransfection as a fraction of their respective 
negative control 1 siRNA cotransfection. Each was done in triplicate. Error bars represent standard deviation.  
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PAX8 
 
Before any analysis can begin, checks on whether the co-transfection assay had 
worked had to be done. The pGL4 siRNA was co-transfected with the plasmid construct 
containing the B1 core promoter which was the strongest plasmid construct amongst all the 
other plasmid constructs on their own in a luciferase assay. Compared to the B1 plasmid 
construct on its own, the co-transfection of the B1 plasmid constructs with pGL4 siRNA 
did manage to knock it down by 74.3%, close to the 80% seen during the optimization 
experiment (Figure 5.2.8). Next, co-transfection of plasmid constructs with negative control 
1 siRNA was compared to transfections with plasmids only to observe whether there was 
no significance difference between the two conditions. Out of the ten plasmid constructs 
used, none of the plasmid constructs that had been co-transfected with negative control 1 
varied significantly from their respective plasmid only co-transfection. 
  
The first observable effect of reducing the level of PAX8 in the cell was that no 
significant effect was seen for any of the MAPT plasmid construct used, regardless of the 
haplotype effect. This demonstrated that the transcription factor PAX8 did not specifically 
act on the promoter region of MAPT. As a transcription factor specific control, PAX8 had 
not been previously shown to interact with rs242557 and this was still the case. 
 179 
 
Figure 5.2.8: Effects of PAX8 siRNA knockdown on various regions of MAPT core promoter plasmid constructs.   
SH-SY5Y cells were transfected with negative control 1 siRNA (neg ctrl 1) or target siRNAs (#1&2) along with six different MAPT core 
promoter regions (B1, B1+B2, C, B1+C, B1+D+C and D+C), four of which were from a H1b or H1c background (C, B1+C, B1+D+C and 
D+C). Top: Relative luminescence for each transfection condition with pGL4 siRNA as a positive control knockdown of B1. Bottom: 
Representation of target siRNA cotransfection as a fraction of their respective negative control 1 siRNA cotransfection. Each was done in 
triplicate. Error bars represent standard deviation.  
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Figure 5.2.8 (continued): Effects of PAX8 siRNA knockdown on various regions of MAPT core promoter plasmid constructs.  SH-
SY5Y cells were transfected with negative control 1 siRNA (neg ctrl 1) or target siRNAs (#1&2) along with two different MAPT core 
promoter regions (C and D+C), from a H1b or H1c background. Top: Relative luminescence for each transfection condition with pGL4 
siRNA as a positive control knockdown of B1. Bottom: Representation of target siRNA cotransfection as a fraction of their respective 
negative control 1 siRNA cotransfection. Each was done in triplicate. Error bars represent standard deviation.  
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5.3 Discussion on functional assays of shortlisted DNA-binding proteins 
 
 The choice of the transcription factor PAX8 as a control transcription factor for the 
functional assays was completely random. A titration of the PAX8 antibody with nuclear 
extracts of undifferentiated SH-SY5Y neuroblastoma cells showed that PAX8 was 
expressed in these cells and could be used as a transcription factor to be knocked down in 
the functional assays (result not included). 
 
 PAX8 belongs to the PAX family of transcription factors primarily involved in the 
development of the central nervous system.
261
 The protein structure consists of two regions 
of nuclear localization signal as well as an activating and an inhibitory region (Figure 
5.3.1A).
262
 In humans, there are four isoforms of PAX8 generated through alternative 
splicing.
263
 PAX8 was found to be expressed at the midbrain-hindbrain boundary, kidney 
and thyroid. In Wilm’s tumour, a paediatric renal carcinoma, PAX8 was found to be 
abnormally upregulated (Figure 5.3.1B).
264
 Based on its expression, it was subsequently 
found that PAX8 regulates the neural cell adhesion molecule (NCAM), Wilms’ tumour 
(WT1) and thyroperoxidase, a primary enzyme in thyroid hormone synthesis, genes (Figure 
5.3.1C).
265,266,267,268
 More recently, it was shown in glioma using EMSA, quantitative PCR 
and a telomerase activity assay that PAX8 bound directly to the promoter of both 
telomerase catalytic subunit (TERT) and the telomerase RNA component (TR).
269
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Figure 5.3.1: Schematic of PAX8 protein, its expression pattern and genes it acts on.   
(A) PAX8 consists of a paired box domain (striped), octapeptide (filled) and residual paired-type homeodomain (dotted). Nuclear 
localization signal (NLS), repressor (R) and activation (A) domains indicated. (B) In mice, the PAX8 expression is across the midbrain-
hindbrain boundary, kidney and thyroid. (C) Some of the genes known to be regulated by PAX8 include neural cell adhesion molecule 
(NCAM), E2F1 and Wilms’ tumour (WT1) genes.390,391,394,395,399  
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Before we can analyse the effects of the protein knockdowns on the C region (where 
rs242557 resides), downstream of the MAPT promoter region, or in different combinations 
with different elements of the MAPT promoter, we also need to analyse their effects on the 
core promoter if any. This would allow us to see if these proteins could be part of a 
transcriptional complex that forms the framework for the interaction of the core promoter 
and the regulatory (enhancer/repressor) C region. We looked at the effects of the individual 
protein knockdowns on the core promoter region B1 of MAPT and an extended promoter 
region which included the conserved region (B2) immediately downstream of B1 and of 
approximately the same size, thus named B1+B2 (Figure 5.3.2). This study did not include 
the effects of the individual protein knockdowns on B2 on its own. Hence, it would not be 
possible to attribute any effect seen on B1+B2 to either B1 or B2 or a synergistic effect of 
both elements. In light of the current results, however, it might be worth to investigate this 
further.  
  
Since this was a protein knockdown assay, any increase in the promoter luciferase 
read out would mean that a reduction of that protein led to that increase in activity and that 
the protein acts as a promoter repressor. An example of this is TDP-43. Reducing the level 
of TDP-43 in the cell using siRNA knockdown led to approximately a three-fold increase in 
promoter activity of B1 and this was the same with B1+B2. The control protein PAX8 
knockdown did not have any effect on the activity of B1 or B1+B2. All the protein 
knockdown effects were compared to the effects seen with knocking down with a 
scrambled control siRNA. 
 
When a reduction in the level of a protein leads to a reduction in the readout of the 
promoter luciferase assay, the protein could be an enhancer of promoter activity. Proteins 
knockdowns that reduced the activity of both B1 and B1+B2 were U2AF2, hnRNPU and 
PTB1. Both promoter elements B1 and B1+B2 were most significantly affected by U2AF2 
knockdown. This would suggest that the interplay of the opposing effects U2AF2 and 
TDP43 might be of importance in regulation of transcription with the possibility of the 
involvement of hnRNPU and PTB1. 
 
Noting the significant differences between the protein knockdown on B1 compared 
to B1+B2, keeping in mind no work was done on B2 alone, PTBP1, hnRNPD0 and CP2 
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stood out. For example, PTBP1 knockdown had a stronger effect on the extended promoter 
region B1+B2 compared to B1 alone. Knockdown of hnRNPD0 which had an enhancing 
effect on B1 alone and CP2 which had a repressive effect on B1 alone, both did not have 
any effect on B1+B2. Further study into B2 would need to be done to explain these effects, 
especially in light of the work currently being done to ascertain the natural antisense 
transcript being encoded in that region.  
 
After looking at the effects of the protein knockdowns on the core promoter 
elements, the next step is to look at the effects on the downstream C region in isolation to 
see if there were any allele-specific effects based on rs242557-G (H1b / H2) with rs242557-
A (H1c) (Figure 5.3.3). From earlier experiments, it was evident that TDP-43 does not 
interact with the rs242557 region. Hence, knocking this protein down had no significant 
effect on the transcriptional activity of the C region as was the case with the control protein 
knockdown of PAX8.  
 
With the neutral allelotype, C-H1b, most of the protein knockdowns had very little 
effect. U2AF2 and PTBP1 played a role in the transcriptional activity of C-H1b as reducing 
the levels of these proteins led to a reduction in the luciferase promoter assay. Knockdown 
of hnRNPU, hnRNPD0 and CP2 either had negligible or mildly enhancing effects on the C-
H1b element. Comparing these effects on C-H1b, the proteins of interest had a more 
pronounced effect on the region C-H1c risk allele. U2AF2 showed least difference between 
the two alleles. Nevertheless, U2AF2 knockdown did have an effect on C-H1c, albeit less 
pronounced compared to the other proteins of interest. hnRNPU knockdown enhanced C-
H1b, caused a slightly reduced activity of C-H1c. Conversely, knockdown of PTBP1 which 
repressed C-H1b, had negligible effect on C-H1c. Knockdown of hnRNPD0 like hnRNPU 
had a slightly enhancing effect on C-H1b but unlike hnRNPU, it repressed the activity of 
C-H1c more strongly. The biggest effect was seen with CP2 knockdown. Although it had 
negligible effect on C-H1b, it resulted in 2.5-fold enhancement of C-H1c activity.
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Figure 5.3.2: Effects of shortlisted DNA-binding proteins on the core promoter of MAPT plasmid constructs.   
Only shortlisted proteins that showed significant difference between the different plasmid constructs were included. Each was done in 
triplicate. Error bars represent standard deviation. *: p<0.01, **: p<0.001 (two-tailed T-test).   
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Figure 5.3.3: Effects of shortlisted DNA-binding proteins on the haplotype difference of the downstream promoter region of MAPT 
plasmid constructs. Only shortlisted proteins that showed significant difference between the different plasmid constructs were included. 
Each was done in triplicate. Error bars represent standard deviation. *: p<0.01, **: p<0.001 (two-tailed T-test).  
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After analyzing the effects of protein knockdown on the individual elements of the 
core promoter B1, B1+B2 and the C region, the effect on these elements combined were 
assessed (Figure 5.3.4). Although this is not representative of the native gene promoter 
structure, which is at over 70kb is prohibitively large, it nevertheless provides a simplified 
model to assess the allele-specific influence of the repressor C region on the core promoter.  
With the B1 core promoter region combined with the C region, knockdown of U2AF2 
caused a reduction of promoter activity like with B1 alone and this effect was not 
influenced by allelotype of the C region. 
 
 With knockdown of other proteins of interest such as hnRNPU, PTBP1 and CP2, 
there was a clear allele-specific effect of the C region on B1. For example, the repressive 
effect of hnRNPU knockdown on B1 was not modified by the presence of C-H1c but when 
combined with C-H1b, this effect was abolished. The reverse was true with knockdown of 
PTBP1 and CP2 in that their effects on B1 were not modified by C-H1b but in combination 
with C-H1c, the effect of PTBP1 knockdown was exacerbated whereas the effect of CP2 
was diminished.  
 
The only protein whose effect was modified by both allelotypes of the C region was 
hnRNPD0. In the first place, enhancing effect on B1 with hnRNPD0 knockdown was 
completely abolished in the presence of C-H1b. However, when combined with C-H1c, 
hnRNPD0 knockdown had a strongly opposing effect on the enhancing effect of B1 alone 
in that it represses of B1+C-H1c activity.   
 
 Hence, although the luciferase reporter vectors do not represent the full length 
promoter and could be missing vital regulatory elements in the omitted regions, these data 
show that the C region could be an allele-specific regulator of the upstream core promoter 
and this regulatory function is mediated by interaction with various trans-acting DNA-
binding proteins. These proteins are possibly part of a complex that juxtaposes the C region 
with the core promoter, thereby manifesting the allele-specific effects of rs242557.
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Figure 5.3.4: Effects of shortlisted DNA-binding proteins on the haplotype difference of the downstream promoter region on the core 
promoter of MAPT plasmid constructs.  
Only shortlisted proteins that showed significant difference between the different plasmid constructs were included. Each was done in 
triplicate. Error bars represent standard deviation. *: p<0.01, **: p<0.001, ***: p<0.0001 (two-tailed T-test).
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Another region of the promoter highlighted from work in our group as being 
potentially significant in MAPT gene regulation was entitled the D-region (Victoria Kay & 
Roberto Simone; personal communication). The D-region is located directly upstream to 
the C-region that contains rs242557. It has a high propensity to form strong secondary 
structures that might stop the progression of the RNA polymerase activity. The presence of 
structures was deduced from bioinformatic predictions made by TTS mapping software and 
from primary sequence analysis. When the D-region was combined with the C-region in the 
correct context, upstream to the C region, it has a stronger influence on the risk haplotype 
C-H1c than C-H1b (Figure 5.3.5).  
 
With knockdown of most of the proteins of interest, excepting hnRNPD0 and CP2, 
the D region had little effect on their previously described effects on C-H1b. It is possible 
that other trans factors are recruited to the D-region which lead to the reversal of the effect 
of hnRNPD0 knockdown from mildly enhancing to mildly repressive accounting for D+C-
H1b’s activity. These factors might also be involved in the increased enhancing effect on 
D+C-H1b by knockdown of CP2. Interestingly, similar effects that the D-region had on C-
H1b were also seen with C-H1c i.e. the role of hnRNPD0 knockdown on D+C-H1c was 
reversed and the enhancing effect of CP2 knockdown on D+C-H1c was exacerbated.  
 
 Unlike the limited effect of the D region on C-H1b variants, addition of the D 
region in context to C-H1c resulted in responsiveness to knockdown of all the proteins of 
interest. In the first place, addition of the D-region resulted in reversal of the response seen 
with knockdown of hnRNPU, hnRNPD0 and PTBP1 on C-H1c were reversed while the 
effect of U2AF2 knockdown in repressing the activity of D+C-H1c was diminished. It was 
interesting to note that the allelic effect of the C-region was more pronounced when the D-
region was introduced (Figure 5.3.6). This was the first instance where the activity of D+C-
H1c was much more muted through the series of increased repressive effects from the 
proteins of interest hnRNPU, hnRNPD0 and CP2 as well as the smaller role U2AF2 had in 
stimulating its activity. This was in contrast with D+C-H1b where U2AF2 was the main 
driver for its function. The role of PTBP1 was the only protein that was not influenced by 
the haplotype effect as a result of the D-region.
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Figure 5.3.5: Effects of shortlisted DNA-binding proteins on the longer downstream promoter region for each downstream 
haplotype of MAPT plasmid constructs.  
Only shortlisted proteins that showed significant difference between the different plasmid constructs were included. Each was done in 
triplicate. Error bars represent standard deviation. +: p<0.05, *: p<0.01, **: p<0.001, ***, p<0.0001 (two-tailed T-test).  
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Figure 5.3.6: Effects of shortlisted DNA-binding proteins on the haplotype difference of the longer downstream promoter region of 
MAPT plasmid constructs.  
Only shortlisted proteins that showed significant difference between the different plasmid constructs were included. Each was done in 
triplicate. Error bars represent standard deviation. *: p<0.01, **: p<0.001 (two-tailed T-test).   
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The observation that addition of the D-region to the region C-H1c risk allele caused 
stronger activity enhancement with knockdown of proteins of interest, compared to the D-
region in conjunction with C-H1b was also seen when the core promoter B1 region was 
included (Figure 5.3.7). Although the addition of the D region did not change the repressive 
effect of U2AF2 on B1+C-H1c, it completely abolished this. The same effect was also seen 
with PTBP1. While the enhancing effects of hnRNPD0 and TDP43 knockdown on B1 
alone were also seen with B1+D+C-H1c as opposed to repression with B1 alone. The effect 
of D+C-H1b on the B1 core promoter was less straightforward. The neutral H1b haplotype 
seemed to result in the genetic elements to be more resistant to the effects of the trans 
factors being investigated. Whether the proteins of interest were demonstrating a positive or 
negative effect on the construct, the intensity of the effect was reduced. Knockdown of 
U2AF2 and PTBP1 were necessary for the repression of the construct while knockdown of 
hnRNPU, hnRNPD0 and CP2 were responsible for the enhancement of the construct.   
 
 The inclusion of the D-region has proven to be insightful and promising as without 
the inclusion of it, a very different discussion and conclusion would have arisen. The D 
region adds complexity to the genetic regulation of MAPT. However, this is not to say that 
all these elements provide a complete picture as other elements that could be included 
might change the dynamics again. This stresses the shortcoming of the luciferase reporter 
constructs used in this study in that they only include small elements of the large MAPT 
promoter and the ultimate importance of including as many functional elements when 
studying the interaction between genetic elements and trans factors. Due to the large size of 
the MAPT promoter region (>70 kb), this was not possible within the framework of this 
project.  
 
From Figure 5.3.8, it is clear that the D-region modulates the allelic effects of 
B1+D+C-H1b and B1+D+C-H1c similar to the effects of the D-region on the C-region 
alone. However, with the inclusion of the core promoter as well, the modulation that D-
region exerted was different, highlighting the possibility of crosstalk amongst the different 
genetic elements. While CP2 was unaffected, U2AF2 and PTBP1 no longer had any effect 
on B1+D+C-H1c. Knockdown of hnRNPU and hnRNPD0 led to the enhancement of the 
construct with the inclusion of the D-region than without. The neutral H1b was less 
susceptible to the modulation exerted by the D-region. The results from the B1+D+C-H1b 
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construct showed that U2AF2 was unaffected and the knockdown of PTBP1 was only 
slightly enhanced. hnRNPU and hnRNPD0 were affected to lesser extents as well. The only 
notable effect the D-region had on B1+D+C-H1b was that where CP2 used to be important 
for the activity of the construct, it now had an inhibitory role.
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Figure 5.3.7: Effects of shortlisted DNA-binding proteins on the haplotype difference of the longer downstream promoter region on 
the core promoter of MAPT plasmid constructs.  
Only shortlisted proteins that showed significant difference between the different plasmid constructs were included. Each was done in 
triplicate. Error bars represent standard deviation. *: p<0.01, **: p<0.001, ***, p<0.0001 (two-tailed T-test).
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Figure 5.3.8: Effects of shortlisted DNA-binding proteins on the longer downstream promoter region for each haplotype of core 
promoter and downstream of MAPT plasmid constructs.  
Only shortlisted proteins that showed significant difference between the different plasmid constructs were included. Each was done in 
triplicate. Error bars represent standard deviation. *: p<0.01, **: p<0.001, ***, p<0.0001 (two-tailed T-test).
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Comparing the allele-specific differences between the non-risk H1b/H2 haplotype 
with the risk H1c haplotype as in Figure 5.3.9, it would seem that without the D-region 
(B1+C-H1b and B1+C-H1c); the allele-specific effect was very slight. Knockdown of 
hnRNPU and hnRNPD0 showed the strongest allele-specific differences with B1+C 
variants with negligible effect on the H1b allele and repression on the H1c allele. However, 
addition of the D region caused enhancement for both alleles. In the case of CP2 
knockdown, an allele-specific difference was only seen in the presence of the D-region. For 
the most extensive construct used to study the haplotypic effect i.e. B1+D+C-H1b and 
B1+D+C-H1c, the haplotype effect was much more substantial. As been previously 
mentioned, the risk allelotype served to elicit a more repressive state with the knockdown 
of U2AF2 and PTBP1. This led to an increase in the repressive function of hnRNPD0 and 
TDP43 which was not seen in any previous analyses. The role of hnRNPU was unchanged 
between the two allelotypes while the repressive effect CP2 had on the neutral H1b 
haplotype was removed and played an active role on the risk H1c haplotype.  
 
 In summary, the knockdown of U2AF2 and PTBP1 showed the most consistent 
effects on all ten promoter reporter variants that were studied (Table 5.3.10), supporting 
their possible importance in regulating the tau promoter. This was especially apparent with 
their allele-specific effects on B1+D+C. The strong repressive effect of TDP-43 was 
limited to the core promoter B1 and was not influenced by the other promoter elements 
other than an allele-specific effect on the B1+D+C. The effects of hnRNPU, hnRNPD0 and 
CP2 knockdown are less consistent and clear cut. Apart from the promoter only constructs 
(B1, and B1+B2), these proteins had more variable effects in the presence of the C and D 
regions. They seem to be much more sensitive to various genetic elements as well as 
haplotype effects. Besides their dynamic nature, for the majority of the constructs excluding 
promoter only constructs, they behave in a repressive manner towards them.  
 
 This work shows that the regulation of MAPT gene regulation is a highly complex 
process involving the different promoter regulatory motifs. More work still needs to be 
done to elucidate the extended core promoter B1+B2 effects on that haplotype differences 
as well as what makes the D-region such an influential genetic element. All the knockdown 
work was done on individual proteins, a combinatorial approach might highlight the 
intricacies of the relationship between MAPT and its trans factors.
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Figure 5.3.9: Effects of shortlisted DNA-binding proteins on the haplotype difference of the downstream promoter regions with the 
core promoter of MAPT plasmid constructs.  
Only shortlisted proteins that showed significant difference between the different plasmid constructs were included. Each was done in 
triplicate. Error bars represent standard deviation. *: p<0.01, **: p<0.001, ***, p<0.0001 (two-tailed T-test).  
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% Δ in siRNA / neg ctrl 1 B1 B1+B2 C-H1b C-H1c B1+C-H1b B1+C-H1c B1+D+C-H1b B1+D+C-H1c D+C-H1b D+C-H1c 
U2AF2 -70 -70 -57 -48 -47 -54 -42 -4 -55 -32 
hnRNPU -63 -58 12 -21 4 -57 58 46 10 39 
PTBP1 -51 -64 -40 13 -64 -68 -42 -2 -34 -25 
hnRNPD0 100 -6 30 -58 -1 -43 34 135 -30 97 
CP2 -57 -13 8 147 -54 -41 33 -53 37 202 
TDP43 224 227 -2 -9 191 219 170 242 -11 -13 
PAX8 5 27 -3 27 9 4 -1 29 3 -7 
 
Table 5.3.10: Summary of effects of shortlisted DNA-binding proteins on different MAPT promoter constructs. Top: Table of all 
percentage change (% Δ) in the promoter strength of all the MAPT plasmid constructs as a result of the siRNA knockdown of the protein of 
interest relative to their respective negative control 1 siRNA co-transfection. Bottom: Table of all percentage change (% Δ) of the function of 
the protein of interest had on all the MAPT plasmid constructs. Red – Most negative % Δ. Yellow – Moderate negative % Δ. Green – 
Moderate positive % Δ. Blue – Most positive % Δ for each column. Numbers centered showed non-significance with another value in the 
same column. Numbers centered and bold showed non-significance with more than one value in the same column. Pairs of adjacent values in 
a row that had been boxed together showed significance difference with each other
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U2AF2 and PTBP1 have been shown previously to be involved with MAPT exon 6 
and its splicing.
270
 They were both shown to act on the branch point / polypyrimidine tract 
region, overlapping but distinct sites. The effect was seen in both COS cells and SKN cells. 
PTBP1 is potent in preventing the inclusion of exon 6 while U2AF2 favours the inclusion 
of exon 6, seemingly by favouring the strongest branch point when the 3’ splice site was 
present. Another isoform of PTBP1, PTBP2 or neuronal PTBP (nPTBP), was also shown to 
exclude exon 6.
271
 However, since nPTBP was not seen in our protein identification, it was 
not pursued. In our study, we also did see a close relationship between U2AF2 and PTBP1, 
probably due to overlapping and distinct sites as well. A tau expression and / or splicing 
assay would be needed to investigate whether they have opposing effects and what their 
downstream effects are. Work on the splicing of exon 10 showed that U2AF2 and PTBP1 
both strongly inhibit exon 10 splicing.
272
 Hence, depending on their location and sites of 
interaction, their effects and outcomes could be very different. Since they are splicing 
proteins, they might be recruited by RNA polymerase II at the promoter region and follow 
the course of transcription.  
 
Another group of proteins that have been shown to interact with MAPT is the 
hnRNP family of proteins. Although hnRNPU and hnRNPD0 have not been specifically 
shown to associate with the tau gene, other members have been shown to interact. hnRNPG 
was shown to inhibit MAPT exon 10 splicing, most likely in concert with other trans factors 
as a complex with SR proteins.
273
 Using tau exon 10 as bait in a yeast three-hybrid screen, 
hnRNPE2 was found to interact with it.
274
 It is interesting to note that the screen also 
picked up 60S ribosomal protein L23 which was also found in our protein pull-down 
interacting with rs242557. Co-transfection assays later showed that hnRNPE2 moderately 
activates exon 10 splicing. Through similar experiments, hnRNPE3 was also found to 
modestly activate exon 10 splicing.
275
 Lastly, hnRNPK could post-transcriptionally regulate 
the tau mRNP complex by affecting its nuclear export and translation but not 
transcription.
276
 It is unsurprising then comparing these results with our own that hnRNPU 
and hnRNPD0 were able to give such a varied response depending on the constructs that 
were used. Since members of the hnRNP family can interact with each other and exert their 
influence in the nucleus as well as in the cytoplasm, more detailed experiments would be 
needed to ascertain their full nature with regards to the tau gene and the co-regulation of 
transcription and splicing.  
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Although no previous work in the literature showed that the transcription factor CP2 
interacted with the tau gene, it had been predicted to bind the rs242557 region by other 
groups and studied intensively within the field of Alzheimer’s disease. For example, it was 
shown that the intracellular domain (ICD) of amyloid precursor like protein 2 (APLP2) 
interacted with CP2 in the nucleus and induced the expression of GSK-3β.277 The 
identification of CP2 with the tau gene might open up a new range of upstream signalling 
and interactions that might subsequently impinge on the genetic regulation of MAPT and 
coordination of this disease-associated gene with other disease-associated genes and 
pathways. Furthermore, TDP-43, the protein of a disease-associated gene which was also 
found in the inclusions of FTLD-U, was found to be highly involved in the state of the core 
promoter of MAPT. Again, more work will be needed to study the various trans factors 
regulating tau gene expression. 
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6 Conclusions and Future Work 
 
6.1 Conclusions 
 
 The tau protein is a dynamic architectural protein that is involved in various cellular 
processes. In neurology, the tau protein and the tau gene have been implicated in causing or 
playing a role in various neurological disorders. The H1c sub-haplotype of the tau gene, 
MAPT, drives the association of increased risk in PSP and CBD and is also weakly 
associated with AD. rs242557 is a H1c-specific SNP in a highly conserved C-region 
downstream of the MAPT core promoter and is associated with significantly higher 
transcription and elevated levels of mRNAs containing the alternatively spliced exon 10. It 
is one of nine H1c-specific SNPs. This PhD set out to elucidate how rs242557 might affect 
transcription by identifying DNA-binding proteins that bind to it and their effects on the C 
region and the core promoter.  
 
 Nuclear extracts from SH-SY5Y neuroblastoma cell line were used to carry out 
EMSA. This experiment showed that the H1b/H2-G allelotype of rs242557 was able to 
recruit more DNA-binding proteins as compared to the A allelotype. Concatamers of 
rs242557-containing oligonucleotides were used to purify the DNA-binding proteins and 
separated on a 1-D SDS PAGE gel. The bands were then identified using mass 
spectrometry. 36 unique proteins were identified and these were stratified using 
bioinformatics software such as STRING and Reactome. An additional protein predicted by 
MatInspector and Transfac to bind to the rs242557 region was also included. Hence, 14 
promising DNA-binding protein candidates were pursued further. 
 
 These proteins were validated using antibodies raised specific to those proteins. The 
antibodies were used to identify the DNA-binding proteins from the pull-down experiments 
as well as in native blots. The pull-down experiments worked much better than the native 
blots. As a result, five DNA-binding proteins of interest (U2AF2, hnRNPU, PTBP1, 
hnRNPD0 and CP2) were progressed to the co-transfection luciferase assays to begin to 
understand the trans effects of these proteins on genetic regulatory regions of MAPT. 
TDP43 was also included in the co-transfection assays through its growing importance as a 
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neurologically relevant protein and gene as well as personal communication with other 
members of the lab.  
 
 Knock down of U2AF2 and PTBP1 on the B1+D+C-H1b demonstrated that they 
have a role in C-H1b transcription but they were not observed to participate in the 
transcription of B1+D+C-H1c. This allele specificity was not observed from the 
knockdown of hnRNPU and hnRNPD0, both of which enhanced the transcription of 
B1+D+C-H1b&c. Knock down of TDP43, too, did not show any allele specificity but it did 
show core promoter specificity, indicating that TDP43’s role is intimately linked with the 
core promoter. Lastly, the only other protein that was knocked down but was not identified 
through mass spectrometry was CP2. It was a transcription factor predicted to interact with 
rs242557. Knock down of CP2 enhanced the transcription of B1+D+C-H1b but repressed 
the transcription of B1+D+C-H1c. Hence, the three proteins that demonstrated rs242557 
allele specificity were the splicing factor U2AF2, the splicing repressor PTBP1 and the 
transcription factor CP2. 
 
 Understanding how genes function requires an appreciation of the dynamic nuclear 
architecture (Figure 6.1.1).
278
 Studies on various animal models have using next generation 
sequencing after micrococcal nuclease digestion consistently revealed that nucleosomes 
occupy exons 1.5-fold more than introns.
279
 In humans and mice, exons were also found to 
be enriched in post-translational histone modifications.
280
 Hence, these findings suggest the 
plausibility of an RNAPII mediated cross-talk between chromatin and the exon-intron 
architecture (Figure 6.1.2). The results discussed so far are promising in highlighting the 
relationship between the risk associations of a SNP with neurological diseases and how a 
SNP influences the biology and subsequently the pathology of a neurological disease. 
Furthermore, the nucleus is a three-dimensional structure and is filled with chromosomes 
and proteins, interacting in three dimensions.
281
 From the co-transfection luciferase assays, 
the inclusion of the core promoter had modulated the knockdown results of the C-region 
alone or D+C regions. This might suggest that in the in vivo context, a complex or various 
complexes or chromatin modifications could account for this interaction. hnRNPU and 
hnRNPD0 are versatile proteins that are able to bind to DNA sequences as well as RNA 
such A+U-rich element in the 3’-UTR of mRNA and other proteins. This makes them 
highly likely candidate proteins to bridge RNAPII function with chromatin dynamics. 
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Specifically, hnRNPU had already been shown to be involved with the CTD of RNAPII as 
well as complexes involved in histone acetylation.
221,223,224
 
 
 U2AF2 and PTBP1, besides already been shown to be involved in the splicing of 
MAPT exon 6, have also been studied together with other genes.
185,186,366
 From our results, 
more is known about how the splicing of MAPT is coordinated by these splicing proteins. 
Although direct binding of these proteins to the C region containing rs242557 through ChIP 
had not been completed, all our results point towards U2AF2 and PTBP1 being 
functionally involved in an allele-specific manner. How this interaction with rs242557 ties 
in with their function with the splicing of exon 6 or other splicing events within MAPT will 
require further investigation.   
 
 The transcription factor CP2 is a protein that was predicted to bind to the rs242557 
region. It might have been pulled down by rs242557 as a band similar to its molecular 
weight was seen on a SDS-PAGE gel. The mass spectrometer was not able to identify that 
gel band, possibly due to degraded peptides or insufficient peptides. However, with the 
blots of the native gels, CP2 came across as binding to the rs242557 probe in a highly 
specific manner as no band was seen with one of the random probes. Moreover, the binding 
was allele-specific. While a lot of study involving CP2 protein had been done in 
Alzheimer’s disease, they revolved around the amyloid pathway. Although other groups 
have postulated that CP2 would bind to the C region, our work has been the first in 
progressing that further. The allele-specific functionality surrounding CP2 binding warrants 
further study into this transcription factor, especially in light of the allele-specific binding 
of U2AF2 and PTBP1 as well. 
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Figure 6.1.1: Chromosomal territories and nuclear bodies present in the nucleus. 
Modified from 
374
.
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Figure 6.1.2: The interplay of chromatin with SNPs, transcription and splicing. (A) Mechanisms of how nucleosomes may add to the 
complexity of the exon-intron architecture: slowing transcription sterically, A, or through histone modifications, B, or the CTD domain of 
RNAPII and nucleosome interacting with splicing factors, C, or chromatin remodelers, D. (B) Chromatin remodeling is an intricate process 
with various entities attenuating the process. (C) SNPs may influence chromatin crosstalk through chromosome loops and or bridges. 
Modified from
375,377,282
 206 
6.2 Future work 
 
All the work carried out in this PhD had been done on undifferentiated SH-SY5Y 
neuroblastoma cells. Although these cells in their undifferentiated form do retain certain 
neuronal characteristics such as dopamine-β-hydroxylase activity and converting glutamate 
to GABA, their morphology does not resemble neurons. To fully differentiate these cells, 
they would be treated with retinoic acid before treating them with brain derived 
neurotrophic factor (BDNF). This process however is expensive due to the BDNF, time 
consuming and leaves with a very low yield of fully differentiated SH-SY5Y cells. For the 
purpose of this study, it would have been impractical. However, retinoic acid is relatively 
inexpensive compared to BDNF and the process of partially differentiating these cells with 
retinoic acid is much speedier than the full differentiation process. There is also a greater 
yield of partially differentiated cells.  
 
Retinoic acid, a vitamin A metabolite and a lipohilic signaling molecule, binds to its 
receptor and retinoid X receptor to regulate transcription.
283
 Treatment of SH-SY5Y cells 
with retinoic acid had been shown to induce the expression of the neurotrophin receptor 
TrkB and that it was functional.
284
 In our own experiment, a 1.5-fold increase in the 
expression of TrkB was seen in both the nuclear and cytoplasmic extracts after treatment 
with retinoic acid (Figures 6.2.1 and 6.2.2). Although it was known that undifferentiated 
SH-SY5Y cells produced significant levels of neurotransmitters such as dopamine, 
acetylcholine and GABA, how these would be affected upon retinoic treatment was not 
known. Here, our treatment of cells with retinoic acid led to an approximately four- and 
two-fold increase in dopamine-β-hydroxylase in the nuclear and cytoplasmic fractions 
respectively. Vasoactive intestinal polypeptide (VIP), a cholinergic marker had been 
previously shown to be upregulated in retinoic acid-treated SH-SY5Y cells especially in the 
neuritic processes through immunohistochemistry.
285
 In our experiment, nuclear VIP was 
significantly decreased with a concomitant increase in cytoplasmic VIP reflecting that 
immunohistochemistry result. The oncoprotein Bcl-2 was also seen to be moderately 
increased upon differentiation with retinoic acid in the nuclear extracts. This was confirmed 
by previous published work from other groups as a key marker of SH-SY5Y 
differentiation.
286,287
 A key architectural protein in neuronal cells is neurofilament-M 
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(NFM). From figures 6.2.1 and 6.2.2, the expression of this protein was induced further 
with differentiation especially in the cytoplasmic fractions with a 1.5-fold increase. 
 
Besides analyzing neuron-specific cytoplasmic markers, the methyl CpG 
transcription factor MeCP2 was also investigated. Besides the increase in expression with 
retinoic acid treatment, MeCP2 had been shown to indirectly control BDNF 
expression.
288,289
 This protein like Bcl-2 was seen to be moderately upregulated in the 
nuclear extract of retinoic acid-differentiated cells in our experiment. As MeCP2 is a 
transcription factor, a slight increase might be sufficient to cause significant changes in its 
gene targets. Finally, as this PhD revolves around the tau gene MAPT, it was also important 
to look at the expression of the tau protein before and after retinoic acid treatment. It had 
been previously shown by various groups that upon differentiation of SH-SY5Y cells, 
levels of tau and its phosphorylation state had increased, in part because of the increased 
expression of GSK-3β.290,291 ,292 In our experiment however, we did not see this effect. In 
fact, the levels of tau were observed to decrease in both the nuclear and cytoplasmic 
fractions. It could be that other isoforms of tau was expressed but was undetected.  
 
As controls, the neuron-specific enolase, GAPDH, actin and MCM2 were used 
(Figure 6.2.1 continued). No change in protein levels was detected either in the nuclear or 
cytoplasmic fractions after treatment with retinoic acid. However, the other nuclear control 
protein, HDAC1, was upregulated upon differentiation. Hence, it would be important in 
going forward to put the results of this PhD to the test with a variety of cell culture models, 
either retinoic-acid differentiated neuroblastoma cells or primary neuronal cell cultures. 
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Figure 6.2.1: Western blot analysis of neuronal specific differentiation protein markers of SH-SY5Y cells treated with retinoic acid. 
SH-SY5Y neuroblastoma cells were treated with retinoic acid for a week before cytoplasmic and nuclear fractions were extracted (Diff Cyt 
and Diff Nuc) and analysed. The same cells with the same passage number were left untreated before being extracted (Undiff Cyt and Undiff 
Nuc) and analysed too. N =3 
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Figure 6.2.1 continued: Western blot analysis of neuronal specific differentiation protein markers of SH-SY5Y cells treated with 
retinoic acid. SH-SY5Y neuroblastoma cells were treated with retinoic acid for a week before cytoplasmic and nuclear fractions were 
extracted (Diff Cyt and Diff Nuc) and analysed. The same cells with the same passage number were left untreated before being extracted 
(Undiff Cyt and Undiff Nuc) and analysed too. N = 3 
 210 
 
Figure 6.2.2: Plot of the blot density of proteins from retinoic acid differentiated fractions relative to the blot density of proteins 
from undifferentiated fractions.   
Red bars represent the blot density of proteins from the nuclear extracts of retinoic acid differentiated cells relative to the blot density of the 
same proteins from nuclear extracts of undifferentiated cells. Blue bars represent similar comparisons of the same proteins found in the 
cytoplasmic fractions.
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Another key experiment that was started during my PhD but was not successfully 
completed during the period was chromatin immunoprecipitation (ChIP). As this was a 
technique new to the laboratory, a lot of optimisation needed to be done. It was a bold step 
to start off with ChIP of frozen human brain tissue. After many months, this route did not 
prove successful, possibly due the amount of cells needed and the condition of the samples. 
Another attempt was pursued with SH-SY5Y cells and various ChIP protocols were tested. 
However, because of restraints on time and resources, the ChIP results shown in Figures 
6.2.3 and 6.2.4 were not repeated and should be seen as part of the further work that needs 
to be undertaken.  
 
 The ChIP experiment was designed to include various controls. Besides the input 
control where 10% of the sheared genomic DNA was used to show selective enrichment, 
there was also an antibody negative control consisting of IgG and a positive antibody 
control against RNAPII and looking at its binding to the GAPDH promoter. These were the 
controls suggested by the ChIP protocol. On top of this, we designed primers for regions 
directly upstream and downstream of the rs242557 region, primers for the B region as well 
as a predicted Sp1-binding consensus site. These additional primers designed were tested 
on genomic DNA so that they only amplified unique regions of comparable sizes (Figure 
6.2.3 genomic DNA).  
 
 Although quantitative PCR had not been done and no replicates were done either, 
early indications show that there is potential for the proteins of interest U2AF2, hnRNPU, 
PTBP1, hnRNPD0 and CP2 to bind to the rs242557 region. These binding seem to be 
stronger than the positive control of RNAPII binding to the GAPDH promoter. Furthermore, 
there seem to be modest binding of U2AF2 and PTBP1 to the core promoter B region while 
CP2 seem to bind to the B region as much as it does to the rs242557 region. Repeat 
experiments, however, need to be done to see if these indications of binding hold up.
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Figure 6.2.3: Agarose separation of PCR products of ChIP from proteins of interest on different regions of MAPT.   
Genomic DNA and proteins were crosslinked in vivo with formaldehyde, extracted and sheared enzymatically. Antibodies targeting proteins 
of interest were incubated with the sheared DNA-protein complex. The enriched DNA fragments were purified and identified using PCR. L: 
1kb DNA ladder, 1: Input DNA, 2: IgG negative control antibody, 3: Sp1 predicted site, 4: rs242557, 5: region directly upstream of 
rs242557, 6: region directly downstream of rs242557, 7: B region, 8: GAPDH negative control, 9: RNAPII-GAPDH positive control. 
Genomic DNA panel shows that designed primers work accordingly. 
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Figure 6.2.4: Analysis of ChIP from proteins of interest on different regions of MAPT.   
Top panel: The density blot for each ChIP band was measured and was plotted relative to the average density of the stringent negative 
controls of directly upstream and downstream of rs242557. No repeats were done hence no error bars. Bottom panel: The ChIP values 
were expressed relative to the positive control of RNAPII antibody-GAPDH PCR values. 
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7 Appendix 
201.5 kDa band – P35580 Myosin Heavy Chain 
           
Figure 3.4.2: Coverage of MS peptide data generated for 201.5 kDa band. 27 Blue – matched to a peptide, 14 red – matched 
to a partial peptide, 7 green – matched to a modified peptide, 7 yellow – matched to a partial modified peptide. Other colours 
arise from different peptide types with overlapping sequences. List of modifications can be found at 
http://www.abrf.org/index.cfm/dm.home?AvgMass=all 
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Figure 3.4.3: Coverage of MS peptide data generated for 109.4 kDa. 15 Blue – matched to a peptide, 9 red – matched  
to a partial peptide, 3 green – matched to a modified peptide, 3 yellow – matched to a partial modified peptide. Other colours 
arise from different peptide types with overlapping sequences. List of modifications can be found at 
http://www.abrf.org/index.cfm/dm.home?AvgMass=all 
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Figure 3.4.4: Coverage of MS peptide data generated for 103.5 kDa. 21 Blue – matched to a peptide, 10 red – matched  
to a partial peptide, 3 green – matched to a modified peptide, 5 yellow – matched to a partial modified peptide. Other colours 
arise from different peptide types with overlapping sequences. List of modifications can be found at 
http://www.abrf.org/index.cfm/dm.home?AvgMass=all 
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Figure 3.4.5: Coverage of MS peptide data generated for 95.4 kDa and fragmentation data for one of the peptides. Blue – 
matched to a peptide, red – matched to a partial peptide, green – matched to a modified peptide, yellow – matched to a 
partial modified peptide. Other colours arise from different peptide types with overlapping sequences. List of modifications 
can be found at http://www.abrf.org/index.cfm/dm.home?AvgMass=all 
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Figure 3.4.5 continued: Coverage of MS peptide data generated for 95.4 kDa and fragmentation data for one of the peptides. 
Blue – matched to a peptide, red – matched to a partial peptide, green – matched to a modified peptide, yellow – matched to a 
partial modified peptide. Other colours arise from different peptide types with overlapping sequences. List of modifications 
can be found at http://www.abrf.org/index.cfm/dm.home?AvgMass=all 
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Figure 3.4.6: Coverage of MS peptide data generated for 93 & 34.3 kDa and fragmentation data for one of the peptides. Blue 
– matched to a peptide, red – matched to a partial peptide, green – matched to a modified peptide, yellow – matched to a 
partial modified peptide. Other colours arise from different peptide types with overlapping sequences. List of modifications 
can be found at http://www.abrf.org/index.cfm/dm.home?AvgMass=all 
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Figure 3.4.7: Coverage of MS peptide data generated for 93 & 31.6 kDa and fragmentation data for two of the peptides. Blue 
– matched to a peptide, red – matched to a partial peptide, green – matched to a modified peptide, yellow – matched to a 
partial modified peptide. Other colours arise from different peptide types with overlapping sequences. List of modifications 
can be found at http://www.abrf.org/index.cfm/dm.home?AvgMass=all 
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Figure 3.4.8: Coverage of MS peptide data generated for 64 kDa. 7 Blue – matched to a peptide, 4 red – matched to a partial 
peptide, 1 green – matched to a modified peptide, 1 yellow – matched to a partial modified peptide. Other colours arise from 
different peptide types with overlapping sequences. List of modifications can be found at 
http://www.abrf.org/index.cfm/dm.home?AvgMass=all 
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Figure 3.4.9: Coverage of MS peptide data generated for 55 kDa. 6 Blue – matched to a peptide, 6 red – matched to a partial 
peptide, 6 green – matched to a modified peptide, 9 yellow – matched to a partial modified peptide. Other colours arise from 
different peptide types with overlapping sequences. List of modifications can be found at 
http://www.abrf.org/index.cfm/dm.home?AvgMass=all 
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Figure 3.4.10: Coverage of MS peptide data generated for 52.5 kDa and fragmentation data for one of the peptides. Blue – 
matched to a peptide, red – matched to a partial peptide, green – matched to a modified peptide, yellow – matched to a 
partial modified peptide. Other colours arise from different peptide types with overlapping sequences. List of modifications 
can be found at http://www.abrf.org/index.cfm/dm.home?AvgMass=all 
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Figure 3.4.11: Coverage of MS peptide data generated for 48.3 kDa. 5 Blue – matched to a peptide, 1 red – matched to  
a partial peptide, 4 green – matched to a modified peptide, 3 yellow – matched to a partial modified peptide. Other colours 
arise from different peptide types with overlapping sequences. List of modifications can be found at 
http://www.abrf.org/index.cfm/dm.home?AvgMass=all 
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Figure 3.4.12: Coverage of MS peptide data generated for 43.9 kDa. Blue – matched to a peptide, red – matched to a partial 
peptide, green – matched to a modified peptide, yellow – matched to a partial modified peptide. Other colours arise from 
different peptide types with overlapping sequences. List of modifications can be found at 
http://www.abrf.org/index.cfm/dm.home?AvgMass=all 
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Figure 3.4.12 continued: Coverage of MS peptide data generated for 43.9 kDa and fragmentation data for two of the peptides. 
Blue – matched to a peptide, red – matched to a partial peptide, green – matched to a modified peptide, yellow – matched to a 
partial modified peptide. Other colours arise from different peptide types with overlapping sequences. List of modifications 
can be found at http://www.abrf.org/index.cfm/dm.home?AvgMass=all 
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Figure 3.4.13: Coverage of MS peptide data generated for 42.2 kDa and fragmentation data for one of the peptides. Blue – 
matched to a peptide, red – matched to a partial peptide, green – matched to a modified peptide, yellow – matched to a 
partial modified peptide. Other colours arise from different peptide types with overlapping sequences. List of modifications 
can be found at http://www.abrf.org/index.cfm/dm.home?AvgMass=all 
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Figure 3.4.14: Coverage of MS peptide data generated for 34.1 kDa and fragmentation data for one of the peptides. Blue – 
matched to a peptide, red – matched to a partial peptide, green – matched to a modified peptide, yellow – matched to a 
partial modified peptide. Other colours arise from different peptide types with overlapping sequences. List of modifications 
can be found at http://www.abrf.org/index.cfm/dm.home?AvgMass=all 
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Figure 3.4.15: Coverage of MS peptide data generated for 30.7 kDa and fragmentation data for one of the peptides. Blue – 
matched to a peptide, red – matched to a partial peptide, green – matched to a modified peptide, yellow – matched to a 
partial modified peptide. Other colours arise from different peptide types with overlapping sequences. List of modifications 
can be found at http://www.abrf.org/index.cfm/dm.home?AvgMass=all 
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Figure 3.4.16: Coverage of MS peptide data generated for 30 kDa and fragmentation data for one of the peptides. Blue – 
matched to a peptide, red – matched to a partial peptide, green – matched to a modified peptide, yellow – matched to a 
partial modified peptide. Other colours arise from different peptide types with overlapping sequences. List of modifications 
can be found at http://www.abrf.org/index.cfm/dm.home?AvgMass=all 
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Figure 3.4.17: Coverage of MS peptide data generated for 28.2 kDa. 3 Blue – matched to a peptide, 5 red – matched to  
a partial peptide, 2 green – matched to a modified peptide, 3 yellow – matched to a partial modified peptide. Other colours 
arise from different peptide types with overlapping sequences. List of modifications can be found at 
http://www.abrf.org/index.cfm/dm.home?AvgMass=all 
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Figure 3.4.18: Coverage of MS peptide data generated for 21.6 kDa and fragmentation data for one of the peptides. Blue – 
matched to a peptide, red – matched to a partial peptide, green – matched to a modified peptide, yellow – matched to a 
partial modified peptide. Other colours arise from different peptide types with overlapping sequences. List of modifications 
can be found at http://www.abrf.org/index.cfm/dm.home?AvgMass=all 
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Figure 3.4.18 continued: Coverage of MS peptide data generated for 21.6 kDa and fragmentation data for one of the peptides. 
Blue – matched to a peptide, red – matched to a partial peptide, green – matched to a modified peptide, yellow – matched to a 
partial modified peptide. Other colours arise from different peptide types with overlapping sequences. List of modifications 
can be found at http://www.abrf.org/index.cfm/dm.home?AvgMass=all 
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Figure 3.4.19: Coverage of MS peptide data generated for 16 kDa and fragmentation data for two of the peptides. Blue – 
matched to a peptide, red – matched to a partial peptide, green – matched to a modified peptide, yellow – matched to a 
partial modified peptide. Other colours arise from different peptide types with overlapping sequences. List of modifications 
can be found at http://www.abrf.org/index.cfm/dm.home?AvgMass=all 
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Figure 3.4.19 continued: Coverage of MS peptide data generated for 16 kDa and fragmentation data for one of the peptides. Blue – 
matched to a peptide, red – matched to a partial peptide, green – matched to a modified peptide, yellow – matched to a partial 
modified peptide. Other colours arise from different peptide types with overlapping sequences. List of modifications can be found at 
http://www.abrf.org/index.cfm/dm.home?AvgMass=all
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